

Applicants : Naldini et al.,
USSN : 10/554,181
Filed : 12/27/2005
Examiner : David Guzo
Page : 6

Atty. Dkt. No. : 1130-PCT-US
Art Unit : 1636
Date of office action : 11/16/2007
Date of response : 03/17/2008

REMARKS

Claim Status

Claims 1-18 are pending. Applicants have canceled claim 2 without prejudice to pursue the subject matter in a future application. Claims 1, 3, 12, 14, 15 and 16 have been amended.

Support for the amendments to the claims

Support for amended claim 1 may be found *inter alia* on page 17 of the Specification, lines 15-27; claim 1 and claim 2 as filed.

Support for amended claim 3 may be found *inter alia* on page 17 of the Specification, lines 21-24.

Support for amended claim 12 may be found *inter alia* on page 5 of the Specification, line 10.

Support for amended claims 13-16 may be found *inter alia* in claims 13-16 as filed.

Applicants respectfully request the entry of this Amendment. Upon entry, Claims 1, 3-18 are pending and under examination.

Rejections Under 35 U.S.C. §112

Claims 12-13 are rejected under 35 U.S.C. §112, second paragraph, as being indefinite. The rejection is respectfully traversed.

Claim 12 has been amended to recite that the tissue animal cells are brain neurons. Claim 13 has been amended to clarify that the aim is to express the sequences in an animal cell. Applicants submit that claim 12 and 13 have been amended to obviate the rejection. Accordingly, Applicants respectfully

Applicants : Naldini et al.,
USSN : 10/554,181
Filed : 12/27/2005
Examiner : David Guzo
Page : 7

Atty. Dkt. No. : 1130-PCT-US
Art Unit : 1636
Date of office action : 11/16/2007
Date of response : 03/17/2008

request that the rejection of claims 12-13 under 35 U.S.C. §112, second paragraph, be withdrawn.

Rejections Under 35 U.S.C. §102

Claims 1-4 and 6-15 are rejected under 35 U.S.C. §102(e) as being anticipated by Chtarto et al. The rejection is respectfully traversed.

Chtarto et al. is directed exclusively to a vector comprising a bi-directional antibiotic controlled activator-responsive promoter. In particular, the promoter comprises a tetracycline (Tet) responsive element.

The Tet responsive promoter is a synthetic sequence composed of 7 repetitions of an 8 nucleotide-long prokaryotic sequence. Such promoter is not able to exploit the endogenous mammalian transcriptional machinery in order to work properly. Therefore, to render this promoter functional, it is necessary to express an additional transgene encoding for a chimeric transcriptional activator composed of two halves, the first one being of prokaryotic origin and the second one being of viral or human origin.

A fundamental feature of the tetracycline-responsive expression system is that the promoters used must be insulated from nearby competing enhancers in order to prevent inappropriate transactivation and preserve integrity of modulation by doxycycline. Therefore, only minimal promoters have been so far used in this system. Moreover, the Tet-regulated system depends on the expression (or exogenous administration) of transactivators, whose expression (or administration) may encounter problems in vivo.

Applicants : Naldini et al.,
USSN : 10/554,181
Filed : 12/27/2005
Examiner : David Guzo
Page : 8

Atty. Dkt. No. : 1130-PCT-US
Art Unit : 1636
Date of office action : 11/16/2007
Date of response : 03/17/2008

In contrast, the present invention is directed to **synthetic eukaryotic bidirectional promoters**, based on the juxtaposition of a core promoter element placed upstream and in opposite orientation to an efficient promoter, that exploits the endogenous transcriptional machinery available to most animal cells types to drive robust expression of two divergent transcripts. The fact that the bidirectional promoter of the present invention comprises a minimal **viral** promoter **and** a **full length animal** promoter represents a fundamental difference over the prior art in general, and over Chtarto et al. in particular.

It is well known in this art that the eukaryotic and prokaryotes promoters act differently. For example,

The promoter contains specific DNA sequences, response elements, that are recognized by proteins known as transcription factors. These factors bind to the promoter sequences, recruiting RNA polymerase, the enzyme that synthesizes the RNA from the coding region of the gene.

- *In prokaryotes, the promoter is recognized by RNA polymerase and an associated sigma factor, which in turn are brought to the promoter DNA by an activator protein binding to its own DNA sequence nearby.*
- *In eukaryotes, the process is more complicated, and at least seven different factors are necessary for the transcription of an RNA polymerase II promoter."*

See Exhibit A, 5 pages.

In addition, it is well known from general biology text books that a promoter of a prokaryote organism cannot work in the environment of an eukaryote organism and vice versa.

The bidirectional promoter of the present invention can be based on **any eukaryotic promoter**: ubiquitous, constitutive, tissue specific or endogenously regulated.

Applicants :	Naldini et al.,	Atty. Dkt. No.	: 1130-PCT-US
USSN	: 10/554,181	Art Unit	: 1636
Filed	: 12/27/2005	Date of office action	: 11/16/2007
Examiner	: David Guzo	Date of response	: 03/17/2008
Page	: 9		

In nature, few instances of bidirectional promoters have been documented and only very recently recent surveys of the human genome have indicated an abundance of divergently transcribed gene pairs representing more than 10% of the human genome, whose transcriptional start sites are separated by less than 1 kb. In addition, it has been suggested that more than half of the human promoters does not exhibit strong directionality in transcript initiation and can function in a bidirectional fashion. Thus, the synthetic bidirectional promoters of the present invention may mimic a well-represented and evolutionary conserved feature of eukaryotic transcription, providing a structural basis for their robust performance.

More specifically, Chtarto et al. require the use of a transactivator factor encoded by a reverse antibiotic controlled transactivator nucleotide sequence for activating the bi-directional promoter. See, for instance, Chtarto et al. column 5, lines 12-16:

In said construct or system the bi-directional antibiotic controller activator responsive promoter/operator sequence 4 is advantageously activated by the transactivator factor 7, encoded by the reverse antibiotic controlled transactivator 7, encoded by the reverse antibiotic controlled transactivator nucleotide sequence 6 in the presence of said antibiotic 5.

That Chtarto et al. is only directed to an antibiotic inducible/repressible genetic construct is clear throughout the document. See further Fig. 6, column 4, lines 42-43, column 5, lines 22-32.

The present invention offers the construction of a bidirectional promoter comprising a minimal viral promoter and a full length eukaryotic promoter. See, for instance, description page 7, lines 3-8:

Applicants : Naldini et al.,
USSN : 10/554,181
Filed : 12/27/2005
Examiner : David Guzo
Page : 10

Atty. Dkt. No. : 1130-PCT-US
Art Unit : 1636
Date of office action : 11/16/2007
Date of response : 03/17/2008

A bidirectional promoter made by minimal core promoter elements from the human cytomegalovirus (mCMV) joined upstream, and in opposite orientation, to an efficient promoter, derived from the human phosphoglycerate kinase (PGK) or poly-ubiquitin UBI-C gene, was driving divergent transcription of two RNAs.

In conclusion, Chtarto et al. do not anticipate the present invention because Charto et al. do not teach each and every aspect of the present invention. Accordingly, Applicants respectfully request that the rejection of claims 1-4 and 6-15 under 35 U.S.C. §102(e) be withdrawn.

Claims 1-4 and 6-11 and 13-18 are rejected under 35 U.S.C. §102(e) as being anticipated by Itoh et al. The rejection is respectfully traversed.

Itoh et al. is directed exclusively to a vector comprising a low molecular weight compound-responsive bidirectional promoter and a DNA encoding a low molecular weight compound-controlled transactivator. In particular, the low molecular weight compound is tetracycline or doxycycline and the low molecular weight compound-controlled transactivator is a reverse tetracycline transactivator.

Therefore, arguments presented above concerning Chtarto et al. are also valid in respect to Itoh et al.

In conclusion, Itoh et al. do not anticipate the present invention because Itoh et al. do not teach each and every aspect of the present invention. Accordingly, Applicants respectfully request that the rejection of claims 1-4 and 6-11 and 13-18 under 35 U.S.C. §102(e) be withdrawn.

Applicants :	Naldini et al.,	Atty. Dkt. No.	: 1130-PCT-US
USPN	: 10/554,181	Art Unit	: 1636
Filed	: 12/27/2005	Date of office action	: 11/16/2007
Examiner	: David Guzo	Date of response	: 03/17/2008
Page	: 11		

Claims 1-4, 7-8, 10 and 14 are rejected under 35 U.S.C. §102(b) as being anticipated by Fux et al. The rejection is respectfully traversed.

Fux et al. discloses the construction of two vectors, pDuoRex7 and pDuoRex8 (see page 114, left column, last paragraph) which contain two antibiotic-responsive expression units in divergent orientation. Such pDuoRex-based dual regulated expression requires concomitant production of tTA and PIT (see page 114, right column, first paragraph).

Thus, arguments presented above concerning Chtarto et al. are also valid in respect to Fux et al.

In conclusion, Fux et al. do not anticipate the present invention because Fux et al. do not teach each and every aspect of the present invention. Accordingly, Applicants respectfully request that the rejection of claims 1-4, 7-8, 10 and 14 under 35 U.S.C. §102(b) be withdrawn.

It should be noted that none of the cited prior art documents discloses a bidirectional promoter comprising a minimal viral promoter and a full length animal promoter. Therefore none of the cited documents anticipate the present invention.

Moreover, starting from the teaching of Chtarto et al., or Itoh et al. or Fux et al. and due to the evolutionary distance between prokaryotes and mammals and to their differences in the transcriptional machinery, the person skilled in the art would not predict and foresee that mammalian promoters could be also exploited for building a bidirectional promoter. Therefore, the invention is not obvious in respect to such cited prior art documents.

Applicants :	Naldini et al.,	Att'y. Dkt. No.	:	1130-PCT-US	
USSN	:	10/554,181	Art Unit	:	1636
Filed	:	12/27/2005	Date of office action	:	11/16/2007
Examiner	:	David Guzo	Date of response	:	03/17/2008
Page	:	12			

Rejections Under 35 U.S.C. §103

Claim 5 is rejected under 35 U.S.C. §103(a) as being unpatentable over Chtarto et al. or Itoh et al., in view of Hope et al. (US 6,136,597).

Chtarto et al. and Itoh et al. have been discussed above. Hope et al. disclose an RNA export element which mediates efficient transport of RNA from the nucleus to the cytoplasm. This RNA export element is referred to as WPRE. WPRE is a post transcriptional regulatory element. Hence, Hope et al. teach using WPRE to increase transgene expression.

Therefore, even though assuming it is appropriate to combine Chtarto et al., and Hope et al., or Itoh et al., and Hope et al., (which the Applicants do not concede), such combination would not teach or suggest all of the features of dependent claim 5. In particular, the combined teaching of Chtarto, Itoh and Hope does not teach or suggest constructing a bidirectional promoter comprising a minimal viral promoter and a full length animal promoter.

Accordingly, Applicants respectfully request that the rejection of claim 5 under 35 U.S.C. §103(a) be withdrawn.

For the Examiner's information, the corresponding **European Application** of this subject application has been granted and is attached hereto as **Exhibit B, 71 pages**.

Applicants : Naldini et al.,
USSN : 10/554,181
Filed : 12/27/2005
Examiner : David Guzo
Page : 13

Atty. Dkt. No. : 1130-PCT-US
Art Unit : 1636
Date of office action : 11/16/2007
Date of response : 03/17/2008

Conclusion

In summary, Applicants believe that all grounds of rejections have been addressed and earnestly request the Examiner to place this application in condition for allowance.

If a telephone interview would be of assistance in advancing prosecution of the subject application, Applicants' undersigned attorney invites the Examiner to telephone him at the number provided below. If any other fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 50-1891.

Respectfully submitted,

Albert Wai-Kit Chan

Albert Wai-Kit Chan
Registration No. 36,479
Attorney for Applicants
Law Offices of Albert Wai-Kit
Chan, PLLC
World Plaza, Suite 604
141-07 20th Avenue
Whitestone, NY 11357
Tel: (718) 799-1000
Fax: (718) 357-8615
e-mail: chank@kitchanlaw.com

EXHIBIT A

Promoter

From Wikipedia, the free encyclopedia

In biology, a **promoter** is a regulatory region of DNA located upstream (towards the 3' region of the anti-sense strand) of a gene, providing a control point for regulated gene transcription.

Contents

- 1 Overview
- 2 Identification of relative location
- 3 Promoter elements
 - 3.1 Prokaryotic promoters
 - 3.1.1 Probability of occurrence of each nucleotide
 - 3.2 Eukaryotic promoters
- 4 Detection of promoters
- 5 Evolutionary change
- 6 Binding
- 7 Diseases associated with aberrant promoter function
- 8 Canonical sequences and wild-type
- 9 Diseases associated with promoter elements
- 10 References
- 11 External links

Overview

The promoter contains specific DNA sequences, response elements, that are recognized by proteins known as transcription factors. These factors bind to the promoter sequences, recruiting RNA polymerase, the enzyme that synthesizes the RNA from the coding region of the gene.

- In prokaryotes, the promoter is recognized by RNA polymerase and an associated sigma factor, which in turn are brought to the promoter DNA by an activator protein binding to its own DNA sequence nearby.
- In eukaryotes, the process is more complicated, and at least seven different factors are necessary for the transcription of an RNA polymerase II promoter.

Promoters represent critical elements that can work in concert with other regulatory regions (enhancers, silencers, boundary elements/insulators) to direct the level of transcription of a given gene.

It is worth noting that promoters are not DNA specific, and can in fact locate upstream towards the 3' end of an RNA genome, e.g. Respiratory Syncytial Virus (RSV).

Identification of relative location

As promoters are typically immediately adjacent to the gene in question, positions in the promoter are designated relative to the transcriptional start site, where transcription of RNA begins for a particular

gene (i.e., positions upstream are negative numbers counting back from -1, for example -100 is a position 100 base pairs upstream).

Promoter elements

- Core promoter - the minimal portion of the promoter required to properly initiate transcription
 - Transcription Start Site (TSS)
 - Approximately -34
 - A binding site for RNA polymerase
 - RNA polymerase I: transcribes genes encoding ribosomal RNA
 - RNA polymerase II: transcribes genes encoding messenger RNA and certain small nuclear RNAs
 - RNA polymerase III: transcribes genes encoding tRNAs and other small RNAs
 - General transcription factor binding sites
- Proximal promoter - the proximal sequence upstream of the gene that tends to contain primary regulatory elements
 - Approximately -250
 - Specific transcription factor binding sites
- Distal promoter - the distal sequence upstream of the gene that may contain additional regulatory elements, often with a weaker influence than the proximal promoter
 - Anything further upstream (but not an enhancer or other regulatory region whose influence is positional/orientation independent)
 - Specific transcription factor binding sites

Prokaryotic promoters

In prokaryotes, the promoter consists of two short sequences at -10 and -35 positions *upstream* from the transcription start site. Sigma factors not only help in enhancing RNAP binding to the promoter but helps RNAP target which genes to transcribe.

- The sequence at -10 is called the Pribnow box, or the -10 element, and usually consists of the six nucleotides TATAAT. The Pribnow box is absolutely essential to start transcription in prokaryotes.
- The other sequence at -35 (the -35 element) usually consists of the six nucleotides TTGACA. Its presence allows a very high transcription rate.
- Both of the above consensus sequences, while conserved on average, are not found intact in most promoters. On average only 3 of the 6 base pairs in each consensus sequence is found in any given promoter. No promoter has been identified to date that has intact consensus sequences at both the -10 and -35; it is thought that this would lead to such tight binding by the sigma factor that the polymerase would be unable to initiate productive transcription.
- Some promoters contain a UP element (consensus sequence 5'-TGNTATAAT-3') upstream of the -35 element; the presence of the -35 element appears to be unimportant for transcription from the UP element-containing promoters.

It should be noted that the above promoter sequences are only recognized by the sigma-70 protein that interacts with the prokaryotic RNA polymerase. Complexes of prokaryotic RNA polymerase with other sigma factors recognize totally different core promoter sequences.

```

      <-- upstream                                downstream -->
5'-XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX-3'
      -35      -10      Gene to be transcribed

(note that the optimal spacing between the -35 and -10 sequences is 17 nt)

```

Probability of occurrence of each nucleotide

```

for -10 sequence
T   A   T   A   A   T
77% 76% 60% 61% 56% 82%

```

```

for -35 sequence
T   T   G   A   C   A
69% 79% 61% 56% 54% 54%

```

Eukaryotic promoters

Eukaryotic promoters are extremely diverse and are difficult to characterize. They typically lie upstream of the gene and can have regulatory elements several kilobases away from the transcriptional start site. In eukaryotes, the transcriptional complex can cause the DNA to bend back on itself, which allows for placement of regulatory sequences far from the actual site of transcription. Many eukaryotic promoters, but by no means all, contain a TATA box (sequence TATAAA), which in turn binds a TATA binding protein which assists in the formation of the RNA polymerase transcriptional complex.^[1] The TATA box typically lies very close to the transcriptional start site (often within 50 bases).

Eukaryotic promoter regulatory sequences typically bind proteins called transcription factors which are involved in the formation of the transcriptional complex. An example is the E-box (sequence CACGTG), which binds transcription factors in the basic-helix-loop-helix (bHLH) family (e.g. BMAL1-Clock, cMyc).^[2]

Detection of promoters

A wide variety of algorithms have been developed to facilitate detection of promoters in genomic sequence, and promoter prediction is a common element of many gene prediction methods.

Evolutionary change

A major question in evolutionary biology is how important tinkering with promoter sequences is to evolutionary change, for example, the changes that have occurred in the human lineage after separating from chimps.

Some evolutionary biologists, for example Allan Wilson, have proposed that evolution in promoter or regulatory regions may be more important than changes in coding sequences over such time frames.

Binding

The binding of a promoter sequence (P) to a sigma factor-RNAP complex (R) is a two-step process:

1. $R+P \leftrightarrow RP(\text{closed}). K = 10^7$
2. $RP(\text{closed}) \rightarrow RP(\text{open}). K = 10^{-2}$

Diseases associated with aberrant promoter function

Though OMIM is a major resource for gathering information on the relationship between mutations and natural variation in gene sequence and susceptibility to hundreds of diseases, it requires a sophisticated search strategy to extract those diseases that are associated with defects in transcriptional control where the promoter is believed to have direct involvement.

This is a list of diseases that evidence suggests have some involvement of promoter malfunction, either through direct mutation of a promoter sequence or mutation in a transcription factor or transcriptional co-activator.

Keep in mind that most diseases are heterogeneous in etiology, meaning that one "disease" is often many different diseases at the molecular level, though the symptoms exhibited and the response to treatment might be identical. How diseases respond differently to treatment as a result of differences in the underlying molecular origins is partially addressed by the discipline of pharmacogenomics.

Not listed here are the many kinds of cancers that involve aberrant changes in transcriptional regulation owing to the creation of chimeric genes through pathological chromosomal translocation.

Canonical sequences and wild-type

The usage of canonical sequence for a promoter is often problematic, and can lead to misunderstandings about promoter sequences. Canonical implies perfect, in some sense.

In the case of a transcription factor binding site, then there may be a single sequence which binds the protein most strongly under specified cellular conditions. This might be called canonical.

However, natural selection may favor less energetic binding as a way of regulating transcriptional output. In this case, we may call the most common sequence in a population, the wild-type sequence. It may not even be the most advantageous sequence to have under prevailing conditions.

Recent evidence also indicates that several genes (including the proto-oncogene c-myc) have G-quadruplex motifs as potential regulatory signals.

Diseases associated with promoter elements

- Asthma^{[3][4]}
- Beta thalassemia^[5]
- Rubinstein-Taybi syndrome^[6]

References

- [^] Smale ST, Kadonaga JT (2003). The RNA polymerase II core promoter. *Annu Rev Biochem.* 72, 449-479. PMID 12651739 PDF
- [^] Levine M, Tjian R (2003). Transcription regulation and animal diversity. *Nature.* 424(6945), 147-151. PMID 12853946 PDF
- [^] population genetics study: Hobbs, K.; Negri, J.; Klinnert, M.; Rosenwasser, L.J.; and Borish, L. (1998). Interleukin-10 and transforming growth factor-beta promoter polymorphisms in allergies and asthma. *Am J Respir Crit Care Med.* 158 (6), 1958-1962. PMID 9847292
- [^] population genetics study: Burchard, E.G.; Silverman, E.K.; Rosenwasser, L.J.; Borish, L.; Yandava, C.; Pillari, A.; Weiss, S.T.; Hasday, J.; Lilly, C.M.; Ford, J.G.; and Drazen, J.M. (1999). Association between a sequence variant in the IL-4 gene promoter and FEV(1) in asthma. *Am J Respir Crit Care Med.* 160 (3), 919-922. PMID 10471619
- [^] Kulozik, A.E.; Bellan-Koch, A.; Bail, S.; Kohne, E.; and Kleihauer, E. (1991). Thalassemia intermedia: moderate reduction of beta globin gene transcriptional activity by a novel mutation of the proximal CACCC promoter element. *Blood.* 77 (9), 2054-2058. PMID 2018842
- [^] Petrij F, Giles RH, Dauwerse HG, Saris JJ, Hennekam RC, Masuno M, Tommerup N, van Ommen GJ, Goodman RH, Peters DJ, et al. (1995). Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. *Nature.* 376 (6538), 348-351. PMID 7630403

External links

- Directory of computational tools for detecting promoters in sequence data*: BioDirectory (Directory). *BioDirectory*. Oxford Informatics. Retrieved on 2006-12-11.
- ORegAnno - Open Regulatory Annotation Database
- MeSH *Promoter Regions (Genetics)*
- SwitchDB - An online database used to analyze promoters and transcription start sites (TSSs) throughout the human genome.
- Pleiades Promoter Project - a research project with an aim to generate 160 fully characterized, human DNA promoters of less than 4 kb (MiniPromoters) to drive gene expression in defined brain regions of therapeutic interests.

Retrieved from "http://en.wikipedia.org/wiki/Promoter"

Categories: Gene expression

Hidden categories: Articles with unsourced statements since January 2007 | All articles with unsourced statements

- This page was last modified on 4 March 2008, at 14:27.
- All text is available under the terms of the GNU Free Documentation License. (See **Copyrights** for details.)
Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a U.S. registered 501(c)(3) tax-deductible nonprofit charity.

EXHIBIT B

(19)



(11)

EP 1 616 012 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
19.12.2007 Bulletin 2007/51

(51) Int Cl:
C12N 15/79 (2006.01)

(21) Application number: 04728627.3

(86) International application number:
PCT/IT2004/000227

(22) Date of filing: 21.04.2004

(87) International publication number:
WO 2004/094642 (04.11.2004 Gazette 2004/45)

(54) SYNTHETIC BI-DIRECTIONAL PROMOTERS AND USES THEREOF

SYNTHETISCHE BIDIREKTIONALE PROMOTOREN UND DEREN VERWENDUNGEN
PROMOTEURS BIDIRECTIONNELS DE SYNTHÈSE, ET LEURS UTILISATIONS

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PL PT RO SE SI SK TR

(30) Priority: 24.04.2003 US 465080 P

(43) Date of publication of application:
18.01.2006 Bulletin 2006/03

(73) Proprietor: FONDAZIONE CENTRO SAN
RAFFAELE DEL MONTE TABOR
20132 Milano (IT)

(72) Inventors:

- NALDINI, Luigi
20132 Milano (IT)
- AMENDOLA, Mario
20132 Milano (IT)
- VIGNA, Elisa
20132 Milano (IT)

(74) Representative: Capasso, Olga et al
de Simone & Partners SpA
Via V. Bellini 20
00198 Roma (IT)

(56) References cited:
WO-A-03/087294 US-B1-6 630 324

- YU XIAOBING ET AL: "Lentiviral vectors with two independent internal promoters transfer high-level expression of multiple transgenes to human hematopoietic stem-progenitor cells." MOLECULAR THERAPY: THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY. JUN 2003, vol. 7, no. 6, June 2003 (2003-06), pages 827-838, XP002303041 ISSN: 1525-0016

- FUX CORNELIA ET AL: "Bidirectional expression units enable streptogramin-adjustable gene expression in mammalian cells." BIOTECHNOLOGY AND BIOENGINEERING. 5 SEP 2003, vol. 83, no. 5, 5 September 2003 (2003-09-05), pages 618-625, XP002303042 ISSN: 0006-3592
- FUX CORNELIA ET AL: "Toward higher order control modalities in mammalian cells: Independent adjustment of two different gene activities." BIOTECHNOLOGY PROGRESS, vol. 19, no. 1, 18 January 2003 (2003-01-18), pages 109-120, XP002305563 ISSN: 8756-7938
- UNSINGER J ET AL: "Retroviral vectors for the transduction of autoregulated, bidirectional expression cassettes." MOLECULAR THERAPY: THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY. NOV 2001, vol. 4, no. 5, November 2001 (2001-11), pages 484-489, XP002258698 ISSN: 1525-0016
- UNSINGER J ET AL: "Stable and strictly controlled expression of LTR-flanked autoregulated expression cassettes upon adenoviral transfer" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 319, no. 3, 2 July 2004 (2004-07-02), pages 879-887, XP004512521 ISSN: 0006-291X
- XIE M.; HE Y.; GAN S.: "Bidirectionalization of polar promoters in plants." NATURE BIOTECHNOL. vol. 19, July 2001, pages 677 - 679, XP00239685

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

[0001] The present invention relates to bidirectional promoters allowing efficient and coordinate expression of two or more genes, to gene transfer vectors containing these promoters, to particles transducing said vectors into a cell, to the use of said vectors for the delivery and expression of multiple genes in target cells, also for gene therapy, and for the manufacturing of medicaments.

TECHNICAL BACKGROUND

[0002] Expression of multiple transgenes within the same target cells is required for several gene transfer and therapy applications¹. Gene-function studies are best performed by expressing cDNAs together with a marker gene; by this approach, genetically-modified cells can be identified and monitored *in vitro* and *in vivo*. Similarly, gene therapy applications can be improved by purification of gene-corrected cells before *in vivo* administration, taking advantage of coordinate expression of selectable markers. Genetically-modified cells can be amplified *ex vivo* or *in vivo* by introducing growth-promoting or drug-resistance genes together with the therapeutic gene, as recently shown by MGMT-mediated selection of transduced Hematopoietic Stem Cells (HSC)²; using this approach, the efficacy of gene therapy can be increased, and its application potentially extended to a wide spectrum of diseases^{3,4}.

[0003] Conversely, genetically-modified cells expressing conditionally cytotoxic genes, together with the therapeutic gene, can be eliminated *in vivo*, if adverse events occur; this approach is used to control graft-versus-host disease following donor T-lymphocytes infusion to treat leukemia relapse⁵; it may also provide an important safety provision in HSC gene transfer, given the recent occurrence of leukemia related to vector integration in a successful clinical trial of X-linked Severe Combined Immunodeficiency⁶. Coordinate expression of more than one transgene is essential when the activity to be reconstituted by gene transfer depends on multiple subunits encoded by different genes, or requires the synergism of separate molecules. For instance, reconstitution of the dopamine biosynthetic pathway in striatal neurons of Parkinson's disease patients requires co-expression of tyrosine hydroxylase with GTP-cyclohydrolase I and/or DOPA decarboxylase⁷; cancer gene therapy may require co-expression of multiple antigens and/or cytokines in antigen-presenting cells for immunotherapy, and of two T-cell receptor chains in T-cells engineered for adoptive transfer⁸.

[0004] In spite of such well-recognized needs, reaching coordinate, high-level expression of multiple transgenes in the majority of target cells has been a significant challenge for gene transfer technology. Two different transgenes have been expressed by two separate vectors; yet, only a fraction of target cells was transduced by both vectors and a heterogeneous population of cells was obtained that expressed either one or two genes in different ratios, preventing reliable studies and/or efficacious applications. Alternatively, two or more transgenes have been expressed by different promoters within the same vector⁹; yet, different tissue specificity and mutual interference between promoters often prevented efficient co-expression in the same target cells¹⁰. Differential splicing generates multiple transcripts from the same promoter, but it has proven difficult to adapt to viral delivery of multiple transgenes¹¹. Chimeric polyproteins that self-process co-translationally into separate components have been generated using the self-cleaving peptide of the Foot and Mouth Disease Virus 2A^{12, 13}; however, application of this technology to multiple gene transfer has been limited until now because it requires sophisticated engineering, restricts both proteins to the same cellular compartment, and introduces sequence changes that may affect protein activity, stability, and immunogenicity.

[0005] The most satisfactory approach to multiple gene transfer until now has relied on using internal ribosome entry sites (IRES's)¹⁴. These sequences, identified in viral and cellular transcripts, control translation in a mRNA^{5'}Cap-independent manner and, when inserted between two genes in a bicistronic messenger RNA, allow translation of the downstream gene. The authors tested the performance of different IRES's in the context of self-inactivating (SIN) lentiviral vectors (LVs), and found significant limitations of this approach.

[0006] WO 02/064804 describes bi-directional dual promoter complexes that are effective for enhancing transcriptional activity of promoters in plants.

[0007] The bi-directional promoters of the invention include a modified enhancer region with at least two core promoters on either side of the modified enhancer in a divergent orientation. The application refers to gene expression in plants. In addition, the approach requires the duplication of tandem oriented enhancer sequences in a modified internal region of the construct, to be joined by two identical or homologous minimal promoters on either sides. The instant invention does not require duplication of enhancer or any other sequences in the efficient promoter of the bi-directional construct, nor are need that the core promoters on either sides of it to share at least 30% identity. Finally, tandem duplication may be incompatible with retro/lentiviral delivery.

[0008] US 6,388,170 discloses plant vectors, having bi-directional promoters, comprising a minimal promoter and a common promoter, wherein said minimal promoters is operably linked to said common promoter, in opposite orientation to said common promoter, and 5' to said common promoter. Promoter sequences derived from plants and plant-infecting viruses are disclosed and tested in plant cells or plant parts.

[0009] Given the substantial evolutionary distance between plants and animals, US 6,388,170 does not teach how to

engineer animal promoters for bidirectional activity and whether bi-directional promoters may effectively work in animal cells. In addition, US 6,388,170 does not teach how to engineer bi-directional promoters for gene expression in animals and in animal cells using the available gene transfer methods.

[0010] WO01/34825 discloses cell lines, plasmids and vectors useful for the production of recombinant viruses such as adenoviruses, which are useful in gene therapy. The cell lines, plasmids and vectors comprise inducible promoters, such as bi-directional promoters for the coordinate expression of bidirectionally cloned gene. However only bi-directional Tet-regulated constructs are disclosed.

[0011] Thus, the authors explored novel strategies to take full advantage of gene transfer systems, such as LV, that allow efficient ex vivo transduction and direct in vivo administration.

DESCRIPTION OF THE INVENTION

[0012] The authors developed a novel vector design in which synthetic bi-directional promoters mediated coordinate transcription of two divergent RNAs. The authors show that LVs carrying bi-directional promoters coordinately expressed two transgenes in the vast majority of transduced cells clearly outperforming the bicistronic vectors. The efficient performance of the new bi-directional LVs in primary hematopoietic cells, assayed ex vivo and after transplantation, and in several tissues in vivo, after direct vector delivery or transgenesis was established. The invention overcomes a long-standing hurdle in the quest for improved gene-expression tools and are expected to advance the reach and safety of gene therapy.

[0013] It is therefore an object of the instant invention a bidirectional promoter for expression of at least two coding sequences in opposite direction in animal cells comprising 5' end to 3' end:

- a) a first minimal promoter sequence derived from cytomegalovirus (CMV) or mouse mammary tumor virus (MMTV) genomes;
- b) a full efficient promoter sequence derived from an animal gene;

the two promoter sequences driving a coordinate transcription of said coding sequences in the opposite orientation.

[0014] In the ambit of the instant invention a full efficient promoter sequence means a sequence driving an efficient transcription of primary transcript. Preferably It comprises an enhancer region and a minimal promoter sequence, either distinct or overlapping. More preferably the full efficient promoter sequence derives from the phosphoglycerate kinase or from the ubiquitin promoter.

[0015] It is an object of the invention a bidirectional expression cassette essentially comprising the bidirectional promoter as above disclosed, convenient insertion sites positioned downstream to each promoter, and polyadenylation sites positioned downstream to each insertion site.

[0016] Preferably the bidirectional expression cassette further comprises at least one post-transcriptional regulatory element positioned upstream to one or each polyadenylation site. More preferably the bidirectional expression cassette further comprises at least one internal ribosome entry site (IRES) sequence to express three or more genes.

[0017] It is an object of the invention an expression construct containing the bidirectional promoter, as above disclosed.

[0018] It is an object of the invention an expression construct containing the bidirectional expression cassette, as above disclosed.

[0019] It is an object of the invention a gene transfer expression vector containing the expression construct as above disclosed further comprising lentiviral or retroviral sequences.

[0020] It is an object of the invention the use of the gene transfer expression vector for the preparation of a delivery and expression system in animal cells, preferably in vivo tissue animal cells, more preferably, brain neurons.

[0021] It is an object of the invention an in vitro method for the coordinate expression of two exogeneous coding sequences into an animal cell comprising the following steps:

- a) cloning said coding sequences into the gene transfer expression vector according to claim 8, each coding sequence under the control of one of the two promoters of the bidirectional promoter;
- b) transforming animal cells by means of said vectors;
- c) allowing the expression of the vector.

[0022] Preferably the animal cell is a human cell, more preferably the human cell is a retransplantable human cell, even more preferably the retransplantable human cell is an hematopoietic cell.

[0023] Alternatively, the transformation of tissue cells in vivo may be performed by direct delivery of the vector, such as into brain neurons.

[0024] It is an object of the invention a method for generating a transgenic non human organism comprising the step of transforming appropriate cells by means of the gene transfer expression vector as disclosed above.

[0025] The vectors of the invention can be advantageously utilized for gene function and target validation studies in vitro and in vivo; gene therapy; expression of multiple genes in animal cells; generation of transgenic animals and eventually knock down of multiple genes; and for manufacturing of medicaments, as well.

FIGURE LEGENDS

[0026] The invention will be now described with reference to following Figures:

Fig. 1. Gene transfer performance of bicistronic lentiviral vectors. (a) Scheme of the proviral vector form. A bicistronic expression cassette containing an internal ribosome entry site (IRES) derived either from the encephalomyocarditis virus (EMCV), with wild-type (wt) or mutated (mut) translation start site, or from the 5' untranslated NF- κ B repressing factor mRNA (NRF) was driven by the human immediate early cytomegalovirus (CMV) or phosphoglycerate kinase (PGK) promoter. Δ U3, R and U5, LTR regions with deletion in U3; SD and SA, splice donor and acceptor site; ψ , encapsidation signal including the 5' portion of the gag gene (GA); RRE, Rev-response element; cPPT, central polyuridine tract; WPRE, woodchuck hepatitis virus post-transcription regulatory element. (b) Southern blot analysis of HeLa cells transduced by the indicated monocistronic (CMV) or bicistronic vectors expressing luciferase (gene 1) and GFP (gene 2) from the CMV promoter, probed for the WPRE sequence. All vector integrated with the expected length of DNA. Vector copy number was determined relative to a plasmid standard curve and used to normalize vector stocks and ensure similar levels of integration for each vector in a given target cell type in the experiments shown in c-f. (c-f) Luciferase and GFP expression in human HeLa cells (c), umbilical vein endothelial cells (HUVEC, d), peripheral blood lymphocytes (PBL, e), and cord blood-derived CD34+ progenitors (f) transduced 5-7 days before with a monocistronic (□, CMV) or the indicated bicistronic CMV-luciferase-GFP vector. Left column, histograms representing net luciferase activity in cells extracts, mean \pm SD. Right panel, dot plots representing GFP expression by FACS analysis, the frequency and the mean fluorescence intensity (MFI, X) of GFP+ cells is indicated. The control monocistronic vector expressed luciferase in the histogram (□), and GFP in the leftmost dot plot (CMV) for each cell type. (g, h) FACS analysis of Δ NGFR and GFP expression in 293T cells (g) and CD34+ progenitors (h) transduced by a EMCV wt IRES vector expressing Δ NGFR and GFP from the PGK promoter. Histograms in panel (h) show the distribution of Δ NGFR expression in all viable cells analysed (left), and of GFP expression in the gated (M1) Δ NGFR+ cells (right). Experiments shown are representative of at least three performed with similar results.

Fig. 2. Gene transfer performance of bidirectional lentiviral vectors. (a) Scheme of the proviral vector form. A bidirectional promoter made by minimal core promoter elements from the human cytomegalovirus (hCMV) joined upstream, and in opposite orientation, to an efficient promoter, derived from the human phosphoglycerate kinase (PGK) or poly-ubiquitin UBI-C gene, was driving divergent transcription of two RNAs. CTE, constitutive transport element from the Mason-Pfizer monkey virus; pA, polyadenylation site A from the Simian Virus 40. Other vector features as in the legend to figure 1. (b) Net luciferase activity and (c-e) GFP expression in HeLa cells transduced 5-7 days before with LVs carrying the indicated bi-directional or control expression cassettes. The frequency and MFI (X) of GFP+ cells at FACS analysis is indicated in the dot plots to the right. Luciferase activity was determined for the two marked vectors (□, ■). (f-j) Δ NGFR and GFP expression in HeLa cells transduced 5-7 days before with serial 10-fold dilutions of LVs carrying the indicated expression cassette. The frequency of Δ NGFR+ (upper left region) and Δ NGFR/GFP double positive (upper right region) cells, with the respective MFI of Δ NGFR (Y) and GFP (X), are indicated in the FACS dot plots. Experiments shown are representative of at least three performed with similar results.

Fig. 3. Comparison of bi-directional and bicistronic lentiviral vectors performance. Δ NGFR and GFP expression in 293T cells transduced 3 weeks before with serial 10-fold dilutions of LVs carrying the indicated expression cassette. The total percentage of Δ NGFR-expressing cells and of Δ NGFR/GFP double positive cells (in brackets) are indicated above the FACS dot plots. The average number of vector Copies per Cell (CpC) is indicated in each plot, with the expected frequency of transduced cells according to the Poisson's distribution of random independent events. Although virtually all integrated vectors expressed Δ NGFR, its level of expression and the fraction of transduced cells co-expressing GFP were much higher for the two bi-directional vectors tested (MA1 and MA4) as compared to the EMCV wt IRES bicistronic vector.

Fig. 4. Dual-gene transfer in hematopoietic cells by bi-directional vectors. (a-c) Human cord blood CD34+ progenitors were transduced by the GFP- Δ NGFR MA1 vector in the presence of early acting cytokines as described²³, and analysed either after 7 days of culture in the same medium (a), and after additional 10 days in medium promoting myeloid differentiation (b), or after seeding in methylcellulose-based clonogenic medium. For (a) and (b), a dot plot showing Δ NGFR and GFP expression by FACS analysis is shown, together with histograms showing the distribution of Δ NGFR expression in all viable cells analysed (top), and of GFP expression in the gated (M1) Δ NGFR+ cells (bottom). The percentage of immature progenitors expressing CD34, and of differentiating cells expressing the CD 13 myeloid marker at the time of analysis is indicated. For (c), representative light (left) and fluorescent (right)

micrograph of the indicated type of CFC are shown. (d, e) Human peripheral blood lymphocytes were transduced either after 2-day activation with anti-CD3 and anti-CD28 antibodies (d), or after 4-day treatment with Interleukin-7, as described²⁴, (e), and analyzed for Δ NGFR and GFP expression as described above. (f, g) Purified (lin-) murine bone marrow progenitors were transduced without cytokine stimulation as described⁴⁸, and analyzed for Δ NGFR and GFP expression after 7 days in liquid culture (f), or immediately transplanted into lethally-irradiated syngeneic recipients. FACS analysis of the peripheral blood of a representative mouse 2 months after transplant is shown in g. Experiments shown are representative of three performed with similar results. In d-f, cells transduced to low vector copy numbers are shown for more stringent performance analysis.

Fig. 5 In vivo dual-gene transfer by bi-directional vectors. High-titer of GFP- Δ NGFR MA1 LV were stereotactically injected into the striatum of adult mice. Cryostatic brain sections were obtained two months after injection and analyzed by immunofluorescence and confocal microscopy. Representative pictures of the injected area are shown, after immunostaining for Δ NGFR (red), GFP (green), and TO-PRO3 staining for nuclear DNA (blue). Fluorescent signals were sequentially acquired from single optical sections and are shown individually and after merging (merge). Original magnification 200X (Scale bar = 120 μ m)

Fig. 6 Dual-transgenesis by bi-directional vector. Transgenic mouse lines were generated by direct injection of GFP- Δ NGFR MA1 LV into the perivitelline space of single-cell embryos, as described¹⁹, and the indicated tissues were analyzed for Δ NGFR (red) and GFP (green) expression by immunofluorescence and confocal microscopy on cryostatic sections. Nuclei were stained by TO-PRO3 (blue). Fluorescent signals were sequentially acquired from single optical sections and are shown individually and after merging (merge). The pictures shown were obtained from an F1 mouse carrying two vector genomes integrated into the germ-line. Similar pictures were obtained from other transgenic mice analyzed that carried similar or higher number of vector copies. Original magnification 200X (spleen, lung), 400X (heart, kidney, brain, liver), 630X (gut) (Scale bar = 120 μ m)

Fig. 7a Map of the plasmid containing the lentiviral vector construct RRL-MA1-lucif/GFP.

Fig. 7b Sequence of the plasmid containing the lentiviral vector construct RRL-MA1-lucif/GFP.

Fig. 8a Map of the plasmid containing the lentiviral vector construct CCL-MA1-GFP/deltaLNGFR.

Fig. 8b Sequence of the plasmid containing the lentiviral vector construct CCL-MA1-GFP/deltaLNGFR.

Fig. 9a Map of the plasmid containing the lentiviral vector construct RRL-MA2-lucif/GFP.

Fig. 9b Sequence of the plasmid containing the lentiviral vector construct RRL-MA2-lucif/GFP.

Fig. 10a Map of the plasmid containing the lentiviral vector construct CCL-MA3-GFP/deltaLNGFR.

Fig. 10b Sequence of the plasmid containing the lentiviral vector construct CCL-MA3-GFP/deltaLNGFR.

Fig. 11a Map of the plasmid containing the lentiviral vector construct CCL-MA4-GFP/deltaLNGFR.

Fig. 11b Sequence of the plasmid containing the lentiviral vector construct CCL-MA4-GFP/deltaLNGFR.

EXAMPLE 1

MATERIALS AND METHODS

Plasmid construction

[0027] All transfer vectors were built from plasmid pCCL.sin.cPPT.PGK.GFP.WPRE¹⁵ using the following previously described sequence elements: EMCV IRES's with the downstream gene coding sequence starting at the 11th ATG of the IRES (wt) or with the 11th ATG of IRES mutated to create a HindIII cloning site and allow translation initiation at the downstream transgene ATG¹⁶(EMCVmut), the NRF IRES¹⁶, the MPMV CTE²¹, a minimal CMV core promoted²⁰, a 1226 bp fragment from the Ubiquitin-C promoter¹⁹.

Construction of lentiviral vector with bi-directional promoters

[0028] To generate the lentiviral construct **RRL-MA1**, an XhoI-XhoI fragment containing the SV40polyA.CTE.Luciferase.minhCMV elements (derived from the lentiviral construct

[0029] pRRL.sin.cPPT.SV40polyA.CTE.Luciferase.minhCMV.TetO7.minMMTV.eGFP) was cloned into the lentiviral vector construct pRRL.sin.cPPT.hPGK.eGFP.Wpre (Follenzi et al., 2000) cut with the same enzyme to obtain RRL-MA1-lucif/GFP (pRRL.sin.cPPT.SV40polyA.CTE.Luciferase.minhCMV.hPGK.eGFP.Wpre).

[0030] To generate the lentiviral construct **CCL-MA1**, two fragments were cloned into the lentiviral construct pRRL.sin.cPPT.hPGK.ALNGFR.Wpre first cut with KpnI, blunted and then cut with XhoI, the first fragment containing the minhCMV.eGFP elements was derived from the lentiviral construct pRRL.sin.cPPT.SV40polyA.CTE.Luciferase.minMMTV.TetO7.minhCMV.eGFP cut with KpnI, blunted and then with XhoI and the second derived from the construct pRRL.sin.cPPT.SV40polyA.CTE.1TA2.Wpre cut with BamHI, blunted and then cut with NotI. The resulting lentiviral construct pRRL.sin.cPPT.SV40polyA.CTE.Luciferase.minMMTV.TetO7.minhCMV.eGFP was cut with NotI and AvrII

and the fragment containing the cPPT.SV40polyA.CTE.eGFP.minhCMV.hPGK. Δ LNFRWpre was cloned into the lentiviral construct pCCL.sin.cPPT.hPGK.eGFP.Wpre cut with the same enzymes to obtain CCL-MA1-GFP/ Δ LNFR (pCCL.sin.cPPT.SV40polyA.CTE.eGFP.minhCMV.hPGK. Δ LNFRWpre).

[0031] To generate the lentiviral construct RRL-MA2, a HindIII-BamHI fragment containing the hFGK.Luciferase elements (derived from the lentiviral vector construct pRRL.sin.cPPT.hPGK.Luciferase.IRES.Wpre) was cloned into the retroviral construct SF2-clCM2G (obtained from Rainer Loew, University of Heidelberg, FRG) cut with the same enzymes to obtain the construct cPPT.SV40polyA.CTE.Luciferase.hPGK.minMIVITV.eGFP. This construct was first cut with SalI, blunted and then cut with BamHI and the fragment containing the Luciferase.hPGK.minMMTV.eGFP elements was cloned into the lentiviral vector construct pRRL.sin.cPPT.SV40polyA.CTE.IA2.Wpre cut in the same way, to obtain RRL-MA2-lucif/GFP (pRRL.sin.cPPT.SV40polyA.CTE.Luciferase.hPGK.minMMTV.eGFP.Wpre).

[0032] To generate the lentiviral construct CCL-MA3, two fragments were cloned into the pBKS+ cut with HindIII and XhoI, the first fragment containing the CTE.SV40polyA elements was derived from the lentiviral vector construct pRRL.sin.cPPT.SV40polyA.CTE.IA2 cut with HindIII and XbaI and the second fragment containing the minMMTV.GFP elements derived from the construct cPPT.SV40polyA.CTE.Luciferase.hPGK.minMMTV.eGFP cut with XhoI and XbaI to obtain the construct pBKS+ minMMTV.GFP.CTE.SV40polyA. The resulting construct was cut with EcoRV and XhoI and the fragment containing the minMMTV.GFP.CTE.SV40polyA was cloned into the lentiviral vector construct pCCL.sin.cPPT.hPGK. Δ NGFR. Wpre cut with the same enzymes, to obtain the final lentiviral vector construct CCL-MA3-GFP/ Δ NGFR (pCCL.sin.cPPT.SV40polyA.CTE.GFP.minMMTV.hPGK. Δ NGFR.Wpre).

[0033] To generate the lentiviral construct CCL-MA4 the fragment derived from pHR⁺.UBI-C.eGFP cut with PacI, blunted and cut with PstI, containing the UBI-C promoter sequence, was inserted into the place of the PGK promoter into construct pCCL.sin.cPPT.SV40polyA.CTE.GFP.minCMV.PGK. Δ NGFR.Wpre cut with EcoRV and PstI to obtain the final lentiviral vector construct CCL-MA4-GFP/ Δ NGFR (pCCL.sin.cPPT.SV40polyA.CTE.GFP.minCMV.UBI-C. Δ NGFR.Wpre).

[0034] The maps and the nucleotide sequences of the RRL-MA1-lucif/GFP, CCL-MA1-GFP/ Δ LNFR, RRL-MA2-lucif/GFP, CCL-MA3-GFP/ Δ NGFR, CCL-MA4-GFP/ Δ NGFR constructs are shown respectively in figures 7a-11a and figures 7b-11b.

Vector production and titration

[0035] VSV-pseudotyped third-generation LV were produced by transient 4-plasmid co-transfection into 293T cells and purified by ultracentrifugation as described¹⁵, with the modification that 1 mM NaButyrate was added to the cultures for vector collection⁴⁷. Expression titer of GFP or Δ LNFR vectors were estimated on HeLa cells by limiting dilution. Vector particle was measured by HIV-1 gag p24 antigen immunocapture (NEN Life Science Products). Vector infectivity was calculated as the ratio between titer and particle for the vector expressing GFP or Δ NGFR. Vector expression titer in the 293T supernatant ranged from 0.7 to 1×10^7 Transducing Units^{rel.u}(TU)/ml for monocistronic CMV or PGK vector, from 3 to 8×10^5 TU/ml for bicistronic vectors and bi-directional vectors. Vector infectivity ranged from 0.5 to 1×10^5 TU/ng of p24 for monocistronic CMV or PGK vector, and from 2 to 6×10^4 TU/ng of p24 for bicistronic and bi-directional vectors.

Cell cultures

[0036] Continuous cultures of HeLa and 293T cells were maintained in Iscove's modified Dulbecco's medium (IMDM; Sigma, Milan, Italy) supplemented with 10% fetal bovine serum (FBS; Gibco, Invitrogen Corporation, UK) and a combination of penicillin-streptomycin and glutamine. Primary cultures of human umbilical vein endothelial cells (HCTVECs), peripheral blood lymphocytes, and cord blood CD34+ progenitors were obtained and maintained as described¹⁵. CD34+ progenitors were transduced with 5×10^7 TU/ml of LV and cultured for at least 7 days in the presence of recombinant human interleukin 6 (rhIL6, 20 ng/ml), recombinant human stem cell factor (rhSCF, 100 ng/ml), recombinant human FLT-3 ligand (rhFLT-3 ligand, 100 ng/ml), all from PeproTech (Rocky Hill, NJ), and recombinant human thrombopoietin (rhTPO, 20 ng/ml; Amgen, Thousand Oaks, CA) as described²³. For differentiating conditions, transduced progenitors were cultured for 10 days in the presence of rhSCF, 50 ng/ml, recombinant human granulocyte monocyte-colony stimulating factor (rhGM-CSF, 20 ng/ml), recombinant human monocyte-colony stimulating factor (rhG-CSF, 20 ng/ml), all from PeproTech. For clonogenic assays, transduced cells were plated at a density of 800 cells/ml in human complete MethoCult medium (StemCell Technologies, Vancouver, CA) and were scored by light and fluorescence microscopy 14 days later.

[0037] Human peripheral blood lymphocytes were purified by Ficoll gradient and transduced with 0.5×10^7 TU/ml of vector either after 2-day activation with 30 ng/ml anti-CD3 antibodies (Orthoclone, Milan, Italy) plus 1 μ g/ml anti-CD28 antibodies (PharMingen, San Diego, CA), or after 4-day treatment with 5 ng/ml interleukin-7 (Boehringer Mannheim-Roche GmbH, Mannheim, Germany), as described²⁴.

[0038] Purification of lineage marker-negative cells from C57BL/6 mouse bone marrow with a magnetic cell depletion

technique (StemCell Technologies, Vancouver, CA), *ex vivo* transduction in serum-free StemSpan medium (StemCell Technologies, Vancouver, CA) with $0.5\text{--}2 \times 10^7$ TU/ml of vector, and transplantation into lethally irradiated syngenic recipients were performed as described⁴⁸.

Mice

[0039] CD1, C57BL/6 and FVB mice were purchased from Charles Rivers Laboratories (Calco, Italy) and maintained in SPF conditions. All animal procedures were performed according to protocols approved by the Hospital San Raffaele Institutional

[0040] Animal Care and Use Committee.

DNA analysis: Southern and real time PCR

[0041] Vector copies per genome were quantified by Real-Time PCR from 300 ng template DNA extracted from cells by a commercial kit (Qiagen), using one set of primers and probe to detect the LV backbone:

LV forward primer, 5'-TGAAAGCGAAAGGGAACCA-3';

LV reverse primer, 5'-CCGTGCGCGCTTCAG-3';

LV probe, 5'-(VIC)-CTCTCTCGACGACGAGACT-(TAMRA)-3'.

[0042] Reactions were carried out according to manufacturer instructions and analysed using the ABI Prism 7700 sequence detection system (PE-Applied Biosystem). For Southern blot, DNA was extracted from transduced cells, digested with Afl-II to release the expression cassette from integrated vector DNA and analysed with a WPRE probe to detect vector sequences. The average number of integrated vector copies was determined relative to a plasmid standard curve.

[0043] These numbers were used to calculate vector integration titer and normalize vector stocks for all subsequent transduction experiments to ensure similar levels of integration for each vector tested.

Experimental Design and Stereotactic Injection.

[0044] Nine weeks-old C57BL/6 mice were anesthetized with intraperitoneal injection of Tribromoethanol 1.25% (SIG-MA), positioned in a stereotactic frame (David Kopf Instruments, Tujunga, CA) and the skull exposed by a small incision. Two μ l of vector concentrate (2×10^8 TU/ μ l) was injected by a Hamilton syringe with a 33G blunt tip needle (Hamilton; Reno, NV) into the left hemisphere striatum (stereotactic coordinates in mm from bregma: AP=+0.74, ML=-1.9 and DV=-3.5 from skull surface) at a rate of 0.2 μ l/min. The needle was left in place for additional 5 minutes before slow removal.

Transgenesis

[0045] Transgenic mice were generated using LV as described by Lois et al.¹⁹. Briefly, female FVB mice were super-ovulated with a combination of pregnant mare serum and human chorionic gonadotropin. On average between 20 and 30 embryos were collected per female and microinjected into the perivitelline space with 10-100 pL of 5×10^7 TU/ml LV stock on the same day. Manipulated embryos were immediately implanted into the oviduct of pseudopregnant CD1 mice. Pups were genotyped for the presence of the GFP sequence by PCR analysis as described⁴⁹. Positive mice were bred to test germ-line transmission of the transgene. DNA was extracted from the tail and used to quantify vector copy number by real time PCR in founder and F1 progeny mice.

Flow cytometry and Luciferase assay

[0046] Transduced cells were grown for at least 4 days before FACS analysis to reach steady state GFP expression and to rule out pseudotransduction. Before FACS analysis, adherent cells were detached with 0.05% trypsin-EDTA, washed, and fixed in phosphate buffer saline (PBS) containing 1% paraformaldehyde (PAF) and 2% FBS. Cells grown in suspension were washed and resuspended in PBS containing 2 μ g/ml propidium iodide (PI) (BD Bioscience Pharmingen, San Diego, CA) and 2% FBS. For immunostaining, 10^5 cells were blocked in PBS 5% mouse serum, 5% human serum, 2% FBS for 15 min at 4°C. After blocking, 10 μ l of R-phycoerythrin (RPE)-conjugated antibodies (anti-CD34 and anti-CD13, Dako, Glostrup, Denmark, and anti- Δ LNGFR, BD Bioscience Pharmingen, San Diego, CA) were added and the cells were incubated for 30 min at 4°C, washed, stained with PI, and analyzed by three-color flow cytometry. Only viable, PI-negative cells were used for the analysis.

[0047] Luciferase was assayed in cell lysates prepared as described by the manufacturer (luciferase assay system,

Promega). RLU were measured with a Lumat LB9507 luminometer (Berthold) after mixing cell lysates (normalized for protein content measured by BCA Protein Assay Reagent kit Pierce) with Luciferase Substrate (Promega).

Tissue analysis

[0048] Anesthetized mice were perfused with 0.9% NaCl followed by 4% PAF in PBS. Tissue samples were collected, equilibrated in 20% sucrose in PBS for 48 h at 4°C, and embedded in optimal-cutting-temperature compound (OCT) for quick freezing. 10µm (for transgenic mice) and 20µm (for stereotactically injected mice) thick cryostat sections were post-fixed in PAF and frozen at -80 °C. Sections were blocked with 5% goat serum (Vector Laboratories) in PBS containing 1% bovine serum albumin (BSA) and 0.1% Triton X-100 (PBS-T), and incubated with rabbit affinity-purified GFP antibody (Molecular Probes) and R-phycocerythrin (RPE)-conjugated ΔLNGFR monoclonal antibody (BD Bioscience PharmLing, San Diego, CA) for 1 h, washed and stained with AlexaFluor488-conjugated goat anti-rabbit antibody (Molecular Probes) in PBS-T and 1% BSA for 1 h. Cell nuclei were stained with TOPRO-3 after 1 h of RNase treatment (Molecular Probes). Sections were mounted and analyzed by three-laser confocal microscope (Radiance 2100; BioRad). Fluorescent signals from single optical sections were sequentially acquired and analyzed by PhotoShop 7.0 (Adobe).

RESULTS

Bicistronic LVs

[0049] In order to express more than one transgene from a single vector, the authors first evaluated the performance of different IRES's in the context of late-generation self-inactivating LVs¹⁸. They used the strong CMV and PGK promoters to drive expression of bicistronic transcripts encoding, from the 5' to the 3' end, the luciferase reporter, an IRES, and the cell-associated GFP marker (fig. 1a). Two IRES's were derived from the Encephalomyocarditis virus; a wild-type (EMCVwt) and a mutant (EMCVmut) form^{16,17}, that differed for the ATG from which downstream translation started. Another IRES was derived from the 5' untranslated sequence of the NF-κB transcription Repressing Factor (NRF) mRNA¹⁸.

[0050] They generated high-titer VSV-pseudotyped stocks of all bicistronic and control monocistronic vectors, and normalized them for transducing activity measuring Integration in HeLa cells by Southern blot (fig. 1b). They then compared gene expression in cells transduced to equal vector copy numbers (Fig. 1c-f). Although luciferase activity was similar in HeLa cells transduced by CMV-luciferase vector and in cells transduced by the best performing bicistronic vector, only a small fraction of the latter cells expressed the IRES-dependent GFP gene, with a ten-fold decrease in expression titer as compared to cells transduced by the control CMV-GFP vector (Fig. 1c). Moreover, the GFP mean fluorescence intensity (MFI) was significantly lower in cells expressing the protein from the IRES's than in cells expressing it from the mRNA^{Cap}. They then tested bicistronic LVs in primary human cells, including umbilical vein endothelial cells, peripheral blood lymphocytes, and CD34⁺ cord blood hematopoietic progenitors (HPC) (Fig. 1d-f). All cell types were transduced efficiently, as indicated by the frequency of GFP-positive cells in cultures transduced by control CMV-GFP vector, but IRES-dependent GFP expression was only observed in a fraction of cells transduced by bicistronic vectors. IRES activity varied extensively with the target cell type; the NRF IRES was the only one reaching detectable downstream gene expression in lymphocytes, while the EMCVwt IRES was the most efficient in the other cell types. In addition, all IRES's decreased, in some cases more than one log, upstream gene expression, as compared to the control CMV-luciferase vector.

[0051] They also evaluated IRES-based vectors by expressing two cell-associated markers, GFP and a truncated version of the low-affinity NGF receptor (ΔLNGFR) (Fig. 1g,h). Among HeLa cells transduced by a low dose of the best-performing bicistronic vector, only the cells expressing high levels of ΔLNGFR also expressed GFP, with an average of one out of four ΔLNGFR-positive cells expressing GFP to detectable levels (Fig. 1g). Similarly, only a small fraction of transduced CD34⁺ progenitors expressing ΔLNGFR also expressed GFP to detectable levels (Fig. 1h). Overall, these results indicated that IRES-based bicistronic vectors failed to ensure coordinate expression of two transgenes in most target cell types tested, and that multi-copy transduction or selection of transduced cells for downstream gene expression were required to obtain a population expressing both transgenes in the majority of cells. *Bidirectional LVs*

[0052] To overcome the limitations of bicistronic vectors, the authors explored a new promoter design for coordinate transgene expression. They joined a minimal core promoter upstream, and in opposite orientation, to an efficient promoter. Rationale of this design was that upstream elements in the efficient promoter, when closely flanked by core promoters on both sides, may drive transcriptional activity in both directions. If such bi-directional activation occurred, expression of both transcripts would be coordinately regulated. They tested two ubiquitously expressed promoters, previously shown to drive robust and efficient transgene expression in LV; the above mentioned 516 bp fragment from the human phosphoglycerate kinase promoter (PGK)¹⁹ and a 1226 bp fragment from the human ubiquitin C promoter (UBI C)¹⁹. They joined them to a minimal core promoter derived from the cytomegalovirus (minCMV) that was previously developed to

couple initiation of eukaryotic transcription to tetracycline (Tc)-dependent operators²⁰. They flanked the bi-directional promoter with two expression cassettes optimized for LV-mediated gene delivery (fig. 2a). The upstream cassette - in anti-sense orientation relative to the vector LTR - included the constitutive transport element (CTE) of the Mason-Pfizer virus²¹, and a polyadenylation site from the Simian Virus 40 (SV40). The downstream cassette included the woodchuck hepatitis virus post-transcriptional regulatory element (WPRE)²² and the SIN HIV-1 LTR polyadenylation site.

[0053] As described above for bicistronic LVs, they verified correct transfer and normalized transduction of each vector by Southern blot analysis and real-time PCR of transduced cells. LV carrying bi-directional expression cassettes were produced to high titer and infectivity, similar to those obtained with standard vectors (see Methods). The bi-directional design significantly enhanced transcription from the upstream minimal promoter without affecting downstream expression from the efficient promoter (fig. 2b-h). Luciferase expression from the minCMV promoter, for instance, was increased at least one log when fused upstream to the PGK promoter (fig. 2b). Remarkably, the bi-directional PGK promoter allowed detecting GFP (or Δ LNFR, not shown) to the same frequency and to similar expression levels in cells transduced by the bi-directional vector and expressing the protein from either side of the promoter (fig. 2c,d), as in cells transduced by the control PGK vector (fig. 2e). Using two cell-associated markers, Δ LNFR and GFP, they showed stable, efficient and coordinate expression of bi-directional LVs, both at high and low vector copy number (fig. 2f). At high vector input, they reached high-level expression of both transgenes in virtually every target cell. At low vector input, when most transduced cells carried one proviral copy, they showed transgene co-expression in virtually every labeled cell, indicating the occurrence of divergent transcription from the bi-directional promoter. In both conditions, transgene expression was maintained to similar levels in cells analyzed at early and late times post-transduction (not shown, and Fig. 3 below). Transgene-expressing cells tended to distribute along a diagonal line in the two-color FACS plot, indicating that expression of the two transgenes was coordinately regulated.

[0054] Intriguingly, they observed coordinate bi-directional expression, although to significantly lower efficiency on the upstream side than the downstream side, when they tested the sole PGK promoter in the context of the bi-directional expression cassette that they developed (fig. 2g). They reproduced this finding after swapping the position of the two transgenes on each side of the PGK promoter (not shown). These results indicated that transcription-activating elements in the PGK promoter are intrinsically capable of triggering divergent transcription and thus provide the main driving force for dual-gene expression in the new LV, ensuring coordinate regulation of transcription on both sides of the bi-directional promoter. Apposition of the minCMV core promoter, which had a very low activity *per se* (fig. 2h, and 2b above), enhanced upstream transcription from the PGK promoter possibly because of more efficient initiation (compare fig. 2g and 2f). When they changed the driving promoter in bi-directional vectors from PGK to UBI-C, they reproduced the findings observed with the PGK promoter (fig. 2i). They revealed an intrinsic bi-directional activity of the UBI-C promoter (fig. 2j) that was significantly enhanced by the upstream addition of the minCMV promoter.

[0055] They then compared directly the performance of bi-directional and bicistronic vectors in relation to the number of integrated copies, as measured by real-time PCR (Fig. 3). By analyzing 293T cells transduced with increasing vector doses, they proved that the vast majority of integrated bi-directional vectors based on the PGK (MA1) or UBI-C (MA4) promoter efficiently expressed both transgenes, clearly outperforming the best IRES-based bicistronic vector.

Ex Vivo and In Vivo Dual-Gene Transfer

[0056] They then assessed the performance of the bi-directional MA1 LV in more relevant targets for gene therapy applications and by different delivery strategies. They transduced human cord-blood HPC and PBL with Δ LNFR-GFP MA1 LV *ex vivo*, according to previously optimized protocols^{23, 24} (Fig. 4). Both gene products were coordinately expressed to high-levels in a large fraction of HPC scored both as immature cells grown in the presence of early-acting cytokines (Fig. 4a), and after differentiation in liquid culture (Fig. 4b) or clonogenic assay (Fig. 4c, GFP only). Similarly, they obtained coordinate Δ LNFR and GFP expression in PBL transduced in standard conditions of proliferation, triggered by CD3/CD28 co-stimulation (Fig. 4d), and as non-proliferating cells, treated only with IL-7 to maintain naive cell properties (Fig. 4e). They also performed transplantation studies with transduced murine HPC, enriched from the bone marrow by negative selection, to prove stable dual-transgene expression in the progeny of long-term repopulating HSC (Fig. 4f). Δ LNFR and GFP were coordinately expressed to similar levels in the *ex vivo* transduced cells, before transplantation, and in the white blood cells of long-term engrafted mice. Overall, these results validated the new LV for proficient dual gene transfer in primitive, committed, and differentiated hematopoietic cells.

[0057] They injected concentrated Δ LNFR-GFP MA1 LV in the striatum of adult mice and scored transgene expression 4 weeks after injection by confocal microscopy of brain sections immuno-stained for GFP and Δ LNFR (fig. 5). They observed robust co-expression of both transgenes in the brain tissue surrounding the injection site. As previously reported after striatal injection of VSV-pseudotyped LV²⁵⁻²⁷, the vast majority of cells expressing the markers had the typical morphology of striatal neurons. Thus, the new bi-directional LV enabled efficient *in vivo* dual-gene transfer.

Dual-Transgenesis

[0058] They evaluated whether the new bi-directional LV allowed generation of dual-transgenic mouse lines. As previously described by Lois et al¹⁹, they microinjected the Δ NGFR-GFP LV into the perivitelline space of single-cell embryos, and implanted them into pseudopregnant females. We obtained transgenic mice to high frequency, as assessed by the presence of vector DNA (more than 50% of newborns), and proved vector integration in the germ line by crossing some founder mice and analyzing their progeny for vector DNA content and transgene expression (Fig. 6). In the two F1 mice analyzed, carrying 2 and 5 vector copies in the genome, they found remarkably consistent expression of both transgenes in virtually every cell in the tissues studied, which included brain, liver, spleen, gut, heart, skeletal muscle, and kidney. Vector expression was also well detectable in the bone marrow and peripheral blood of the same mice, although in less than 100% of the cells, and more clearly for Δ NGFR than GFP (not shown). These data indicated that bi-directional LV transgenesis is a rapid and efficient method to obtain robust, stable and coordinate expression of two transgenes in genetically-engineered mice. In addition, they show that the minCMV-PGK bi-directional promoter that they developed governs dual transgene expression in the majority of differentiated tissues of the mouse, and maintains expression after inheritance through the germ-line.

DISCUSSION

[0059] In the pursuit of strategies enabling efficient dual-gene transfer, they initially faced significant limitations of IRES-based approaches. When tested in the context of bicistronic LV, IRES-dependent gene expression was significantly lower than that dependent on the mRNACap, and required multi-copy transduction to co-express the downstream gene in a sizable fraction of transduced cells. In addition, IRES's decreased expression of the upstream gene in the transcript, and displayed significant cell type-dependent variation in activity. Similar limitations have been reported when incorporating IRES's into other types of gene transfer vectors^{14,28-32}. Thus, selection for downstream gene expression is likely to be required when using IRES to ensure co-expression in all target cells. Although selection protocols are compatible with some *ex vivo* gene transfer and therapy applications, they may adversely affect the biological properties of gene-corrected cells, in particular when selectable marker expression is inefficient. In fact, prolonged *ex vivo* culture and a limited size or clonal composition of the transduced cell population may reduce engraftment, long-term survival and tissue repopulation after transplantation³³. Even more important, the inefficiency of IRES-dependent expression prevents most application of bicistronic vectors to direct *in vivo* gene transfer. Thus, authors explored novel strategies to take full advantage of gene transfer systems, such as LV, that allow efficient *ex vivo* transduction and direct *in vivo* administration³⁴.

[0060] They have developed a new promoter design based on the juxtaposition of core promoter elements upstream, and in opposite orientation, to an efficient promoter. The bi-directional assembly drove divergent transcription, indicating that upstream enhancer/promoter elements within the efficient promoter were capable of promoting transcription in an orientation-independent manner and from both sides simultaneously. Upon incorporation of these promoters into LV, they reached efficient dual-gene transfer and coordinate expression in continuous cell lines and primary cells *ex vivo*. Because both transgenes were expressed in the vast majority of transduced cells, they did not need to select cells to ensure transgene co-expression. Upon direct injection of bi-directional LV into the CNS, the authors showed coordinate expression of two transgenes in neural cells *in vivo*. In addition, bi-directional LV allowed robust dual transgenesis, leading to pan-cellular expression of both transgenes in all tissues examined. All these results could not be reached until now using currently available technologies.

[0061] By monitoring transduced cells carrying a single vector copy, authors proved that divergent transcription occurred from a single bi-directional promoter, that expression of both transgenes was functionally linked and coordinately regulated, and that bi-directional promoters were consistently active in all types of target cells tested, without being silenced or randomly fixed in one direction of transcription, even after cellular differentiation. Although they did not map how close the two opposite core promoters must be for operational linkage, they may expect that close juxtaposition of the fused minimal core promoter to some of the upstream elements in the efficient promoter, as observed in natural promoters between core and upstream elements, may be required. Both the PGK and UBI-C promoters tested in this work drove divergent transcription when fused to a minimal core promoter in the opposite orientation. Intriguingly, both of these promoters were shown to be intrinsically capable of promoting divergent transcription, although to lower efficiency on the upstream than the downstream side, when incorporated into the bi-directional expression cassette that they developed. This surprising observation may indicate a specific feature of a class of ubiquitously-expressed housekeeping promoters, possibly related to their content of CpG islands (see below and³⁵⁻³⁷). However, they should not forget that both the promoter placement between two efficient expression cassettes endowed with post-transcriptional regulatory elements enhancing translation, and LV-mediated integration, which has been shown to preferentially target transcribed genes in the chromatin, may contribute to unravel latent transcriptional activity. Although the intrinsic bi-directional activity of the housekeeping promoters tested may not be efficient enough for exploitation *per se*, without the upstream assembly of core promoter elements described in this work, it provides the basis for the coordinate regulation of dual-gene ex-

pression reached by our new vectors. On the other hand, the propensity of these promoters to drive divergent transcription should be kept in mind when engineering vectors and analyzing transduced cells or tissues³⁶, and may provide a possible mechanism for the frequently observed interference between nearby promoters in the same vector construct^{10,39}. It is possible that the bi-directional design described here may be successfully applied to tissue-specific promoters to obtain coordinated expression of two transgenes in specific tissues. In addition, by combining bi-directional promoters with bicistronic transcripts one could express more than two transgenes within the same cell, although with the limitations described above for IRES-dependent vectors.

[0062] Inducible bi-directional promoters were originally developed in Tet-regulated expression systems, by duplicating a minimal promoter on both sides of a series of Tet operator repeats, to obtain exogenously regulated expression of two transgenes^{38, 40,41}. This design was recently applied to other systems that also combine prokaryotic enhancer elements with chimeric trans-activators to regulate gene expression⁴². Although these inducible expression systems represent powerful tools for gene-function studies, they are dependent on co-expression and functional activity of protein trans-activators, and pose several challenges when applied to vector-based delivery and *in vivo* applications. A constitutive bi-directional promoter was recently tested for exogenous gene expression in plant biotechnology⁴³. Our results provide the first description of synthetic bi-directional promoters that exploit the endogenous transcriptional machinery available to most animal cell types to drive robust and constitutive expression of two divergent transcripts. In nature, few instances of bi-directional promoters had been documented until recently. Intriguingly, a recent survey of the human genome indicated an abundance of divergently transcribed gene pairs, whose transcription start sites are separated by less than 1 kb^{44,45}. It is likely that many of the promoter elements found between these gene pairs can initiate transcription in both directions, and contain shared elements that regulate both genes⁴⁶. Thus, the synthetic bi-directional promoters that they have developed may mimic a well-represented and evolutionary conserved feature of eukaryotic transcription, providing a structural basis for their robust performance. The new lentiviral vectors built around these bi-directional promoters will likely advance the reach and the safety of gene therapy, the power of gene-function and target validation studies, and the applications of animal transgenesis. If adapted for the expression of short interfering RNA, they may also enable coordinate knock-down of multiple genes.

REFERENCES

[0063]

1. Kay, M.A., Glorioso, J.C. & Naldini, L. *Nat Med* 7, 33-40 (2001).
2. Neff, T. et al. *J Clin Invest* 112, 1581-1588 (2003).
3. Bordignon, C. & Roncarolo, M.G.. *Nat Immunol.* 3, 318-321 (2002).
4. Sadetain, M.. *J Gene Med* 4, 113-121 (2002).
5. Bonini, C. et al. *Science* 276, 1719-1724 (1997).
6. Hacein-Bey-Abina, S. et al.. *Science* 302, 415-419 (2003).
7. Burton, E.A., Glorioso, J.C. & Fink, D.J. *Gene Ther* 10, 1721-1727 (2003).
8. Sadetain, M., Riviere, I. & Brentjens, R.. *Nat Rev Cancer* 3, 35-45 (2003).
9. Miller, A.D. in *Retroviruses*. (eds. J. Coffin, S.H. Hughes & H.E. Varmus) 437-474 (Cold Spring Harbor Laboratory Press, Plainview; 2000).
10. Emerman, M. & Temin, H.M. *Mol Cell Biol* 6, 792-800 (1986).
11. Zhu, Y., et al.. *Mol Ther.* 4,375-382 (2001).
12. Klump, H. et al. *Gene Ther.* 8, 811-817 (2001).
13. Furter, S., et al.. *Gene Ther* 8, 864-873 (2001).
14. Martinez-Salas, E.. *Curr Opin Biotechnol.* 10, 458-464 (1999).
15. Follenzi, A., et al.. *Nat Genet* 25, 217-222 (2000).
16. Ghattas, I.R., Sanes, J.R. & Majors, J.E.. *Mol Cell Biol.* 11, 5848-5859 (1991).
17. Qiao, J., et al.. *Hum Gene Ther* 13, 881-887 (2002).
18. Oumard, A., et al.. 20,2755-2759 (2000).
19. Lols, C., et al.. *Science* 295, 868-872 (2002).
20. Baron, U. & Bujard, H.. *Methods Enzymol.* 327, 401-421 (2000).
21. Bray, M. et al. *Proc Natl Acad Sci USA* 91, 1256-1260 (1994).
22. Zufferey, R., et al.. *J. Virol.* 73, 2886-2892 (1999).
23. Ailles, L. et al.. *Mol Ther* 6, 615-626 (2002).
24. Cavalleri, S. et al.. *Blood* 102, 497-505 (2003).
25. Naldini, L., et al. *Proc Natl Acad Sci USA* 93, 11382-11388 (1996).
26. Baekelandt, V. et al. *Hum Gene Ther* 13, 841-853 (2002).
27. Degion, N. et al.. *Hum. Gene Ther.* 11, 179-190 (2000).

28. Sokolic, R.A. et al. *Blood* 87, 42-50 (1996).
 29. Wong, E.T., Ngai, S.M. & Lee, C.G. *Gene Ther* 9,337-344 (2002).
 30. Kozak, M., *Gene* 318, 1-23 (2003).
 31. Mizuguchi, H., et al., *Mol Ther* 1, 376-382 (2000).
 32. Hennecke, M. et al., *Nucleic Acids Res* 29, 3327-3334 (2001).
 33. Mazurier, F., et al. *Blood* 103, 545-552 (2004).
 34. Vigna, E. & Naldini, L., *J Gene Med* 2, 305-316 (2000).
 35. Gardiner-Garden, M. & Frommer, M., *J. Mol Biol* 196, 261-282 (1987).
 36. Lavia, P., Macleod, D. & Bird, A., *EMBO J* 6, 2773-2779 (1987).
 37. Johnson, P. & Friedmann, T., *Gene* 88, 207-213 (1990).
 38. Scacheri, P.C. et al. *Genesis* 30, 259-263 (2001).
 39. Vigna, E. et al., *Mol Ther* 5, 252-261 (2002).
 40. Baron, U., et al., *Nucleic Acids Res.* 23, 3605-3606 (1995).
 41. Unsinger, J., et al., *Mol Ther* 4,484-489 (2001).
 42. Fux, C. et al., *J Gene Med* 5, 1067-1079 (2003).
 43. Xie, M., He, Y. & Gan, S., *Nat Biotechnol* 19, 677-679 (2001).
 44. Trinklein, N.D. et al., *Genonze Res* 14, 62-66 (2004).
 45. Takai, D. & Jones, P.A. *Mol Biol Evol* 21, 463-467 (2004).
 46. Adachi, N. & Lieber, M.R. *Cell* 109, 807-809 (2002).
 47. Farson, D. et al. *Hum Gene Ther* 12, 981-997 (2001).
 48. De Palma, M., et al., *Nat Med* 9, 789-795 (2003).
 49. Follenzi, A., et al. *Hum Gene Ther* 13, 243-260 (2002).

SEQUENCE LISTING

[0064]

<110> FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR

<120> LENTIVIRAL VECTORS CARRYING SYNTHETIC BI-DIRECTIONAL PROMOTERS AND USES THEREOF

<130> 81240PCT

<140> PCT/IT2004/000227

<141> 2004-04-21

<160> 8

<170> PatentIn version 3.1

<210> 1

<211> 20

<212> DNA

<213> Artificial sequence

<220>

<223> primer

<220>

<221> misc_feature

<222> (1)..(20)

<223> LV forward primer

<400> 1

tgaagcgaa agggaaacca 20

<210> 2

<211> 15

<212> DNA

<213> Artificial Sequence
 <220>
 <223> primer
 5 <220>
 <221> misc_feature
 <222> (1)..(15)
 <223> LV reverse primer
 10 <400> 2
 ccgtgcgcgc ttcaag 15
 <210> 3
 <211> 18
 15 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> probe
 20 <220>
 <221> misc_feature
 <222> (1)..(18)
 <223>
 25 <220>
 <221> misc_feature
 <222> (1)..(18)
 <223> LV probe
 30 <400> 3
 ctctctcgac gcaggact 18
 <210> 4
 <211> 9613
 35 <212> DNA
 <213> Artificial sequence
 <220>
 <223> plasmid
 40 <220>
 <221> misc_feature
 <222> (1)..(9613)
 <223> plasmid containing the lentiviral vector construct RRL-MA1-lucif/ GFP
 45 <400> 4
 50
 55

	caggtggcac	ttttcgggga	aatgtgcgcg	gaacccctat	ttgtttat	ttctaaatac	60
	attcaaatat	gtatccgctc	atgagacaat	aaccctgata	aatgcttcaa	taattattgaa	120
5	aaaggaagag	tatgagtatt	caacatttcc	gtgtcgccct	tattcccttt	tttgcggcat	180
	tttgccttcc	tgtttttct	caccagaaaa	cgctgggtgaa	agtaaaagat	gctgaagatc	240
	agtgggtgc	acgagtggt	tacatcgaa	tgatctcaa	cagcggtgaa	atccttgaga	300
10	gttttcgccc	cgaagaacgt	tttccaatga	tgagcacttt	taaagttctg	ctatgtggcg	360
	cggattatc	ccgtattgac	gccgggcaag	agcaactcgg	tcgccgata	cactattctc	420
	agaatgactt	ggttgagtac	tcaccagtca	cagaaaagca	tcttacggat	ggcatgacag	480
	taagagaatt	atgcagtgtc	gccataacca	tgagtgtata	cactgcggcc	aacttacttc	540
15	tgacaacgat	cggaggacg	aaggagctaa	ccgctttttt	gcacaacatg	ggggatcatg	600
	taactcgctt	tgatcgttgg	gaaccggagc	tgaatgaagc	cataccaaac	gacgagcgtg	660
	acaccacgat	gcctgtagca	atggcaacaa	cgttgcgcaa	actattaact	ggcgaactac	720
20	ttactctagc	ttcccggcaa	caattaatag	actggatgga	ggcgataaaa	gttgacggac	780
	cactcttcgc	ctcgccctt	ccgctggct	ggtttattgc	tgataaatct	ggagccggtg	840
	agcgtgggtc	tcgcggtatc	attgcagcac	tggggccaga	tggtaaagcc	tcccgatctg	900
25	tagttatcta	cacgacgggg	agtcaggcaa	ctatggatga	acgaaataga	cagatcgctg	960
	agataggtgc	ctcactgatt	aagcattggt	aactgtcaga	ccaagtttac	tcatatatac	1020
	tttagattga	tttaaaactt	catttttaat	ttaaaaggat	ctaggtgaag	atcctttttg	1080
30	ataatctcat	gaccaaatac	ccttaacgtg	agttttcgtt	ccactgagcg	tcagaccccg	1140
	tagaaaagat	caaaggatct	tcttgagatc	cttttttctt	gcgcgtaate	tgctgcttgc	1200
	aaacaaaaaa	accaccgcta	ccagcgggtg	ttgttttgcc	ggatcaagag	ctaccaactc	1260
	tttttccgaa	ggtaactggc	ttcagcagag	cgcagatacc	aaatactgtc	cttctagtgt	1320
35	agccgtagt	aggccaccac	ttcaagaact	ctgtagcacc	gcttacatac	ctcgtctgtc	1380
	taatcctgtt	accagtggct	gctgccagtg	gcgataagtc	gtgtcttacc	gggttggaat	1440
	caagacgata	gttaaccggt	aaggcgacg	ggtcgggctg	aacggggggg	tcgtgcacac	1500
40	agcccagctt	ggagcgaacg	acctacaccg	aactgagata	cctacagcgt	gagctatgag	1560
	aaagcggcac	gcttcccgaa	gggagaaagg	cggacaggta	tccggtgaagc	ggcagggtcg	1620

	gaacaggaga ggcacgagg gagcttcag ggggaaacgc ctggtatctt tatagtcttg	1680
	tcgggtttcg ccacctctga ctgagcgtc gatTTTTgtg atgctcgtca ggggggcgga	1740
5	gcctatggaa aaacgccagc aacgcggcct ttttacgggt cctggccttt tgctggcctt	1800
	ttgctcacat gtcttctctc gcgttatccc ctgattctgt ggataaccgt attaccgcct	1860
	ttgagtgaag tgataccgct cgcgcgagcc gaacgaccga gcgcagcgag tcagtgaagc	1920
10	aggaaagcga agagcgccca atacgcaaac cgcctctccc cgcgcgttgg ccgattcaat	1980
	aatgcagctg gcacgacagg ttcccgactt ggaagcggg cagtgaagcg aacgcaatta	2040
	atgtgagtta gctcactcat taggcacccc aggctttaca ctttatgctt ccggctcgta	2100
15	tgctgtgtgg aattgtgagc ggataacaat ttcacacagg aaacagctat gaccatgatt	2160
	acgcaagcg cgcaattaac cctcactaaa gggaaacaaa cctggagctg caagcttaat	2220
	gtagtcttat gcaatactct tgtagtcttg caacatggta acgatgagtt agcaaatgc	2280
	cttacaagga gaaaaaagc accgtgcatg ccgattgggt gaagtaaggt ggtacgatcg	2340
20	tgctctatta ggaaggcaac agacgggtct gacatggatt ggacgaacca ctgaattgcc	2400
	gcattgcaga gatattgtat ttaagtgcct agctcgatac aataaacggg tctctctggt	2460
	tagaccagat ctgagcctgg gagctctctg gctaactagg gaaccactg cttaaagctc	2520
25	aataaaagctt gccttgagtg cttcaagtag tgtgtgcccc tctgtgtgtg gactctggta	2580
	actagagatc cctcagaccc ttttagtcag tgtggaaaat cctcagcagt ggcgccgaa	2640
	cagggacctg aaagcgaaag ggaaccaga gctctctcga cgcaggactc ggcttgctga	2700
30	agcgcgcacg gcaagaggcg aggggcggcg actggtgagt acgccaataa ttttgactag	2760
	cggaggctag aaggagagag atgggtgcga gagcgtcagt attaaagcgg ggagaattag	2820
	atcgcatgg gaaaaaatc ggtaagggc aggggggaaa aaaaaatata aattaaaaca	2880
35	tatagtatgg gcaagcagg agctagaacg attcgcagtt aatcctggcc tgttagaac	2940
	atcagaagcg tgtagacaaa tactgggaca gctacaacca tcccttcaga caggatcaga	3000
	agaacttaga tcattatata atacagtagc aacctctat tgtgtgcac aaaggataga	3060
40	gataaaagac accaagggaag ctttagacaa gatagaggaa gagcaaaaca aaagtaagac	3120
	caccgcacag caagcggcgg ctgatcttca gacctggagg aggagatatg agggacaatt	3180
	ggagaagtga attatataaa tataaagtag taaaaattga accattagga gtacaccca	3240
	ccaagcmaa gagaagagtg gtgcagagag aaaaaagagc agtgggaata ggaagcttgt	3300
45	tccttggggt ctggggagca gcaggaagca ctatgggcgc agcctcaatg acgtgaagc	3360
	tacaggccag acaattattg tctggtatag tgcagcagca gaacaatttg ctgagggcta	3420
	ttgaggcgca acagcatctg ttgcaactca cagtcgggg catcaagcag ctccaggcaa	3480
50	gaatctctggc tgtggaaaga tacctaaagg atcaacagct cctggggatt tggggttgct	3540
	ctggaaaact catttgcacc actgctgtgc cttggaatgc tagttggagt aataaatctc	3600
	tggacagat ttggaatcac acgacctgga tggagtggga cagagaaatt aacaattaca	3660

	caagcttaat acactcctta attgaagaat cgcaaaacca gcaagaaaag aatgaacaag	3720
	aattattgga attagataaa tgggcaagtt tgtggaattg gttaacata acaattggc	3780
5	tgtggtatat aaaattattc ataattgat taggaggctt ggtaggtta agaattggt	3840
	tgtctgact ttctatagt aatagagtta ggcagggata ttcaccatta tctgttcaga	3900
	cccacacctc aaccccgagg ggaccgcaca ggcctgaagg aatagaagaa gaagggtgag	3960
10	agagagacag agacagatcc attcgattag tgaacggatc tgcagggatc cggttaactt	4020
	ttaaagaaa aggggggatt ggggggtaca gtgcagggga aagaatagta gacataatag	4080
	caacagacat acaaaactaaa gaattacaaa acaaaattac aaaaattcaa aattttatcg	4140
15	atcacgagac tagcctcgag agatctgatc ataatcagcc ataccacatt tgtagagggt	4200
	ttacttgctt taaaaaacct cccacacctc cccctgaacc tgaacataaa aatgaatgca	4260
	attgttggtt ttaacttggt tattgcagct tataatggtt acaataaagg caatagcatc	4320
20	acaaatttca caaataaggc atttttttca ctgacttcta gttttgggtt gtccaaactc	4380
	atcaatgtat cttatcatgt ctggatctca aatccctcgg aagctcgccc tgtcttaggt	4440
	tggagtata cattttttatc acttttaccg gtctttggat taggcagtag ctctgacggc	4500
25	ctctctgtct taggttagtg aaaaatgtca ctctcttacc cgtcatttgg tctcagctt	4560
	agctcgaggg ggaggtgggt tggatcctct agaattacac ggcgactctt ccgcccctct	4620
	tggcctttat gaggatctct ctgatttttc ttgcgtcgag tttccggta agacctttcg	4680
	gtacttcgtc cacaaacaca actcctccgc gcaacttttt cgcggttggt acttgactgg	4740
30	ccacgtaatc cagatctctt ttttccgtca tctcttttcc gtgctccaaa acaacaacgg	4800
	cggcgggaag ttaccggcg tcatcgtcgg gaagacctgc gacacctgc tcaagatgt	4860
	tgggtgtgtg gagcaagatg gattccaatt cagcgggagc caectgatag ctttgtact	4920
35	taatcacaga cttcaggcgg tcaacgatga agaagtgttc gtcttcgtcc cagtaagcta	4980
	tgtctccaga atgtagccat ccatccttgt caatcaaggc gttggtcgtc tccggattgt	5040
	ttacataacc ggacataatc ataggacctc tcacacacag ttccgctctt tgattaacgc	5100
40	ccagcgtttt cccggatacc agatccacaa ccttcgcttc aaaaaatgga acaactttac	5160
	cgaccgcgcc cggtttatca tccctctcgg gtgtaacag aatagctgat gtatctcag	5220
	tgaaccata tccttgccgt atacctggca gatggaacct cttggcaacc gcttcccaga	5280
	cttcccttaga gaggggagcg ccaccagaag caatttcgtg taaattagat aaatcgtatt	5340
45	tgtcaatcag agtgcctttg gcgaagaagg agaatagggt tggcaccagc agcgcacttt	5400
	gaatcttgta atcctgaagg ctctcagaa acagctcttc tcaaatcta tacattaaga	5460
	cgactcgaaa tcacataatc aaatatccga gtgtagtaaa cattccaaaa ccgtgatgga	5520
50	atggaacaac acttaaaatc gcagtatccg gaatgatttg attgccaaaa ataggatctc	5580
	tggatcgca gaatctcagc caggcagttc tatgagcgag agcgacacct ttagcgagac	5640
	cagtagatcc agaggagttc atgatcagtg caattgtctt gtccctatcg aaggactctg	5700

	gcacaaaatc gtattcatta aaaccgggag gtagatgaga tgtgacgaac gtgtacatcg	5760
	actgaaatcc ctggtaaatcc gttttagaat ccatgataat aatttttttg atgattggga	5820
5	gctttttttg cacgttcaaa attttttgca accccttttt ggaaacgaac accacggtag	5880
	gtctcgaaat cccataactg ttgagcaatt caggttcatt ataatgtcg ttccgggcg	5940
	caactgcac tccgataaat aacgcgcca acaccggcat aaagaattga agagagtttt	6000
10	cactgcatac gacgattctg tgatttgat tcagcccata tcgrrttcata gctttcgcca	6060
	accgaacgga catttcgaag tactcagcgt aagtgtatgc cacttcgata tgtgcatctg	6120
	taaaagcaat tgttcaggga accagggcgt atcttcttcat agccttatgc agttgctctc	6180
	cagcggttcc atcttcacag ggatagaatg gcgcccggcc ttcttttatg tttttggcgt	6240
15	cttccatggt gaattccgcg gaggcgtgat cgggtccggc gtcttctatg gaggtcaaaa	6300
	cagcgtgat ggcgtctcca ggcgatctga cggttcacta aacgagctct gcttatatag	6360
	gcctccacc gtacacgctt accctcgaga agcttgatat cgaattccca cgggggttggg	6420
20	gttgcgctt ttccaaggca gccctgggtt tgcgcaggga cgcggtcgt ctgggcctgg	6480
	ttccgggaaa cgcagcggcg ccgacctgg gtctcgcaca ttcttcacgt cegtccgcag	6540
	cgtcacccgg atcttcgcc ctacccttgt gggcccccgc gcgacgctt ctgctcgcg	6600
25	cctaagtcgg gaaggttctt tgcggttcgc ggcgtgcgcg acgtgaacaa cggaaagccg	6660
	acgtctcact agtaccctcg cagacggaca gcgcaggga gcaatggcag cgcgcgacc	6720
	cgatggggt gtggccaata gcggtgctc agcggggcgc gcgagagca gcggccggga	6780
30	aggggcggtg cgggagcgcg ggtgtggggc ggtagtgtgg gccctgttcc tgcccgcgcg	6840
	gtgttccgca ttctgcaagc ctccggagcg cactcgga cgtcgctccc tcgttgaccg	6900
	aatcacgcac ctcttctccc agggggatcc accggtcgcc accatggtag gcaaggcgga	6960
35	ggagctgttc accggggtgg tgcccattctt ggtcgagctg cagcgcgacg taaacggcca	7020
	caagttcagc gtgtccggcg agggcgaggg cgaatgcacc tacggcaacg tgacctgaa	7080
	gtctatctgc accaccggca agctgccgt gccctggccc accctctgta ccacctgac	7140
	ctacggcggt cagtgttca gcgctaccc cgatcacatg aagcagcag cttcttcaa	7200
40	gtccgcatg cccgaaggct acgtccagga gcgcacattc ttcttcaagg acgacggcaa	7260
	ctacaagacc cgcgccgagg tgaagttcga gggcgacacc ctggtgaacc gcatcgagct	7320
	gaaggcgatc gacttcaagg aggaacggcaa catctggggg cacaagctgg agtacaacta	7380
45	caacagccac aacgtctata tcatggccga caagcagaa aacggcatca agtggaactt	7440
	caagatccgc cacaacatcg aggaacggcag cgtgcagctc gccgaccact accagcaga	7500
	cacccccatc ggcgcaggcc cgtgctgct gcccgacaac cactaccta gcaaccagtc	7560
50	cgccctgagc aaagaccca acgagaagcg gcatcacatg gtctctgctgg agttcgtgac	7620
	cgccgcgggg atcactctcg gcatggacga gctgtacaag taaagcgccc gcgtgcacaa	7680
	tcaacctctg gattacaaaa ttgttgaaag attgactggt atttctaact atgtgtctcc	7740

	ttttacgcta tgtgatacg ctgctttaat gcctttgtat catgctattg cttcccgtat	7800
	ggctttcatt ttctcctctt tgtataaaat ctgggtgctg tctctttatg aggagttgtg	7860
5	gcccgtgtgc aggcaacgtg gcgtggtgtg cactgtgttt gctgacgcaa cccccactgg	7920
	ttggggcatt gccaccacct gtcagctcct ttccgggact ttgcctttcc cctccctat	7980
	tgccacggcg gaactcatcg ccgcctgcct tgcccgcgtc tggacagggg ctgcgtctgt	8040
10	gggcactgac aattccgtgg tgtgtctggg gaagctgacg tcctttccat ggcgtctcgc	8100
	ctgtgttgcc acctggattc tgcgcgggac gtcctttcgc tacgtccctt cggccctcaa	8160
	tcacgaggac cttccttccc gcggcctgct gccggctctg cggcctcttc cgcgtctcgc	8220
15	ccttcgccct cagacgagtc ggaatctcct ttgggcgcc tcccgcctg gaattcgagc	8280
	tcggtacctt taagaccaat gacttacaag gcagctgtag atcttagcca ctttttaaaa	8340
	gaaaaggggg gactggaagg gctaattcac tcccaacgaa gacaagatct gctttttgct	8400
	tgtactgggt ctctctggtt agaccagatc tgagcctggg agctctctgg ctaactaggg	8460
20	aaaccaatgc ttaagcctca ataaagcttg ccttgagtc ttcaagtagt gtgtgccctg	8520
	ctgttgtgtg actctggtta cttagatccc ctacagacct tttagtcagt gtggaataac	8580
	tctagagcta gtagttcatg tcatcttatt attcagtatt tataacttgc aaagaaatga	8640
25	atatcagaga gtgagaggaa cttgtttatt gcagcttata atggtataca ataaagcaat	8700
	agcatcacaa atttcacaaa taaagcattt ttttactgc attctagtgt tggtttgtcc	8760
	aaactcatca atgtatctta tcatgtctgg ctctagctat cccgccctca actccgccca	8820
30	gtttccgccca ttctccgcc catggctgac taatttttt tatttatgca gaggccgagg	8880
	ccgcctcggc ctctgagcta ttccagaagt agtgaggagg cttttttgga ggcctaggct	8940
	tttgcgtcga gacgtaccca attccaccta tagtgagtcg tattacgcgc gtcactggc	9000
35	cgctgtttta caacgtcgtg actgggaaaa ccttggcgtt acccaactta atcgctctgc	9060
	agcacatccc cctttcgcca gctggcgtaa tagcgaagag gcccgaccg atcgcccttc	9120
	ccaacagtgt cgcagcctga atggcgaatg gcgcgacgcg cctgtagcg gcgcatttag	9180
	cgcggcgggt gtgggtgtta cgcgcagcgt gaccgtaca cttgccagcg ccttagcgc	9240
40	cgctccttcc gctttcttcc ctctcttctc gcgcacgttc gccgcttcc cccgtcaagc	9300
	tctaaatcgg gggctccctt tagggttccg atttagtct ttacggcacc tegaccacca	9360
	aaaacttgat tagggtagtg gttcacgtag tgggccatcg cctgataga cgttttttcg	9420
45	ccctttgacg ttggagtcca cgttctttaa tagtggaact ttgtccaaa ctggaacaac	9480
	actcaacctt atctcgttct attcttttga ttataaggg attttgccga tttcggccta	9540
	ttggttaaaa aatgagctga ttttaacaaa atttaacgcg aattttaaca aaatattaac	9600
50	gtttacaatt tcc	9613

<210> 5

<211> 9380

55

<212> DNA

<213> Artificial Sequence

<220>

<223> plasmid
 <220>
 <221> misc_feature
 <222> (1)..(9380)
 <223>

5

<220>
 <221> misc_feature
 <222> (1)..(9380)
 <223> plasmid containing the lentiviral vector construct CCL-MA1-GFP/de ItaLNGFR

10

<400> 5

15 Caggtggcac ttttcggga aatgtgctg gaacccctat ttgtttatt ttctaaatc 60
 attcaaatat gtatccgctc atgagacaat aacctgata aatgcttcaa taatattgaa 120
 aaaggaagag tatgagtatt caacatttcc gtgtcgccct tattcccttt ttgctggcat 180
 tttgcttcc tgtttttgct caccagaaa cgtggtgaa agtaaaagat gctgaagatc 240
 20 agttgggtgc acgagtggtg tacatcgaac tggatctcaa cagcggtaa atccttgaga 300
 gttttcgccc cgaagaactt ttccaatga tgagcacttt taaagtctg ctatgtggcg 360
 cgttattatc ccgtattgac gccgggcaag agcaactcgg tcgccgata cactattctc 420
 25 agaatgactt ggttgagtac tcaccagtca cagaaaagca tcttcggat gccatgacag 480
 taagagaatt atgcagtgtc gccataacca tgaagtataa cactgcggcc aacttacttc 540
 tgacaacgat cggaggaccg aaggagctaa ccgcttttt gcacaacatg ggggcatcag 600
 30 taactcgctt tgatcgttgg gaaccggagc tgaatgaagc cataccaaac gacgagctg 660
 acaccacgat gcctgtagca atggcaacaa cgttcgcaa actattaact ggcgaactac 720
 ttactctagc ttcccggcaa caattaatag actggatgga ggcggataaa gttgcaggac 780
 35 cacttctcgc ctcggccctt ccgctggctt ggtttattgc tgataaatct ggagccggtg 840
 agcgtgggtc tcgcggtatc attgcagcac tggggccaga tggtaagccc tcccgatcgc 900
 tagttattcta cacgacgggg agtcaggcaa ctatggatga acgaaataga cagatcgctg 960
 40 agataggtgc ctactgatt aagcattggt aactgtcaga ccaagtttac tcatatatac 1020

45

50

55

	tttagattga	tttaaaactt	cattttta	ttaaaaggat	ctaggtgaag	atcctttttg	1080
	ataatctcat	gaccaaatac	ccttaacgtg	agttttcgtt	ccactgagcg	tcagaccccg	1140
5	tagaaaagat	caaaggatct	tcttgagatc	ctttttttct	gcgcgtaate	tgctgtctgc	1200
	aaacaaaaaa	accaccgcta	ccagcgggtg	ttgtttggcc	ggatcaagag	ctaccaactc	1260
	tttttccgaa	ggtaactggc	ttcagcagag	cgcagatacc	aaatactgtc	cttctagtgt	1320
10	agccgtagtt	aggccaccac	ttcaagaact	ctgtagcacc	gcctacatac	ctcgtctctg	1380
	taatcctgtt	accagtggct	gctgccagtg	gcgataagtc	gtgtcttacc	gggttggact	1440
	caagacgata	gttaccggat	aaggcgacgc	ggctgggggt	aacggggggg	tcgtgcacac	1500
	agcccgactt	ggagcgaaag	acctacacgc	aactgagata	ctacagcgt	gagctatgag	1560
15	aaagcgccac	gcttcccgaa	ggggagaaag	cggacaggta	tcggtgaagc	ggcagggtcg	1620
	gaacaggaga	gcgcacgagg	gagcttccag	ggggaaacgc	ctggtatctt	tatagtccctg	1680
	tcgggtttcg	ccacctctga	cttgagcgtc	gatttttgtg	atgctcgtca	ggggggcgga	1740
20	gcctatggaa	aaacgccagc	aacgcggcct	ttttacggtt	ctggcctttt	tgctggcctt	1800
	ttgctcacat	gttctttcct	gcgttatccc	ctgattctgt	ggataaccgt	attaccgcct	1860
	ttgagtgcgc	tgataccgct	cgccgcagcc	gaacgaccga	gcgcagcgag	tcagtgcgcg	1920
25	aggaagcgga	agagcgccca	atacgcaaac	cgctctcccc	cgcgcgttgg	ccgattcatt	1980
	aatgcagctg	gcacgacagg	tttcccgact	ggaaagcggg	cagtgaagcg	aacgcaatta	2040
	atgtgagtta	gctcactcat	taggcacccc	aggctttaca	ctttatgctt	ccggctcgtc	2100
30	tggtgtgtgg	aattgtgagc	ggataacaat	ttcacacagg	aaacagctat	gaccatgatt	2160
	acgccaagcg	cgcaattaac	cctcactaaa	gggaacaaaa	gctggagctg	caagcttggc	2220
	cattgcatac	gttgatccca	tatcataata	tgatcattta	tattggctca	tgccaacat	2280
	taccgccatg	ttgacattga	tatttgacta	gttattaata	gtaataaatt	acggggtcct	2340
35	tagttcatag	cccataatg	gagttccg	ttacataact	tacggtaaat	ggcccgcctg	2400
	gctgaccgcc	caacgacccc	cgcccattga	cgtaataaat	gacgtatgtt	cccatagtaa	2460
	cgccaatagg	gactttccat	tgactgtcaat	gggtggagta	tttaccgtta	actgcccaact	2520
40	tggcagtaca	tcaagtgtat	catatgccaa	gtacgcccc	tattgacgtc	aatgacggta	2580
	aatggccgcg	ctggcattat	gccacgtaca	tgaccttatg	ggactttctt	acttggcagt	2640
	acatctacgt	attagtctac	gctattacca	tggtgatgcg	gttttggcag	tacatcaatg	2700
45	ggcgtggata	gcggtttgac	tcacggggat	ttccaagtct	ccaccccat	gacgtcaatg	2760
	ggagtttgtt	ttggcaccaa	aatacaacgg	actttccaaa	atgtcgtaac	aactccgcc	2820
	cattgacgca	aatggcggtg	aggcgtgtac	gggtggagggt	ctatataagc	agagctcgtt	2880
50	tagtgaaccg	gggtttctct	gggttagacca	gatctgagcc	tgggagctct	ctggctaact	2940
	agggaaacca	ctgcttaagc	ctcaataaag	cttgccctga	gtgcttcaag	tagtgtgtgc	3000
	ccgtctgttg	tgtgactctg	gtaactagag	atccctcaga	cccttttagt	cagtggtgaa	3060

	aatctctagc agtggcgccc gaacagggac ctgaaagcga aagggaaacc agagctctct	3120
	cgacgcagga ctggccttgc tgaagcgcgc acggcaagag gcgaggggag gcgactgggtg	3180
5	agtacgccaa aaattttgac tagcggaaggc tagaaggaga gagatgggtg cgagagcgtc	3240
	agtattaagc gggggagaat tagatcgca tgggaaaaaa ttcggttaag gccaggggga	3300
	aagaaaaaat ataattaaa acatatagta tgggcaagca gggagctaga acgattcgca	3360
10	gttaatctct gccctgttaga aacatcagaa ggctgtgac aaatactggg acagctacaa	3420
	ccatcccttc agacaggatc agaagaactt agatcattat ataatacagt agcaaccctc	3480
	tattgtgtgc atcaaggat agagataaaa gacaccaagg aagctttaga caagatagag	3540
15	gaagagcaaa acaaaagtaa gaccaccgca cagcaagcgg ccgctgatct tcagacctgg	3600
	aggaggagat atgagggaca attggagaag tgaattatat aaataataag tagtaaaat	3660
	tgaaccatta ggagtagcac ccaccaaggc aaagagaaga gtggtgcaga gaaaaaaag	3720
	agcagtggga ataggagctt tgttccttgg gttcttggga gcagcaggaa gcactatggg	3780
20	cgcagcctca atgacgctga cgttacaggc cagacaatta ttgtctggtg tagtcagca	3840
	gcagaacaat ttgtctaggg ctattgaggc gcaacagcat ctgttgcaac tcacagctctg	3900
	gggcatacag cagctccagg caagaatcct ggctgtggaa agatacctaa aggatcaaca	3960
25	gctcctgggg atttgggggt gctctggaaa actcattttg accactgctg tgccttggaa	4020
	tgctagttag agtaataaat ctctggaaca gattggaatc acacgacctg gatggagtgg	4080
	gacagagaaa ttaacaatta cacaagctta atacactcct taattgaaga atcgcaaaac	4140
30	cagcaagaaa agaataaaca agaattattg gaattagata aatgggcaag tttgtggaat	4200
	tgtgttaaca taacaaattg gctgtggtat ataaaaattt tcataatgat agtaggaggc	4260
	ttggttagtt taagaatagt ttttgctgta cttctatag tgaataagat taggcaggga	4320
35	tattccacct tatcgtttca gaccacctc ccaacccgga ggggaccgga caggcccgaa	4380
	ggaatagaag aagaagggtg agagagagac agagacagat ccattcgatt agtgaacgga	4440
	tcctgcagct atcggttaac ttttaaaaga aaagggggga ttggggggtg cagtgcaggg	4500
40	gaaagaatag tagacataat agcaacagac atacaacta aagaattaca aaaaacaatt	4560
	acaaaaattc aaaattttat cgatcacgag actagcctcg agagattctga tcataatcag	4620
	ccataccaca ttttagaggg ttttacttgc tttaaaaaac tcctccacacc tccccctgaa	4680
	cttgaacatc aaaaatgaatg caattgttgt tgtttaactg tttattgcag cttataatgg	4740
45	ttacaataaa ggcaatagca tcacaaattt cacaaatagt gcattttttt cactgcattc	4800
	tagtttttgt ttgtccaac tcatcaatgt atcttatcat gtcctgatat caaatccctc	4860
	ggaagctcgg cctgtcttag gttggagtga tacattttta tcacttttac ccgtctttgg	4920
50	ataggcagt agctctgacg gccctcctgt cttaggttag tgaaaaaatg cactctctta	4980
	ccgctcattg gctgtccagc tttagctcgca ggggaaggtg tctggtatcg agctcgaatt	5040
	ggccgcttta cttgtacagc tcgtccatgc cgagagtgtt cccggcgccg gtcacgaact	5100

	ccagcaggac catgtgatcg cgcttctcgt tggggctctt gctcagggcg gactgggtgc	5160
	tcaggtagtg gttgtcgggc agcagcacgg ggcgcgtgcc gatgggggtg ttctgctggg	5220
5	agtggtcggc gagctgcacg ctgcgcctct cgaatgtgtg gcggaatctg aagttcacct	5280
	tgatgccgtt ctcttctgtg tcggccatga tatagacgtt gtggctgttg tagttgtact	5340
	ccagcttgtg cccagggatg ttgcgcctct ccttgaagtc gatgcccttc agctcgatgc	5400
10	ggttaccag ggtgtcgccc tcgaacttca cctcggcgcg ggtctgtgag ttgcgtcgt	5460
	ccttgaagaa gatggtgcgc tcttggacgt agccttcggg catggcggac ttgaagaagt	5520
	ctgtcgtcct catgtggtcg gggtagcggc tgaagcactg cagccgtag gtcagggtgg	5580
	tcacgagggg gggccagggc acgggcagct tgcgggtggt gcagatgaac ttcagggtca	5640
15	gcttgcgta ggtggcatcg ccttcgccct cgcgggacac gctgaacttg tggcgttta	5700
	cgctgcgcgc cagctcgacc aggatgggca cccccggg gaacagcttc tcgcccttgc	5760
	tcaccatggt gaattccgcg gaggtggat cggctccggt gtcttctatg gagtcaaaa	5820
20	cagcgtggat ggcgtctcca ggcatctga cggttcacta aacgagctct gcttatatag	5880
	gcctccacc gtacacgcct accctcgaga agcttgatat cgaattccca cggggttggg	5940
	gttgccgctt ttccaaggca gccctgggtt tgcgcaggga cgcgctgctc ctgggctgg	6000
25	ttccgggaaa gcagcggcg cgcacccctg gtctcgcaca ttcttcacgt ccgttcgacg	6060
	cgctaccggg atcttcgccg ctaccctgtt gggcccccgc gcgacgttc ctgctcggc	6120
	cctaagtcgg gaaggtcctt tgcggttcgc ggcgtgccgg acgtgacaaa cgggaagccg	6180
	acgtctcact agtaccctcg cagacggaca gcgcacaggga gcaatggcag cgcgccgacc	6240
30	gcgatgggct gtggccaata gcgctgctc agcggggcgc gccgagagca gcgcccggga	6300
	aggggcgggt cgggagggcg ggtgtggggc ggtagtgtg gccctgttcc tgcccgcgcg	6360
	gtgttccgca ttctgcaagc ctccggagcg cagtcggca gtcggctccc tcgttgaccg	6420
35	aatcacgcac ctctctcccc agggggatcc cccgggctgc aggaattcgg gccgcggcca	6480
	gctccggcgg gcaggggggg cgctggagcg cagcgcagcg cagcccatc agtcgcgaaa	6540
	gcggaccgag ctggaagtcg agcgcctgcg cgggagggcg gcgatggggg cagggtccac	6600
40	cggccgcgcc atggacgggc cgcgcctgct gctgttgctg ctctcggggg tgcctcttg	6660
	aggtgccaaag gaggcagccc ccacaggcct gtacacacac agcgggtgag gctgcaaaac	6720
	ctgcaacctg ggcgaggggt tggccagcct ttgtggagcc aaccagaccg tgtgtgagcc	6780
45	ctgcctggac agcgtgacgt tctccagcgt ggtgagcgcg accgagccgt gcaagccgtg	6840
	caccgagtgct gtggggctcc agagcatgtc ggcgccgtgc gtggaggcgc acgacgcgtg	6900
	gtgcgcgtgc gctacggcct actaccagga tgagcagact gggcgtcgcg aggcgtgcgcg	6960
50	cggtgtgcag gcgggctcgg gcctcgtgtt ctctgccag gacaagcaga acaccgtgtg	7020
	cgaggagtgcc ccgcagggca cgtattccga cgaaggccac cagctggacc cgtgcctgcc	7080
	ctgcacgctg tgcgagagca ccgagcgcca gctccgcgag tgacacgct ggcgcgacgc	7140

	cgagtgcgag gagatccctg gccgttgat tacacggtcc acacccccag agggctcggg	7200
	cagcacagcc ccagcacc agggagcctga ggcacctcca gaacaagacc tcatagccag	7260
5	cacgggtgga ggtgtggtga ccacagtgat gggcagctcc cagccctggg tgacccgagg	7320
	caccaccgac aacctcatcc ctgtctattg ctccatccctg gctgctgagg ttgtgggcct	7380
	tgtggcctac atagccttca agaggtggaa cagggggatc ctctagagtc gagtctagag	7440
10	tcgacaatca acctctggat tacaataatt gtgaagatt gactgtgatt cttaactatg	7500
	ttgctcttt tacgctatgt ggatacgctg ctttaagtcc ttgtatcat gctattgctt	7560
	cccgtatggc ttctatttct tcttcttctg ataaatccct gttgctgtct ctttatgagg	7620
	agttgtggcc cgttgtcagg caacgtggcg tgggtgtcac tgtgttctg cagcgaaccc	7680
15	ccactgggtg gggcattgcc accacctgtc agctcctttc cgggaatttc gctttccccc	7740
	tccctattgc cacggcggaa ctcatcgccg cctgccttgc ccgctgctgg acaggggctc	7800
	ggctgttggg cactgacaat tccgtggtgt tgtcggggaa gctgacgtcc ttctcatggc	7860
20	tgtcgcctg tgttgccacc tggattctgc gcgggacgtc ctctgctac gtccttcgg	7920
	ccctcaatcc agcggacctt ccttcccgcg gcctgctgcc ggctctcgg cctcttcgc	7980
	gtcttcgect tcgcctcag acgagtcgga tctcctttg ggcgcctcc ccgectggaa	8040
25	ttcagactcg gtacctttaa gaccaatgac ttacaaggca gctgtagatc tttagcactt	8100
	tttaaaagaa agggggggac tggagggctt aattcactcc caacgaagac aagatctgct	8160
	ttttgcttgt actgggtctc tctggttaga ccagatctga gcctgggagc tctctggcta	8220
30	actaggggac ccactgctta agcctcaata aagcttgctt tgagtgtctt aagtagtgt	8280
	tgcccgctct ttgtgtgact ctggttaacta gagatccctc agaccctttt agtcagtggt	8340
	gaaaaatctct agcagtagta gtctatgtca tcttattatt cagtatttat aacttgaaa	8400
35	gaaatgaata tcagagagtg agaggaactt gtttatgtca gcttataatg gttacaata	8460
	aagcaatagc atCacaaatt tcacaaataa agcatttttt tcactgcatc ctagtgtgtg	8520
	ttgttccaaa ctcatcaatg tatcttatca tgtctggctc tagctatccc gccctaaact	8580
	ccgccagtt ccgccattc tccgcccat ggctgactaa ttttttttat ttatgcagag	8640
40	gccgaggccg cctcgccctc tgagctattc cagaagtagt gaaggagctt ttttgaggc	8700
	ctaggctttt gcgtcgagac gtaccaatc cggcctatag tgaagctgat tacgcgcgct	8760
	cactggcgtt cgttttacia cgtcgtgact gggaaaaacc tggcgttacc caacttaac	8820
45	gccttcgacg acatccccct ttcgccagct ggcgaataag cgaagaggcc cgcaccgac	8880
	gcctttccca acagttgcgc agcctgaatg gcgaatggcg cgaagcgccc tgtagcggc	8940
	cattaaagcg ggcgggtgtg gtggttacgc gcagcgtgac cgctacactt gccagcgccc	9000
	tagcgcgcgc tctttctgct ttcttccctt ctttctcgc acggttcgcc ggctttcccc	9060
50	gtcaagctctt aaatcggggg ctcccttttag gggtccgatt tagtctctta cggcaactcg	9120
	accctcaaaa acttgattag ggtgatggtt cagctagtgg gccatcgccc tgatagacgg	9180

tttttcggcc tttgacgttg gagtccacgt tctttaatag tggactcttg ttccaaactg 9240
 gaacaacact caacctatc tcggtctatt cttttgattt ataagggatt ttgccgattt 9300
 5 cggcctattg gttaaaaaat gagctgattt aacaaaaatt taacgcgaat tttaacaaaa 9360
 tattaacgtt tacaatttcc 9380

<210> 6
 10 <211> 9718
 <212> DNA
 <213> Artificial Sequence

 <220>
 15 <223> plasmid
 <220>
 <221> misc_feature
 <222> (1)...(9718)
 <223>
 20 <220>
 221> misc_feature
 <222> (1)...(9718)
 <223> plasmid containing the lentiviral vector construct RRL-MA2-lucif/GFP
 25 <400>

caggtggcac ttttcgggga aatgtgcgcg gaacccctat ttgtttattt ttctaaatac 60
 30 attcaaatat gtatccgctc atgagacaat aacctgata aatgcttcaa taatattgaa 120
 aaaggaagag tatgagtatt caacatttcc gtgtcgcctt tattcccttt tttcggcat 180
 tttgccttcc tgtttttgct caccagaaa cgctgggtgaa agtaaaagat gctgaagatc 240
 35 agttgggtgc acgagtggtt tacatcgaac tggatctcaa cagcggtaag atccttgaga 300
 gttttcggcc cgaagaacgt tttccaatga tgagcacttt taaagttctg ctatgtggcg 360
 cggttattatc cggtattgac gccgggcaag agcaactcgg tcgccgcata cactattctc 420
 40 agaatgactt ggttgagtac tcaccagtca cagaaaaaca tcttacggat ggcattgacg 480
 taagagaatt atgcagtgtc gccataacca tgagtataa cactcgggcc aacttacttc 540
 tgacaacgat cggaggaccg aaggagctaa cgcctttttt gcacaacatg ggggatcatg 600
 taactgcctt tgatcgttgg gaaccggagc tgaatgaagc cataccaaac gacgagcgtg 660
 45 acaccacgat gcctgtagca atggcaacaa cgttgcgcaa actattaact ggcgaaactac 720

50

55

	ttactctagc	ttcccgccaa	caattaatag	actggatgga	ggcggataaa	gttgaggagc	780
	cacttctcgc	ctcggccctt	ccggctggct	gggttattgc	tgataaatct	ggagccgggtg	840
5	agcgtgggtc	tcgcggtatc	attgcagcac	tggggcccaga	tggttaagccc	tcccgtatcg	900
	tgtttactta	cacgacgggg	agtcagccaa	ctatggatga	acgaaataga	cagatcctcg	960
	agatagggtc	ctcactgatt	aagcattggt	aactgtcaga	ccaagtttac	tcatatatac	1020
10	tttagattga	tttaaaactt	catttttaat	ttaaaaggat	ctaggtgaag	atcctttttg	1080
	ataatctcat	gaccaaaatc	ccttaacgtg	agttttcgtt	ccactgagcg	tcagaccctg	1140
	tagaaaagat	caaaggatct	tcttgagatc	ctttttttct	gcgcgtaatc	tgctgcttgc	1200
	aaacaaaaaa	accaccgcta	ccagcgggtg	tttgtttgcc	ggatcaagag	ctaccaactc	1260
15	tttttccgaa	ggtaactggc	ttcagcagag	cgcagatacc	aaatactgtc	cttctagtgt	1320
	agccgtagtt	agccaccac	ttcaagaact	ctgtagcacc	gcctacatac	ctcgcctctc	1380
	taatcctgtt	accagtggtc	gctgccagtg	gcgataagtc	gtgtcttacc	gggttggtact	1440
20	caagcgata	gttaccggat	aagcgcgagc	ggtcgggctg	aacggggggt	tcgtgcacac	1500
	agcccagctt	ggagcgaaac	acctacaccg	aactgagata	cctacagcgt	gagctatgag	1560
	aaagcgccac	gcttcccgaa	gggagaaaag	cggacaggtg	tcggttaagc	ggcagggctg	1620
25	gaacaggaga	gcgcacgagg	gagcttccag	ggggaacacg	ctggtatctt	tatagtctcg	1680
	tcgggtttcg	ccacctctga	cttgagcgtc	gattttttgt	atgcctctga	ggggggcgga	1740
	gcctatggaa	aaacgccagc	aacgcggcct	ttttacggtt	ctggcccttt	tgctggcctt	1800
30	ttgctcacat	gttctttctc	gcgttatccc	ctgattctgt	ggataaacgt	attaccgcct	1860
	ttgagtgagc	tgataccgct	cgccgcagcc	gaacgaccga	gcgcagcgag	tcagtgagcg	1920
	aggaagcgga	agagcgccca	atacgcaaac	cgctctctcc	cgcgcgttgg	ccgattcatt	1980
35	aatgcagctg	gcacgacagg	tttccgact	ggaaagcggg	cagtgcgcgc	aacgcaatta	2040
	atgtgagtta	gctcactcat	taggcacccc	aggctttaca	ctttatgctt	ccggctcgta	2100
	tgttgtgtgg	aattgtgagc	ggataacaat	ttcacacagg	aaacagctat	gaccatgatt	2160
	acgccaagcg	cgcaattaac	cctcactaaa	gggaacaaaa	gctggagctg	caagcttaat	2220
40	gtatgtctat	gcataactct	tgtagtcttg	caaatggta	acgatgagtt	agcaacatgc	2280
	cttacaagga	gagaaaaagc	accgtgcagt	ccgattgggt	gaagtaagg	ggtagcatcg	2340
	tgctctatta	ggaaggcaac	agacgggtct	gacatggatt	ggacgaacca	ctgaattgcc	2400
45	gcattgcaga	gatattgtat	ttaagtgcct	agctcgatac	aataaacggg	tctctctggt	2460
	tagaccagat	ctgagcctgg	gagctctctg	gctaactagg	gaaccacatg	cttaagcctc	2520
	aataaagctt	gccttgtagt	cttcaagtag	tgtgtgcccc	tctgttggtg	gactctggta	2580
50	actagagctc	cctcagaccc	ttttagtcag	tgtggaaaaa	ctctagcagt	ggcgcgccga	2640
	caggggacctg	aaagcgaaa	ggaaaacaga	gctctctcga	cgcaggactc	ggcttgccta	2700
	agcgcgcacg	gcaagaggcg	aggggcccgc	actggtgagt	acgcraaaaa	ttttgactag	2760

	cgaggcctag aaggagagag atgggtgcga gagcgctcagt attaagcggg ggagaattag	2820
	atcgcgatgg gaaaaaattc ggttaaggcc aggggggaaa aaaaaatata aattaaaaCa	2880
5	tatagtatgg gcaagcaggg agctagaacg attcgagtt aatcctggcc tgttagaAAC	2940
	atcagaaggc tgtagacaaa tactgggaca gctacaacca tcccttcaga caggatcaga	3000
	agaacttaga tcattatata atacagtagc aacctctcat tgtgtgcacC aaaggataga	3060
10	gataaaagac accaagggaag ctttagacaa gatagaggaa gagcaaaCa aaagtgaagc	3120
	caccgcacag caagcggccg ctgatcttca gaccttgagg aggagatatg agggacaatt	3180
	ggagaagtga attatataaa tataaagtag taaaaattga accattaggga gtagcaccca	3240
15	ccaaggcaaa gagaagagtgt gtgcagagag aaaaaagagc agtgggaata ggagctttgt	3300
	tccttggggt cttgggagca gcaggaagca ctatgggcgc agcctcaatg acgctgacgg	3360
	tacagggcag acaattatgt tctgggtatg tgcagcagca gaacaattgt ctgaggggcta	3420
	ttgaggcgca acagcatctg ttgcaactca cagtctgggg catcaagcag ctccaggcaa	3480
20	gaatcctggc ttgggaaga tacctaaagg atcaacagct cctggggatt tggggttgct	3540
	ctggaaaact catttgcacc actgctgtgc cttggaatgc tagttggagt aataaacttc	3600
	tggaacagat tgaatcaca cgacctggat ggagtgggac agagaaatta acaattacac	3660
25	aagcttataa cactccttaa ttgaagaatc gcaaaaccag caagaaaaga atgaacaaga	3720
	attattggaa ttagataaat gggcaagttt gtggaattgg ttaacataa caaattggct	3780
	gtgggtatata aaattattca taatgatagt aggagcgctg gtaggtttaa gaatagtttt	3840
30	tgctgtactt tctatagtga atagagttag gcagggatat tcaccattat cgtttcagac	3900
	ccacctccca accccgaggg gacccgacag gcccgaaagga atagaagaag aagggtggaga	3960
	gagagacaga gacagatcca ttcgattagt gaacggatct cgacggatc ggtaacatt	4020
35	taaaagaaa ggggggattg gggggtacag tgcaggggaa agaattagtag acataatagc	4080
	aacagacata caaactaaag aattacaataa acaaaattaca aaaattcaaa attttatcga	4140
	tcacgagact agcctcgaga gatctgatca taatcagcca taccacattt gtagaggttt	4200
	tacttgcttt aaaaaacctc ccacacctcc ccttgaacct gaacataaaa atgaatgcaa	4260
40	ttgtgttgt taacttgttt attgcagctt ataattggtta caaataaggc aatagcatca	4320
	caaatttcac aaataaggca tttttttcac tgcattctag ttttggtttg tccaaactca	4380
	tcaatgtatc ttatcatgtc tggatctcaa atccctcgga agctgcgctt gtcttaggtt	4440
45	ggagtgtacat atttttatca cttttaccg tctttggatt aggcagtagc tctgacggcc	4500
	ctcctgtctt aggttagtga aaaatgtcac tctcttaccC gtcattggct gtccagctta	4560
	gctcgagggg gaagtggtct ggtccctgg atatcaagaa ttcgtcctcg agctcagatc	4620
50	ctctagaatt acacgcgcat ctttcgccc ttcttggctt ttatgaggat ctcttgatt	4680
	tttcttgcgt cgagttttcc ggtaagacct ttcggtactt cgtccacaaa cacaactcct	4740
	ccgcgcaact ttttcgcggt tgttacttga ctggccacgt aatccacgat ctctttttcc	4800

	gtcatcgtct tccgtgctc caaaaaca acggcgccg gaagtccacc ggcgtcatcg	4860
	tcgggaagac ctgcgacacc tgcgtcgaag atgttggggt gttggagcaa gatggattcc	4920
5	aattcagcgg gageccactg atageccttg tacttaatac gagaactcag gcggtcaacg	4980
	atgaagaagt gttcgtcttc gtcccagtaa gctatgcttc cagaatgtag ccattcattc	5040
	ttgtcaatac aggcgttggt cgcttccgga ttgtttacat aaccggacat aatcatagga	5100
10	ctcttcacac acagttcgcc tctttgatta acgcccagcg ttttcccggt atccagatcc	5160
	acacacctcg cttaaaaaa tggaaacaact ttaccgacgg cgcccgggtt atcatcccc	5220
	tcgggtgtaa tcagaaatgc tgatgtatgc tcagttagcc catatccttg cctgatacct	5280
	ggcagatgga acctcttggc aaccgcttcc ccgacttctc tagagagggg agcgccacca	5340
15	gaagcaattt cgtgtaatt agataaatcg tatttgcata tcagagtgtc tttggcgaag	5400
	aaggagaata ggttggcgac cagcagcgca cttgaaatc ttgtaacctg aaggctcttc	5460
	agaaacagct ctcttcaaa tctatacatt aagcagactc gaaatccaca tatcaaatat	5520
20	ccgagtgtag taacattcc aaaaccgtga tggaaatgaa caacacttaa aatcgagta	5580
	tcgggaatga ttgtattgcc aaaaatagga tctctggcat gcgagaatct cagcgaggca	5640
	gtctatgag gcagagcgac acctttagcg agaccagtag atccagagga gtccatgatt	5700
25	agtcaattg tctgtccctc atcgaaggac tctggcacia aatcgtattc attaaaaacc	5760
	ggaggtagat gagatgtgac gaacgtgtac atcgactgaa atccctggta atccgtttta	5820
	gaatccatga taataatttt ttggatgatt gggagctttt ttgtcacgtt caaaattttt	5880
30	tgaacccct ttttggaaac gaacaccag gttagctgcg aaatgcccat actgttgagc	5940
	aattcacgtt cattataaat gtcgttcgcg ggcgcaactg caactccgat aaataacgcg	6000
	cccaacaccg gataaaagaa ttgaagagag ttttctctgc atacgacgat tctgtgattt	6060
35	gtattcagcc catatcgttt catagcttct gccaacgaa cggacatttc gaagtactca	6120
	gcgtaagtga ttgccacctc gatattgtca tctgtaaaa caattgttcc aggaaccagg	6180
	gcgtatctct tcatagcctt atgcagttgc tctccagcgg ttccatcttc cagcggatag	6240
	aatggcgccg ggcctttctt tatgtttttg gcgtcttcca tggtagaattc cgatccccct	6300
40	ggggagagag gtcgttgatt cggtcaacga gggagccgac tgccgacgtg cgctccggag	6360
	gcttcgagaa tgcggaacac gcgcggggca ggaacagggc ccaactacc gcccacacc	6420
	ccgcctcccg caccgcccct tcccggccgc tgctctcggc gcgcccgcgt gagcagccgc	6480
45	tattggccac agcccatcgc ggtcggcgcg ctgcatttgc tcccgtggcg tgctcgtctg	6540
	cgagggtact agtgagagct gcggcttcgg tttgtcacgt ccggcagccc gcgaaccgca	6600
	aggaaacctc ccgacttagg ggcggagcag gaagcgtcgc cggggggccc acaagggtag	6660
50	gcgcgaagat ccgggtgacg ctgcgaacgg acgtgaagaa tgtgcgagac ccagggtcgg	6720
	cgccgctgctg tttcccggaa ccacgcccag agcagccgcg tccctgcgca aaccagggcg	6780
	tgccctggaa aaggcgcaac cccaaccccg tgggaattcg atatcaagct tgccatggtt	6840

	cttttgaat ctatccaagt ctatgttaa tgcttatgta aaccataata taaaagagtg	6900
	ctgattttt gagtaaacct gcaacagtc taacattctt ctctcgtgtg tttgtgtctg	6960
5	ttcgccatcc cgtctcgtc cgtcacttat ccttcacttt tcagagggtc cccccgcaga	7020
	tcccggtcac cctcaggtcg ggtcgacaac catggtgagc aaggcgagag agctgttccac	7080
	cggggtggtg cccatcctgg tcgagctgga cggcgacgta aacggccaca agttcagcgt	7140
10	gtccggcgag ggcgagggcg atgccacctt cggcaagctg accctgaagt tcattctgcac	7200
	caccggcaag ctgcccgtgc cctggcccac cctcgtgacc accctgacct acggcggtgca	7260
	gtgcttcagc cgtaccctcg accacatgaa gcagcacgac ttcttcaagt ccgccatgcc	7320
	cgaaggctac gtccaggagc gcaacatctt cttcaaggac gacggcaact acaagaccgg	7380
15	cgccgaggtg aagttcgagg gcgacacctt ggtgaaccgc atcgagctga agggcatgca	7440
	cttcaaggag gacggcaaca tcctggggca caagctggag tacaactaca acagccaca	7500
	cgtctatatc atggccgaca agcagaagaa cggcatcaag gtgaacttca agatccgcca	7560
20	caacatcgag gacggcagcg tgcagctcgc cgaccactac cagcagaaca cccccatcg	7620
	cgacggcccc gtgctgtcgc cgcacaacca ctacctgagc acccagtcgg ccttgagcaa	7680
	agacccaac gagaagcgcg atcacatggt cctgctggag ttctgtgacg ccgccgggat	7740
25	cactctcgcg atggacgagc tgtacaagta aagcggcctc gacaatcaac ctctggatta	7800
	caaaatttgt gaaagattga ctggtattct taactatggt gctcttttta cgtatgtgg	7860
	atacgtgact ttaatgccct tgatatcatgc tattgtctcc cgtatggctt tcattttctc	7920
30	ctccttgat aaatcctggt tgctgtctct ttatgaggag ttgtggcccg ttgtcaggca	7980
	acgtggcggt gtgtgcaactg tgtttgctga cgcacaacccc actggttggg gcattgccac	8040
	cacctgtcac ctcctttccg ggaactttgc ttccccctc cctattgcc aaggcggaact	8100
35	catcgccgcc tgccctgcc gctgctggac aggggctcgg ctgttgggca ctgacaattc	8160
	cgtggtgttg tcgggggaag tgacgtccct tcacatggctg ctgcctctgt ttgccacctg	8220
	gattctgcgc gggagctcct tctgctacgt cccctcggcc ctcaatccag cggaccttcc	8280
	ttcccgcggc ctgctgcggg ctctgcggcc tcttcgcgt cttgccttc gccctcagac	8340
40	gagtcggatc tccctttggg ccgcctcccc gccctggaatt cgagctcggg acctttaaga	8400
	ccaatgactt acaaggcagc tgtagatctt agccactttt taaaagaaaa ggggggagctg	8460
	gaagggtcaa ttactccca acgaagacaa gatctgctt ttgcttgta tgggtctctc	8520
45	tggttgagcc agatctgagc ctgggagctc tctgctaac tagggaaccc actgcttaag	8580
	cttcaataaa gcttgccctg agtgcttcaa gtatgtgtgt cccgtctggt gtgtgactct	8640
	ggttaactaga gatccctcag acccttttag tcagtgtgga aaatctctag cagtagtagt	8700
50	tcattgtcat ttattattca gtatttataa cttgcaaga aatgaatatc agagagtgag	8760
	aggaacttgt ttattgcagc ttataatggt tacaataaaa gcaatagcat cacaaatttc	8820
	acaaataaag catttttttc actgcattct agttgtgggt tgtccaaact catcaatgta	8880

tcttatcatg tctggctcta gctatccgc cccaaactcc gccagttcc gccattctc 8940
 cgcgccatgg ctgactaatt ttttttatt atgcagaggc cgaggccgcc tcggcctctg 9000
 5 agctattcca gaagtagtga ggaggctttt ttggaggcct aggtctttgc gtcgagacgt 9060
 acccaattcg ccctatagtg agtcgtatta cgcgcgtcca ctggccgtcg ttttacaacg 9120
 tcgtgactgg gaaaaccctg gcgttaccca acttaatcgc ctgcagcac atcccccttt 9180
 10 cgcagctgg cgtaatagcg aagaggcccg caccgatcgc ccttcccaac agttgcgcag 9240
 cctgaatggc gaatggcgcg acgcgccctg tagcggcgca ttaagcgcgg cgggtgtggt 9300
 ggttacgcgc agcgtgaccg ctacacttgc cagcgcccta gcgcccgctc ctttcgtttt 9360
 cttcccttcc ttctcgcca cgttcgcgg ctttcccggt caagctctaa atcggggggt 9420
 15 ccttttaggg ttccgattta gtgctttacg gcacctgcac cccaaaaaac ttgattaggg 9480
 tgatggttca cgtagtgggc catcgccctg atagacgggt ttctgcctt tgacgttga 9540
 gtccacgttc tttaatagtg gactcttgtt ccaaaactgga acaacatca accctatctc 9600
 20 ggtctattct ttgtatttat aagggaattt gccgatttcg gcctattggt taaaaaatga 9660
 gctgatttaa caaaaattta acgcgaattt taacaaaata ttaacgttta caatttcc 9718

<210> 7
 25 <211> 9490
 <212> DNA
 <213> Artificial Sequence

<220>
 30 <223> plasmid
 <220>
 <221> misc_feature
 <222> (1)..(9490)
 <223>

35 <220>
 <221> misc_feature
 <222> (1)..(9490)
 <223> plasmid containing the lentiviral vector construct CCL-MA3-GFP/de ItaLNGFR

40 <400> 7
 caggtagcac ttctgggga aatgtagcg gaaccccat tigtattt ttctaaatca 60

45

50

55

	attcaaatat gtatccgctc atgagacaat aaccttgata aatgcttcaa taatattgaa	120
	aaaggaagag tatgagtatt caacatttcc gtgtcgccct tattcccttt ttgcygcat	180
5	tttgccttcc tgtttttgct caccagaaa cgctggtgaa agtaaaagat gctgaagatc	240
	agtgggtgc acgagtgggt tacatcgaaac tggatctcaa cagcggtaag atccttgaga	300
	gttttcgcc cgaagaacgt ttccaatga tgagcacttt taaagttctg ctatgtggcg	360
10	cggtattatc ccgtattgac gccgggcaag agcaactcgg tcgcgcgata cactattctc	420
	agaatgactt ggttgagtac tcaccagtca cagaaaagca tcttaccgat ggcattgacag	480
	taagagaatt atgcagtgc gccataacca tgagtataa cactgcggcc aacttacttc	540
15	tgacaacgat cggaggaccg aaggagctaa ccgctttttt gcacaacatg ggggatcatg	600
	taactcgctt tgatcgttgg gaaccggagc tgaatgaagc cataccaaac gacgagcgtg	660
	acaccagatg gccgttagca atggcaacaa cgttcgcgaa actattaact ggcgactac	720
	ttactctagc tccccgcaa caattaatag actggatgga ggcgataaaa gttgcaggac	780
20	cacttctcgc etcgccctt ccggctggct ggtttattgc tgataaatct ggaagccggtg	840
	agcgtgggtc tcgcggtatc attgcagcac tggggcaga tgtaagccc tcccgatcg	900
	tagttactca cagcagggg agtcaggcaa ctatggatga acgaaataga cagatcgctg	960
25	agatagggtc ctactgatt aagcattggt aactgtcaga ccaagtttac tcataatatac	1020
	tttagattga tttaaaactt catttttaat ttaaaaggat ctagggtgaag atctcttttg	1080
	ataatctcat gacaaaaatc ccttaacgtg agttttcgtt ccactgagc tcagaccctg	1140
30	tagaaaagat caaaggatct tcttgagatc cttttttctt gcgcgtaatc tgctgcttgc	1200
	aaacaaaaa accacgccta ccagcgggtg tttgtttgcc ggatcaagag ctaccaactc	1260
	tttttcgaaa ggttaactggc ttacgcagag cgcagatacc aaatactgtc cttctagtgt	1320
35	agccgtagtt aggcaccac ttcaagaact ctgtagcacc gcctacatac ctgcctctgc	1380
	taatctctgt accagtggtc gctgccagtg gcgataagtc gtgtcttacc gggttggact	1440
	caagacgata gttaccggat aagcgcagc ggtcgggctg aacggggggt tcgtgcacac	1500
40	agccagctt ggagcgaacg acctacaccg aactgagata cctacacgtg gagctatgag	1560
	aaagcgcac gcttccgaa gggagaaaag cggacagta tcgcgtaagc ggcagggtcg	1620
	gaacaggaga gcgcacgag gagcttccag ggggaacgc ctggtatctt tatagctctg	1680
	tcgggtttcg ccacctctga cttgagcgtc gattttttgt atgtcgtca gggggcgga	1740
45	gcctatggaa aaacgccagc aacgcggcct ttttacggtt cctggccttt tgctggcctt	1800
	ttgctcacat gttctttctt gcgttatccc ctgattctgt ggataaccgt attaccgctt	1860
	ttgagtgagc tgataccgct cgcgcagcc gaacgaccga gcgcagcag tcagtgcagc	1920
50	aggaagcga agagcgcaca atacgcaaac gcctctccc cgcgcgttgg ccgattcatt	1980
	aatgcagctg gcacgacagg ttccccgact ggaagcggg cagtgcgcg aacgcaatta	2040
	atgtgagtta gctcactcat taggcacccc aggcctttaca ctttatgctt ccggtctgta	2100

	tgttgtgtgg aattgtgagc ggataacaat ttcacacagg aaacagctat gacctgatt	2160
	acgccaaagc cgcaattaac cctcactaaa gggaaacaaa gctggagctg caagcttggc	2220
5	cattgcatatc gttgtatcca tatcataata tgtacattta tatggctca tgtccaacat	2280
	taccgccatg ttgacattga ttattgacta gttattaata gtaatcaatt acggggctcat	2340
	tagttcatag cccatatatg gagttccgcg ttacataact tacggtaaat ggcgcgctg	2400
10	gctgaccgcc caacgacccc cgcccattga cgtcaataat gacgtatgtt cccatagtaa	2460
	cgccaatagg gactttccat tgacgtcaat ggggtgagta ttacggtaa actgccact	2520
	tggcagtaca tcaagtgat catatgccaa gtacgcccc tattgacgtc aatgacggt	2580
15	aatggcccgc ctggcattat gcccagtaca tgaccttatg ggactttcct acttggcagt	2640
	acatctacgt attagtcac gctattacca tgggtgatcg gttttggcag tacatcaatg	2700
	ggcgtggata cgcggttgac tcacggggat ttccaagctt ccaccccat gacgtcaatg	2760
20	ggagtgtgtt ttggcaccaa aatcaacggg actttccaaa atgtcgtaac aactcgcccc	2820
	cattgacgca aatggcggtt aggcgtgtac ggtgggaggt ctatataagc agagctcgtt	2880
	tagtgaaccg ggtctctct ggttagacca gatctgagcc tgggagctct ctggctaact	2940
	agggaaacca ctgcttaagc ctcaataaag ctgacctga gtgcttcaag tagtgtgtgc	3000
25	ccgtctgttg ttgactctg gtaactagag atccctcaga cctcttagt cagtgtggaa	3060
	aatctctagc agtggcgccc gaacagggac ctgaaagcga aagggaacc agagctctct	3120
	cgacgcagga ctggccttgc tgaagcgcgc acggcaagag cgcggggcg gcgactggtg	3180
30	agtacgccaa aaattttgac tagcggaggc tagaaggaga gagatgggtg cgagagcgtc	3240
	agtattaagc gggggagaat tagatcgcga tgggaaaaaa ttcggttaag gccaggggga	3300
	aagaaaaaat ataaattaaa acatatagta tgggcaagca gggagctaga acgattcgca	3360
35	gttaatcctg gccgtttaga aacatcagaa ggctgtagac aaatactggg acagctacaa	3420
	ccatcccttc agacaggatc agaagaactt agatcattat ataatacagt agcaaccttc	3480
	tattgtgtgc atcaaaggat agagataaaa gacaccaagg aagctttaga caagatagag	3540
40	gaagagcaaa acaaaagtaa gaccaccgca cagcaagcgg ccgctgatct tcagacctgg	3600
	aggaggagat atgagggaca attggaagaag tgaattatat aaataaag tagtaaaat	3660
	tgaaccatta ggagtagcac ccaccaaggc aaagagaaga gtggtgcaga gagaaaaaag	3720
	agcagtgagg ataggagctt tgttccttgg gttcttggga gcagcaggaa gcactatggg	3780
45	cgcagcctca atgacgtga cggtagagc cagacaatta ttgcttggta tagtgcagca	3840
	gcagaacaat ttgctgaggc ctattgagc gcaacagcat ctgttgcaac tcacagcttg	3900
	gggcatacag cagctccagg caaagaatcct ggctgtggaa agatacctaa aggatcaaca	3960
50	gctcctgggg atttgggggt gctctggaaa actcatttgc accactgctg tgccttggaa	4020
	tgctagtgg agtaataaat ctctggaaac gatttggaa cacacgacct ggaatgaagt	4080
	ggacagagaa attaacaatt acacaagctt aatacactcc ttaattgaag aatcgcaaaa	4140

cCagcaagaa aagaatgaac aagaattatt ggaattagat aaatgggcaa gtttgaggaa 4200
 ttggtttaac ataacaattt ggctgtggta tataaaatta ttcaataag tagtaggagg 4260
 5 cttggttaggt ttaagaatag tttttgctgt actttctata gtgaatagag ttaggcaggg 4320
 atattcacca ttatcgtttc agaccacact cccaaacctg aggggacctg acaggctcga 4380
 aggaatagaa gaagaagggt gagagagaga cagagacaga tccatcgat tagtgaacgg 4440
 10 atctcgacgg tatcggttaa cttttaaaag aaaagggggg attggggggg acagtgcagg 4500
 ggaaagaata gtgacataa tagcaacaga catacaact aaagaattac aaaaacaaat 4560
 tacaaaaatt caaaatttta tcgatcacga gactagcctc gaggagatct gatcataatc 4620
 15 agccatacca cattttaga ggttttactt gctttaaana accctccaca cctccccctg 4680
 aacctgaac ataaaatgaa tgcaattggt gttgttaact tgtttattgc agcttataat 4740
 ggtttacaaat aaggcaatag catcacaaat ttcacaaata aggcattttt ttacttgcat 4800
 20 tctagttttg gttgttccaa actcatcaat gtatcttatc atgtctggat ctcaaatccc 4860
 tcggaagctg cgccgtgctt aggttggagt gatacathtt tatcactttt acccgctctt 4920
 ggattaggca gtactctga cgccctctct gcttaggtt agtgaaaaat gtcactctct 4980
 tacccgtcat tggctgtcca gcttagctcg caggggagggt ggtctggatc caccatgtct 5040
 25 agagaatagg aacttcggaa taggaacttc gcggccgctt tacttgata gctcgatcat 5100
 gccgagagtg atcccggcg cggtcacgaa ctccagcagg accatgtgat cgccttctc 5160
 gttggggctt ttgctcagg cggaactgggt gctcaggtag tggttgtcgg gcagcagcac 5220
 30 gggggcgctg cgaatggggg tgttctgctg gtatgtgctg gcgagctgca cgtgcgcgtc 5280
 ctgcatgttg tggcggatct tgaagttcac ctgatgccg tcttctgctt gtcggccat 5340
 gatatagacg ttgtggctgt ttagttgta ctccagcttg tgcccaggga tgttgccgtc 5400
 35 ctctctgaag tcgatgccct tcagctcgat gcggttcacc aggggtgcgc cctcgaaact 5460
 cacttcggcg cggttctgtt agttgctgct gctcttgaag aagatggtgc gtcctygac 5520
 gtgaccttg ggcatggcg acttgaagaa gtctgtctgc ttcattggtt cggggtagcg 5580
 gctgaagcac tgcacgccgt aggtcagggt ggtcacgagg gtgggccagg gcacgggag 5640
 40 ctgtccggtg gtgcagatga acttcagggt cagcttgccg taggtggcat cgcctcgcc 5700
 ctgcggagac acgctgaact tgtggcgtt tacgtcgccg tccagctcga ccaggatggg 5760
 caccaccccg gtgaacagct cctcgccctt gctcacatg gttgtgcacc cgacctgagg 5820
 45 gtgacctgga tctgcggggg gacctctga aaagtgaagg ataagtgcg agcggagagc 5880
 ggaatggcga cagacacaaa cacacgagag aagaattgta ggactgttc aagttactc 5940
 aaaaaatcag cactctttta tattatggtt tacataagca ttacataaag acttgatag 6000
 50 attccaaaag aacataggca agcttgatat cgaattccca cgggggtggg gttgcgcctt 6060
 ttccaaggca gccctgggtt tgcgcaggga cgcggctgct ctggcgctgg ttccgggaaa 6120
 cgcagcggcg cgaccctgg gtctcgaca ttctcacgt cgttgcgag cgtcacccgg 6180

	atcttcgccg ctacccttgt gggccccccg gcgacgttc ctgtccgcc cctaagtcgg	6240
	gaaggttccct tgcggttcgc ggcgtgccgg acgtgacaaa cggaaagccg acgtctcact	6300
5	agtaccctcg cagacggaca gcgccaggga gcaatggcag cgcgccgacc gcgtcgggct	6360
	gtggcacaata cggcctgctc agcggggcgc gccgagagca gcggcggga aggggcggtg	6420
	cgggagcggc ggtgtggggc ggtagtgtgg gccctgttcc tgcccgcgcg gtgttcgcga	6480
10	ttctgcaagc ctccggagcg caggtcggca gtgcgtctcc tctgtgacc aatcaccgac	6540
	ctctctcccc agggggatcc cccgggctgc aggaattcgg gccgcggca gctccggcgg	6600
	gcaggggggg cgtcggagcg cagcgcagcg cagcccatc agtcgcgaaa gcggaccgag	6660
15	ctggaagtgc agcgtctgcc cgggagcggc gcgatggggg caggcgccac cggccgcgcc	6720
	atggacgggc cgcgcctgct gctgttgctg ctctcggggg tgcctcttgg aggtgccaa	6780
	tgaggcatgcc ccacagcgct gtacacacac agcgttgagt gctgcaaac cgtcaacctg	6840
	ggcgagggtg tggcccagcc ttgtggagcc aaccagaccg tgtgtgagcc ctgcctggac	6900
20	agcgtgacgt tctccgacgt ggtgagcgcg accgagccgt gcaagccgtg caccgagtgc	6960
	gtgggctctc agagcatgtc ggcgccgtgc gtggaggcgc acgacgcgtg gtgcgcgtgc	7020
	gcctacggct actaccagga tgagacgact gggcgctcgc aggcgtgcgc cgtgtgcgag	7080
25	gcgggctcgg gcctcgtgtt ctccctgccg gacaagcaga acaccgtgtg cgaggagtgc	7140
	cccgcggcca cgtattccga cggggccaac cagctggacc cgtgcctgcc ctgcaccgtg	7200
	tgcgaggaca ccgagcgcca gctccgcgag tgcacacgct gggccgacgc cgagtgcgag	7260
30	gagatccctg gccgttggat tacacggtcc acaccccag agggctcgga cagcacagcc	7320
	ccagcacc ccaggcctga ggcacctcca gaacaagacc tcatagccag cagcgtggca	7380
	ggtgtggtga ccacagtgtg gggcagctcc cagcccgctg tgaccgagg caccaccgac	7440
35	aacctctacc ctgtctattg ctccatcctg gctgctgtgg ttgtggcct tgtggcctac	7500
	atagccttca agagggtgaa cagggggatc ctctagagtc gagtctagag tcgacaatca	7560
	acctctggat taaaaaattt gtgaaagatt gactggtatt cttaactatg ttgtcctttt	7620
40	tacgctatgt ggatacgtgc ctttaattgcc ttgtatcat gctattgct cccgatggc	7680
	ttctatttcc tctcccttgt ataaatcccg gttgctgtct ctttatgag agttgtggcc	7740
	cgttgtcagg caacgtggcg tgggtgac ttgtttgtct cagcgaaccc ccactgggtg	7800
	gggcattgcc accacctgtc agctcctttc cgggaccttc gctttccccc tccctattgc	7860
45	cacggcggaa ctctcgcgc cctgccttgc ccgctgtcg acaggggctc ggctgttggg	7920
	cactgacaat tccgtggtgt tgcgggggaa cgtgacgtcc tttcatggc tgctcgcctg	7980
	tgttgcacc tggattctgc gcgggacgtc ctctcgtac gtcctctcg cctcctatcc	8040
50	agcggacctt ccttccgcgc gctgtgtgcc ggcctcgcgc cctcttcgcg gcttctgcct	8100
	tcgcctcag acgagtcgga tctccttttg ggcgcctcc ccgcctggaa ttcgagctcg	8160
	gtacctttaa gaccaatgac ttacaaggca gctgtagatc ttagccactt tttaaaagaa	8220

55

aaggggggac tgggaaggct aattcactcc caacgaagac aagatctgct ttttgcttgt 8280
 actgggtctc tctggttaga ccagatctga gcctgggagc tctctggcta actaggggaa 8340
 5 ccaactgcta agcctcaata aagcttgctt tgagtgttc aagtagtgtg tgcccgctcg 8400
 tgtgtgact ctggtaacta gagatccctc agaccctttt agtcagtggt gaaaatctct 8460
 agcagtagta gtcatgtca tcttattatt cagtatttat aacttgcaaa gaaatgaata 8520
 10 tcagagagtg agaggaactt gtttattgca gcttataatg gttacaaata aagcaatagc 8580
 atcacaaatt tcacaaataa agcatttttt tcactgcatt ctagtgtgtg tttgtccaaa 8640
 ctcatcaatg tatcttatca tgtctggttc tagctatccc gccccaact ccgccagtt 8700
 ccgccattc ccgcccat ggctgactaa ttttttttat ttatgcagag gccgaggcg 8760
 15 cctcggtc tgagctattc cagaagtagt gaggaggctt ttttggaggc ctaggctttt 8820
 gcgtcgagac gtacccaatt cgcctatag tgagtcgtat tacgcgcgtc ctaggccgt 8880
 cgttttacaa cgtcgtgact gggaaaacc cgtcgttacc caacttaac gccttcgagc 8940
 20 acatccccct ttcgccagct ggcgtaatag cgaagaggcc cgcaccgac gcccttccca 9000
 acagttgcgc agcctgaatg gcgaatggcg cgacgcgcc tgtacggcg cattaagcg 9060
 ggcgggtgtg gtggttacgc gcagcgtgac cgtacacatt gccacgcc tagcgccgc 9120
 25 tcctttcgct tcttccctt cttttctcgc cagtttcgcc ggcttcccc gtcaagctct 9180
 aaatcggggg ctccctttag ggttccgatt tagtgcttta cggcacctcg accccaaaaa 9240
 acttgattag ggtgatggtt cagtagtggt gccatcgccc tgatagacgg tttttcgccc 9300
 30 tttgacgtgt gagtccacgt tctttaatag tggactcttg ttccaaactg gaacaacact 9360
 caaccctatc tcggtctatt cttttgattt ataagggtt ttgccgattt ggccctattg 9420
 gttaaaaaat gagctgattt aacaaaaatt taacgcgaat ttaacaaaaa tattaacgtt 9480
 35 tacaatttcc 9490

<210> 8
 <211> 10086
 <212> DNA
 40 <213> Artificial Sequence

 <220>
 <223> plasmid
 <220>
 45 <221> misc_feature
 <222> (1)..(10086)
 <223>

 <220>
 50 <221> misc_feature
 <222> (1)..(10086)
 <223> plasmid containing the lentiviral vector construct CCL-MA4-GFP/de ItaNFR

 <400> 8
 55

5
 10
 15
 20
 25
 30
 35
 40
 45
 50
 55

cagggtggcac ttttcgggga aatgtgcgcg gaacccctat ttgtttatct ttctaataac 60
 attcaaatat gtatccgctc atgagacaat aacctcgata aatgcttcaa taatattgaa 120
 aaaggaagag tatgagtatt caacatttcc gtgtcgccct tattcccttt ttgtcggcat 180
 ttgtccttct tgtttttgct caccagaaa cgctggtgaa agtaaaagat gctgaagatc 240
 agttgggtgc acgagtggtt tacatcgaac tggatctcaa cagcggtaag atccttgaga 300
 gttttcgccc cgaagaacgt tttccaatga tgagcacttt taaagttctg ctatgtggcg 360
 cggattattc ccgtattgac gccgggcaag agcaactcgg tcgcccata cactattctc 420
 agaatgactt ggttgagtag tcaccagtca cagaaaagca tcttacggat ggcagtagac 480
 taagagaatt atgcagtgtc gccataacca tgagtgtata cactgcggcc aacttacttc 540
 tgacaaacgt cggaggacgc aaggagctaa ccgctttttt gcacacatg ggggagcatg 600
 taactcgcct tgatcgttgg gaaccggagc tgaatgaagc cataccaaac gacgagcgtg 660
 acaccacgat gccctgtagc atggcaacaa cgctgcgcaa actattaact ggcgaactac 720
 ttactctagc ttcccggcaa caattaatag actggatgga ggcggataaa gttgcaggac 780
 cacttctgcg ctccggcctt ccggttggtt ggtttattgc tgataaatct ggagccgggtg 840
 agcgtgggtc tcgctgtatc attgcagcac tggggccaga tggtaagccc tcccgtatcg 900
 tagttatcta cagcagggg agtcaggcaa ctatggatga acgaaataga cagatcgctg 960
 agataggtgc ctactgatt aagcattggt aactgtcaga ccaagtttac tcatatatac 1020
 tttagattga tttaaaactt catttttaac ttaaaaggat ctagggtgaag atcctttttg 1080
 ataactctat gaccaaaatc ccttaacgtg agttttcgtt ccactgagcg tcagaccctg 1140
 tagaaaagat caaaggatct tcttgagatc ctttttttct gcgcgtaac tgctgcttgc 1200
 aaacaaaaaa accaccgcta ccagcggtgg ttgttttgc ggatcaagag ctaccaactc 1260
 tttttccgaa ggtaactggc ttacgacgag cgcagatacc aaatactgtc ctctagtgt 1320
 agcgttagtt aggccaccac ttcaagaact ctgtagcacc gcctacatac ctctccttgc 1380
 taatcctgtt accagtggct gctgccagtg gcgataagtc gtgtcttacc gggttggact 1440
 caagacgata gttaccgat aaggcgacg ggtcgggctg aacggggggt tcgtgcacac 1500
 agcccagctt ggagcgtaacg acctacacgc aactgagata cctacagct gagctatgag 1560
 aaagccgacg gcttccgaa gggagaagg cgagacagga tcgggtaagc ggcagggtcg 1620
 gaacaggaga gcgcacgag gagcttccag ggggaaacgc ctggtatctt tatagctctg 1680

	tcgggtttcg ccacctctga cttgagcgct gatTTTTgtg atgctcgtca ggggggcgga	1740
	gcctatggaa aaacgccagc aacgcggcct ttttacggtt cctggccttt tgcTggcctt	1800
5	ttgctcatat gttctttcct gcgttatccc ctgattctgt ggataaccgt attaccgcct	1860
	ttgagtgaac tgataccgct cgcgcgagcc gaacgacga gcgcagcgag tcagtgaagc	1920
	aggaaagcga agagcgccca atacgcaaac cgctctccc cgcgcgttgg ccgattcatt	1980
10	aatgcagctg gcacgacagg ttccccgact ggaagcgagg cagtgaagc aacgaatta	2040
	atgtgagtta gctcactcat taggcacccc aggcctttaca ctttatgctt ccggtctgta	2100
	tgttgtgtgg aattgtgagc ggataacaat ttacacaggg aaacagctat gaccatgatt	2160
15	acgccaagcg cgcaattaac cctcactaaa gggaacaaaa gctggagctg caagcttggc	2220
	cattgcatac gttgtatcca tatcataata tgtacattta tattggctca tgctcaacat	2280
	taccgccatg ttgacattga ttattgacta gttattaata gtaatcaatt acggggctcat	2340
	tagttcatag ccataatag gagttccgag ttacataact tacggtaaat gggccgctgt	2400
20	gctgaccgcc caacgacccc cgccatttga cgtcaataat gacgtatgtt cccatagttaa	2460
	cgccaatagg gactttccat tgacgtcaat ggggtgagta ttacggtaa actgccact	2520
	tggcagtaca tcaagtgtat catatgccaa gtacgccccc tattgacgtc aatgacggta	2580
25	aatggcccgcc ctggcattat gccagttaca tgaccttatg ggactttcct acttggcagt	2640
	acatctacgt attagtcatc gctattacca tggtgatgag gttttggcag tacatcaatg	2700
	ggcgtggata gcggtttgac tcacggggat ttccaagtct cccccccatt gacgtcaatg	2760
30	ggagtttgtt ttggcaccaa aatcaacggg actttccaaa atgtcgtaac aactccgcc	2820
	cattgacgca aatggcggtt aggcgtgtac ggtgggaggt ctatataagc agagctcgtt	2880
	tagtgaacgg gggctctctt ggttagacca gatctgagcc tgggagctct ctggctaac	2940
35	agggaaacca ctgcttaagc ctcaataaag cttgccttga gtgcttcaag tagtgtgtgc	3000
	ccgtctgttg tgtactctg gtaactagag atccctcaga cccttttagt cagrtgggaa	3060
	aatctctagc agtggcgccc gaacagggac ctgaaagcga aagggaacc agagctctct	3120
40	cgacgcagga ctgcgcttgc tgaagcgccg acggcaagag gcgagggggc gcgactggtg	3180
	agtacgccaa aaattttgac tagcggaggc tagaaggaga gagatgggtg cgagagcgct	3240
	agtattaaag gggggagaat tagatcgaga tgggaaaaaa ttcggttaag gccaggggga	3300
45	aagaaaaaat ataaattaaa acatatagta tgggcaagca gggagctaga acgattcgca	3360
	gttaatcctg gcctgttaga aacatcagaa ggctgtagac aaatactggg acagctacaa	3420
	ccatcccttc agacaggatc agaagaactt agatcattat ataatacagt agcaaccctc	3480
	tattgtgtgc atcaaggat agagataaaa gacaccaagg aagctttaga caagatagag	3540
50	gaagagcaaa acaaaagtaa gaccaccgca cagcaagcgg ccgctgatct tcagacttgg	3600
	aggaggagat atgagggaca attggagaag tgaattatat aaatataaag tagtaaaaat	3660
55	tgaaccatta ggagtagcac ccaccaaggg aaagagaaga gtggtgcaga gagaaaaag	3720

	agcagtggga ataggagctt tgttccttgg gttcttggga gcagcaggaa gcactatggg	3780
	cgcagcctca atgacgctga cgggtacaggc cagacaatta ttgtctggta tagtgacaga	3840
5	gcagacaatt ttgctgaggg ctattgaggg gcaacagcat ctgttgcaac tcacagtctg	3900
	gggcatcaag cagctccagg caagaatcct ggctgtgaa agatacctaa aggatcaaca	3960
	gctctggggg atttgggggtt gctctggaaa actcatttgc accactgctg tgcttggaa	4020
10	tgctagtgg agtaataaat ctctggaaca gattggaatc acacgacctg gatggagtgg	4080
	gacagagaaa ttaacaatta cacaagctta atacactcct taattgaaga atcgcaaac	4140
	cagcaagaaa agaatagaaca agaattattg gaattagata aatgggcaag ttgttggaat	4200
15	tggtttaaca taacaaattg gctgtggtat ataaaaat tcatatgat agtaggaggc	4260
	ttggtagggt taagaatagt ttttctgtga ctttctatag tgaatagagt taggcaggga	4320
	tattccacct tatcgtttca gaccacctc ccaacccga ggggaccga caggcccgaa	4380
20	ggaatagaag aagaagggtg agagagagac agagacagat actctgatt agtgaacgga	4440
	tctcgacggt atcggttaac ttttaaaaga aaagggggga ttggggggtg cagtgcaggg	4500
	gaaagaatg tagacataat agcaacagac atacaaacta aagaattaca aaaaacaaat	4560
	acaaaaattc aaaattttat cgatcacgag actagcctcg agagattctga tcataatcag	4620
25	ccataccaca ttgttagagg ttttacttgc tttaaaaaac ctcccacacc tccccttgaa	4680
	cctgaacat aaaaatgaatg caattgttgt tgttaacttg tttattgcag cttataatgg	4740
	ttacaaataa ggcaatagca tcacaaattt cacaaataag gcattttttt cactgcattc	4800
30	tagttttggg ttgtccaaac tcattcaatgt atcttatcat gcttggattc caaatccctc	4860
	ggaagctgcy cctgtcttag gttggagtga tacattttta tcacttttac ccgtcttgg	4920
	attaggcagt agctctgacg gccctcctgt cttagggttag tgaaaaaatgt cactctctta	4980
35	cccgctattg gctgtccagc ttagctcgca ggggaggtgg tctggatccg agctcgaatt	5040
	ggcgcgttta cttgtacagc tcgtccatgc cgagagtgt cccggcgcg gtcacgaact	5100
	ccagcaggac catgtgatcg cgcttctcgt tggggtcttt gctcaggcgcg gactgggtgc	5160
40	tcaggtagtg gttgtcgggc agcagcacgg gcccgctgcc gatgggggtg tctgctggt	5220
	agtggctggc gagctgcacg ctgccgtcct cgatgttgtg gcggatcttg aagtccact	5280
	tgatgccgtt cttctgcttg tcggccatga tatagcgtt gtggctgttg tagttgtact	5340
	ccagcttggt cccagagatg ttgccgtcct cttggaagtc gatgcccttc agctcgatgc	5400
45	ggttccaccg ggtgtcggcc tcgaacttca cctcggcgcg ggtctgttag ttgccgtcgt	5460
	ccttgaagaa gatggtgcgc tcctggacgt agccttcggg catggcggac ttgaagaagt	5520
	cgtgctgctt catgtggtcg gggtagcggc tgaagcactg cagccgtag gtcagggtgg	5580
50	tcacgagggg gggccagggc acgggcagct tgccggtggt gcagatgaac ttcagggtca	5640
	gcttgcgcta ggtggcatgc cctcgcctc cgccggacac gctgaacttg tggccgttta	5700
55	cgtcgcgctc cagctcgacc aggatgggca ccaccccggt gaacagctcc tcgcccttgc	5760

	tcaccatggt gaattccgcg gaggctggat cggtcccggg gtcttctatg gaggtaaaaa	5820
	cagcgtggat ggcgtctcca ggcgatctga cggttcacta aacgagctct gcttatatag	5880
5	gcctccaccac gtacacgcct accctcagag agcttgatta acccggtgct gctccagatc	5940
	tggctccgcg gccgggtttt ggcgcctccc gcgggcgcgc ccctctctac ggcgagcgct	6000
	gccacgtcag acgaaggcg cagcgagcgt cctgatcctt ccgcccggac gctcaggaca	6060
10	gcggcccgct gctcataaga ctcgccctta gaacccagat atcagcagaa ggcattttta	6120
	ggagcggact tgggtgactc tagggcactg gttttcttct cagagagcgg aacaggcgag	6180
	gaaaagtagt cccttctcgg cgattctcgc gagggatctc cgtggggcgg tgaacgccga	6240
15	tgattatata aggacgcgcc ggggtgtgca cagctagttc cgtcgagcc gggatttggg	6300
	tcgcggttct tgtttgtgga tcgctgtgat cgtcacttgg tgagttgcgg gctgctgggc	6360
	tggccggggc tttcgtggcc gccggggcgc tcggtgggac ggaagcgtgt ggagagaccg	6420
20	ccaaggggctg tagtctgggt ccgcgagcaa ggttgccctg aactgggggt tggggggagc	6480
	gcacaaaaat gcggctgttc ccgagcttg aatggaagac ccttgtaagg cgggctgtga	6540
	ggtcgttgaa acaagggtgg gggcatggtg ggcggcaaga acccaaggtc ttgaggcctt	6600
	cgctaattgcg ggaagactct tattcgggtg agatgggctg gggcaccatc tggggaccct	6660
25	gacgtgaagt ttgtcactga ctggagaact cgggtttgtc gtctgtgtgc gggggcgcca	6720
	gttatgcggt gccgttgggc agtgacccg tacctttggg agcgcgcgcc tcgtcgtgtc	6780
	gtgacgtcac ccgttctgtt ggcttataat gcaggggtgg gccacctgcc ggtagggtgtg	6840
30	cggttaggctt ttctccgtcg caggacgcag ggttcgggcc tagggtaggc tctcttgaat	6900
	cgacaggcgc cggacctctg gtgaggggag ggataagtga ggcgtcagtt tctttgtcgc	6960
	gttttatgta cctatcttct taagtagctg aagctccggt ttgaaactat gcgctcgggg	7020
35	ttggcgagtg tgttttgtga agttttttag gcaccttttg aaatgtaatc attttgggtca	7080
	atatgtaatt ttcagtgtaa gactagtaaa ttgtccgcta aattctggcc gtttttggct	7140
	tttttgttag acgaagcttg ggcgtcagga attcgggccc cggccagctc cggcgggcag	7200
40	ggggggcgct ggaagcgagc gcagcgagc ccacatcagtc cgcgaagcgg accgagctgg	7260
	aagtcgagcg ctgcgcgggg aggcggggcga tgggggcagg tgccaccggc cgcgccattg	7320
	acggggccgc cctgctgctg ttgctgcttc tgggggtgtc ccttgaggat gccaaaggag	7380
	catgccccc aggcctgtac acacacagcg gtgagtgctg caaagcctgc aacctgggctg	7440
45	agggtgtggc ccagccttgt ggagccaacc agaccgtgtg tgagccctgc ctggacagcg	7500
	tgacgttctc cgacgtgggt agcgcgaccg agccgtgcaa gccgtgcacc gagtgcgtgg	7560
	ggctccagag catgtcggcg ccgtgcgtgg aggcgacga cgcgtgtgc cgtcgcgcct	7620
50	acggctacta ccaggatgag acgactgggc gctgcgaagg gtgcgcgctg tgcgaggcgg	7680
	gctcgggccc cgtgttctcc tgccaggaca agcagaacac cgtgtgcgag gagtgcgccg	7740
	acggcacgta ttccgacgag gccaacacag tggaccctgt cctgccttgc accgtgtgcg	7800
55		

	aggacaccga gcgcagctc cgcgagtga cacgctgggc cgacgccgag tgcgaggaga	7860
	tccctggcgc ttggattaca cggctccacac cccagaggg ctcggacagc acagcccca	7920
5	gcacccaggga gcctgaggca cctccagaac aagacctcat agccagcacg gtggcagggt	7980
	tgggtgaccac agtgatgggc agctccacgc cgcgtgtgac ccgaggcacc accgacaacc	8040
	tcacccctgt ctattgtccc atcctggctg ctgtggttgt gggccttgtg gccacacatg	8100
10	ccctcaagag gtggaacagg gggatcctct agagtcgagt cttagtcga caatcaacct	8160
	ctggattaca aaatttgrga aagattgact ggtattctta actatgttgc tccctttacg	8220
	ctatgtggat acgctgcttt aatgcctttg tatcatgcta ttgtctcccg tatgctctt	8280
15	attttctctt ccttgataa atcctggttg ctgtctcttt atgaggagtt gtggccgctt	8340
	gtcaggcaac gtggcgtggt gtgcactgtg tttgctgacg caacccccc tggttggggc	8400
	attgccacca cctgtcagct cctttccggg accttcgctt tccccctccc tattgccag	8460
	ggcgaactca tcggcgccgt ccttgcccgc tgcaggacag ggcctcgct gttagggcact	8520
20	gacaattccg tgggtgtgtc ggggaagctg acgtcctttc catggctgct cgctgtgtt	8580
	gccactgga ttctgcggg gacgtccttc tgcacgtcc cttcgccct caatcagcg	8640
	gaccttcttt ccgcggcct gctgccggct ctgcggcctc ttcgcgctc tcgctctgc	8700
25	cctcagacga gtgcgatctc cctttgggccc gctcccccgc ctggaattcg agctcggtac	8760
	ctttaagacc aatgacttac aaggcagctg tagatcttag ccacttttta aaagaaaagg	8820
	ggggactgga agggctaatt cactcccaac gaagacaaga tctgcttttt gcttgtactg	8880
30	ggtctctctg gttagaccag atctgagcct gggagctctc tggctaacta gggaaaccac	8940
	tgcctaaagg ccaataaaag ttgccttgag tgcctcaagt agtgtgtgcc cgctctgtgt	9000
	gtgactctgg taactagaga tccctcagac ccttttagtc agtgtggaaa atctctagca	9060
35	gtagtattgc atgtcatctt attattcagt atttataact tgcaaaagaa tgaatatcag	9120
	agagtggagc gaacttgttt attgcagctt ataatggta caaataaagc aatagcatca	9180
	caaatctcac aaataaagca tttttttcac tgcattctag ttgtggtttg tccaaactca	9240
40	tcaatgtatc ttatcatgtc tggctctagc tatcccgccc taaactccgc ccagttccgc	9300
	ccattctccg ccccatggct gactaatctt ttttatttat gcagaggccg agggcgccct	9360
	ggcctctgag ctattccaga agtagtgagg aggccttttt ggaggccctag gcttttgcgt	9420
	cgagacgcat ccaattgcgc ctatagttag tctattacg cgcgtcact ggcgtctggt	9480
45	ttacaacgct gtgactggga aaacctggc gttaccaaac ttaatgcct tgcagcacat	9540
	cccccttgc ccagctggcg taatagcgaa gaggcccgca ccgacgcc tcccaacag	9600
	ttgcgcagcc tgaatggcga atggcgcgac gcgccctgta gcggcgcat aagcgcggcg	9660
50	ggtgtgtggg ttacgcgcag cgtgaccgct acacttgcca gcgccctag gccgctcct	9720
	ttcgctttct tcccttctct tctgcacagc ttgcggcgct tccccgtca agctctaaat	9780
	cgggggctcc ctttaggggt ccgatttagt gctttacggc acctcgaccc caaaaaactt	9840
55		

```

gattagggtg atggttcacg tagtgggcca tcgccctgat agacggtttt tcgcccttgg 9900
acgtttggagt ccacgttctt taatagtga cttctgttcc aaactggaac aacactcaac 9960
5 cctatctcgg tctattcttt tgattataa gggattttgc cgatttcggc ctatttgta 10020
aaaaatgagc tgatttaaca aaaatttaac gcgaatttta acaaaatatt aacgtttaca 10080
atttcc 10086

```

Claims

1. A bidirectional promoter for expression of at least two coding sequences in opposite direction in animal cells comprising 5' end to 3' end:

- a) a first minimal promoter sequence derived from cytomegalovirus (CMV) or mouse mammary tumor virus (MMTV) genomes;
- b) a promoter sequence derived from an animal gene comprising an enhancer region and a second minimal promoter sequence;

the two promoter sequences driving a coordinate transcription of said coding sequences in the opposite orientation.

2. The bidirectional promoter according to claim 1 wherein the full efficient promoter sequence derives from ubiquitously expressed genes comprising the phosphoglycerate kinase or the ubiquitin gene.

3. A bidirectional expression cassette essentially comprising the bidirectional promoter according to previous claims, convenient insertion sites positioned downstream to each promoter, and polyadenylation sites positioned downstream to each insertion site.

4. The bidirectional expression cassette according to claim 4 further comprising at least one post-transcriptional regulatory element positioned upstream to one or each polyadenylation site.

5. The bidirectional expression cassette according to claim 4 or 5 further comprising at least one internal ribosome entry site (IRES) sequence to express three or more genes.

6. An expression construct containing the bidirectional promoter according to claim 1 or 2.

7. An expression construct containing the bidirectional expression cassette according to claims 4-6.

8. A gene transfer expression vector containing the expression construct according to claims 7 or 8 further comprising lentiviral or retroviral sequences.

9. Use of the gene transfer expression vector according to claim 8 for the preparation of a delivery and expression system in animal cells.

10. Use of the gene transfer expression vector according to claim 9 wherein animal cells are tissue animal cells in vivo.

11. Use of the gene transfer expression vector according to claim 10 wherein tissue animal cells are comprising brain neurons.

12. An in vitro method for the coordinate expression of two exogeneous coding sequences into an animal cell comprising the following steps:

- a) cloning said coding sequences into the gene transfer expression vector according to claim 8, each coding sequence under the control of one of the two promoters of the bidirectional promoter;
- b) transforming animal cells by means of said vectors;

c) allowing the expression of the vector.

13. The *in vitro* method for the coordinate expression of two exogeneous coding sequences according to claim 12 wherein the animal cell is an human cell.

14. The *in vitro* method for the coordinate expression of two exogeneous coding sequences according to claim 13 wherein the human cell is a retransplantable human cell.

15. The *in vitro* method for the coordinate expression of two exogeneous coding sequences according to claim 14 wherein the retransplantable human cell is an hematopoietic cell.

16. Method for generating a transgenic non human organism comprising the step of transforming appropriate cells with an expression construct containing the bidirectional cassette according to claims 6 or 7.

17. Method for generating a transgenic non human organism comprising the step of transforming appropriate cells by means of the gene transfer expression vector according to claim 8.

Patentansprüche

1. Bidirektionaler Promotor für die Expression von mindestens zwei Kodierungssequenzen in entgegen gesetzter Richtung in Tierzellen, umfassend vom 5'-Ende zum 3'-Ende:

a) eine erste minimale Promotorsequenz, die aus dem Genom des Zytomegalievirus (ZMV) oder des Maus-mammatumovirus (MMTV) stammt;

b) eine Promotorsequenz, die aus einem Tiergen stammt und die eine Verstärker (Enhancer)-Region und eine zweite minimale Promotorsequenz aufweist;

wobei die beiden Promotorsequenzen eine koordinierte Transkription der Kodierungssequenzen in entgegen gesetzter Richtung steuern.

2. Bidirektionaler Promotor nach Anspruch 1, wobei die voll effiziente Promotorsequenz aus ubiquitär exprimierten Genen stammt, welche das Phosphoglyceratkinasagen oder das Ubiquitinen umfassen.

3. Bidirektionale Expressionskassette, die im Wesentlichen den bidirektionalen Promotor nach den vorherigen Ansprüchen, stromabwärts (downstream) von jedem Promotor positionierte, geeignete Insertionsstellen und (downstream) von jeder Insertionsstelle positionierte Polyadenylierungsstellen aufweist.

4. Bidirektionale Expressionskassette nach Anspruch 4, die des Weiteren mindestens ein stromaufwärts (upstream) von einer oder jeder Polyadenylierungsstelle positioniertes posttranskriptionales regulatorisches Element aufweist.

5. Bidirektionale Expressionskassette nach Anspruch 4 oder 5, die des Weiteren mindestens eine interne Ribosomen-eintrittsstelle(IRES)-Sequenz aufweist, um mindestens drei Gene zu exprimieren.

6. Expressionskonstrukt, welches den bidirektionalen Promotor nach Anspruch 1 oder 2 enthält.

7. Expressionskonstrukt, welches die bidirektionale Expressionskassette nach Anspruch 4-6 enthält.

8. Gentransferexpressionsvektor, welcher das Expressionskonstrukt nach Anspruch 7 oder 8 enthält und des Weiteren lentivirale oder retrovirale Sequenzen aufweist.

9. Verwendung des Gentransferexpressionsvektors nach Anspruch 8 für die Herstellung eines Einführungs- und Expressionssystems in Tierzellen.

10. Verwendung des Gentransferexpressionsvektors nach Anspruch 9, wobei Tierzellen Tiergewebezellen *in vivo* sind.

11. Verwendung des Gentransferexpressionsvektors nach Anspruch 10, wobei Tiergewebezellen Gehirneuronen umfassen.

12. In-vitro-Verfahren für die koordinierte Expression zweier exogener Kodierungssequenzen in eine Tierzelle, umfassend die folgenden Schritte:

- a) Klonieren der Kodierungssequenzen in den Gentransferexpressionsvektor nach Anspruch 8, wobei jede Kodierungssequenz unter der Kontrolle von einem der beiden Promotoren des bidirektionalen Promotors steht;
- b) Transformieren von Tierzellen mittels der Vektoren;
- c) Zulassen der Expression des Vektors.

13. In-vitro-Verfahren für die koordinierte Expression zweier exogener Kodierungssequenzen nach Anspruch 12, wobei die Tierzelle eine menschliche Zelle ist.

14. In-vitro-Verfahren für die koordinierte Expression zweier exogener Kodierungssequenzen nach Anspruch 13, wobei menschliche Zelle einer retransplantierbaren menschlichen Zelle ist.

15. In-vitro-Verfahren für die koordinierte Expression zweier exogener Kodierungssequenzen nach Anspruch 14, wobei die retransplantierbare menschliche Zelle eine hämatopoetische Zelle ist.

16. Verfahren zum Herstellen eines transgenen, nicht menschlichen Organismus, das den Schritt des Transformierens geeigneter Zellen mit einem Expressionskonstrukt, das die bidirektionale Kasette nach Anspruch 6 oder 7 enthält, umfasst.

17. Verfahren zum Herstellen eines transgenen, nicht menschlichen Organismus, das den Schritt des Transformierens geeigneter Zellen mittels des Gentransferexpressionsvektors nach Anspruch 8 umfasst.

Revendications

1. Promoteur bidirectionnel pour l'expression d'au moins deux séquences codantes dans une direction opposée dans des cellules animales comprenant, de l'extrémité 5' à l'extrémité 3' :

- a) une première séquence promotrice minimale dérivée des génomes du cytomégalo virus (CMV) ou du virus de la tumeur mammaire murine (MMTV) ;
- b) une séquence promotrice dérivée d'un gène animal comprenant une région amplificatrice et une seconde région promotrice minimale ;

les deux séquences promotrices régissant une transcription coordonnée desdites séquences codantes dans l'orientation opposée.

2. Promoteur bidirectionnel selon la revendication 1, dans lequel la totalité de la séquence promotrice efficace dérive de gènes exprimés de manière ubiquitaire comprenant la phosphoglycérate kinase ou le gène de l'ubiquitine.

3. Casette d'expression bidirectionnelle comprenant essentiellement le promoteur bidirectionnel selon les revendications précédentes, des sites d'insertion adaptés positionnés en aval de chaque promoteur, et des sites de polyadénylation en aval de chaque site d'insertion.

4. Casette d'expression bidirectionnelle selon la revendication 4, comprenant en outre au moins un élément de régulation post-transcriptionnel positionné en amont de l'un des ou de chaque site(s) de polyadénylation.

5. Casette d'expression bidirectionnelle selon la revendication 4 ou 5, comprenant en outre au moins une séquence IRES (site d'entrée interne du ribosome) pour exprimer trois gènes ou plus.

6. Construit d'expression contenant le promoteur bidirectionnel selon la revendication 1 ou 2.

7. Construit d'expression contenant la casette d'expression bidirectionnelle selon les revendications 4 à 6.

8. Vecteur d'expression de transfert de gènes contenant le construit d'expression selon la revendication 7 ou 8, comprenant en outre des séquences lentivirales ou rétrovirales.

9. Utilisation d'un vecteur d'expression de transfert de gènes selon la revendication 8, pour la préparation d'un système de délivrance et d'expression dans les cellules animales.
10. Utilisation du vecteur d'expression de transfert de gènes selon la revendication 9, dans laquelle les cellules animales sont des cellules de tissu animal *in vivo*.
11. Utilisation d'un vecteur d'expression de transfert de gènes selon la revendication 10, dans laquelle les cellules de tissu animal comprennent des neurones cérébraux.
12. Procédé *in vitro* pour l'expression coordonnée de deux séquences codantes exogènes dans une cellule animale comprenant les étapes suivantes :
 - a) le clonage desdites séquences codantes dans le vecteur d'expression de transfert de gènes selon la revendication 8, chaque séquence codante sous le contrôle de l'un des deux promoteurs du promoteur bidirectionnel ;
 - b) la transformation de cellules animales par les moyens desdits vecteurs ;
 - c) le fait de permettre l'expression du vecteur.
13. Procédé *in vitro* pour l'expression coordonnée de deux séquences codantes exogènes selon la revendication 12, dans lequel la cellule animale est une cellule humaine.
14. Procédé *in vitro* pour l'expression coordonnée de deux séquences codantes exogènes selon la revendication 13, dans lequel la cellule humaine est une cellule pouvant être retransplantée.
15. Procédé *in vitro* pour l'expression coordonnée de deux séquences codantes exogènes selon la revendication 14, dans lequel la cellule humaine pouvant être retransplantée est une cellule hématopoïétique.
16. Procédé de génération d'un organisme transgénique non humain comprenant l'étape consistant à transformer des cellules adaptées avec un construit d'expression contenant la cassette bidirectionnelle selon les revendications 6 ou 7.
17. Procédé de génération d'un organisme transgénique non humain comprenant l'étape consistant à transformer des cellules adaptées par les moyens du vecteur d'expression de transfert de gènes selon la revendication 8.





Figure 1






Figure 3




Figure 4




Figure 5




Figure 6




Fig 7a

[illegible]

Fig. 7b (2of 3)

gaatagaagaagaagggtggagagagagacagacagatocattogattatgaacggatctocagcgtatcggtttaact
 ttttaaaagaaaaggggggattgggggtacagtagcagggaagaatagtagacataatgaacacagcatcaacaacta
 aagaatftacaaaacaaatftacaaaatftacaaatftatcagatcacagagactagctcagagagatcgtatcataicagccat
 accacattttagtagaggttttactgtctttaaanaaccctcccacacctccccgtacactgaanaacataaanaatgaatgaattgtg
 ttgtlaactgtttattgcagcttataatggttacaataaggcaatagcatcacaaaittcaaaaataaggcattttttcactga
 tctlaattgtttgttgcasaactcatcaatglatctatcatctgtctgcatctcaaatctcgtggaaagctgcgocctgtattgggtg
 agtgaatcaatfttatacttttaccgctcttggatttagggcagtagctctgacggccctctcgtttaggttagtgaanaaatgta
 ctctcttaccgctgaatggctgtccagotttagctcagggggaggtggctggatctctagaaatlacacggcgtgactttccg
 cctcttggcctttaggagatctctgattttcttgctcaggtttccgtaagaaacttccggtactcttcccaacaacaa
 ctctcctcggcgaacttttgcgggttacttgcactgcccacgtatccacagatcttttccgctatcgttcttccgctgtcca
 aaacaacacacggcggcgggaagtacacggcgtatcctgctgggaagacctgcgacacctgcgtcgaagatgttgggggt
 ttgtggagcaagatggtatccaattcagcggggagocacgtatgaccccttgaacttaacagagacttcaggcggctcaacgat
 gaagaaagtgtctctcctccagtaagctatgtctccagatgtagccatcatcctgtcaatcaaggcgttgcgtcttc
 cggattgttatacaacggacataatcataggaactctcacacacagttgcctcttgaataacggccagcgttttccggta
 tccagatccacaaccttgcctcaaaaatggaacaacttaccgcccggctttacalcccctcgggtgtatcag
 aatagctgtatgtctcagtgagcccatatccttgcctgatacctggcagatggaactcttggcaacgccttcccgaact
 ccttagaaggggagggcgcacacagaaagcaatttctgttaattagataaactgtattgtcaalcagagctgttttggcgaag
 aagggaagatgggttggcaccagcagcggcacttgaacttctgtaactctgaaggctctcagaacacagcgttcttcaaat
 atacattagaagcagctgaatccacatataatctcaggtgtatgaataacattccaaacccgtgatggatggaacaaca
 cttaaaactgcagatctcgggaatgatttattgtccaaaatatagatctctgcaatggagaatctcacgcagcagcttctatg
 agcagagagatgcgaacctttaggcagaccagtagatccagaggatgtatgatcagtgcaattgtctgtctccctatcgaaggga
 ctctgcacaaaactgtattcatfaaaaacgggaggtagatgagatgtagcgaacgtgtacactgactgaatccctgttga
 tccgttttagaacctatgataaatttttggatgattgggaacttttttgcacgttcaaaaatttttgaacaccttggtagaacg
 aaacaccacggtaggctcggaaatgccatactgttgagcgaattcagctcatataaattgtctgcggggcgcaactgcga
 ctccgataaataacggcccaacacccggcataaagaattgaagagagtttcaatgcatacgaactgttctgattgtattca
 gccatctatctgttcatagcttctgcccaacggacggacatttgaagtacacagctgaagtgaatgccacctcgataatgcata
 ctgtaaaagcaattgttccaggaaccaggcgtatctcttccatagcccttagcagttgtctccagcggttccatctccagc
 gataagatggcgccggccttcttattgttttggcgtcttccatgggtgaattccggagggcggatcgtctccgtctctc
 tatgaggtcaaaaacagcgttgatggcgtctccaggcgtatcagcgggttcaactaaabgagctctcttatataggccctcca
 ccgtacacgcctacccctcagagaagcttgaatcaatccacgggggttgggttggcgttcttcaaggcagccctgggt
 tggcagaggcagcgggtctctggggcgtgtgtccgggaacgcagcggcgccgacccctgggtctcgaactattcaag
 ctctgttcgcgcgcgtacccggatcttccgcgtacccttggggcccccggcgacgtctctcgtccgcctcccaatgctgg
 gaagggtctctggcgggttcggcggtgcggagcgtgacaacggagcgcacgtctcactagctaccctcgcagcggac
 agcgccaggggagcaatggcagcggcgctgactcgatggcgtgtggccatagcggcgtctcagcggcgccggcgga
 gacagcggcccggaaggggcggttggggagggcgggggtggggcggtatgtgggpcctgttctgcgcgcggg
 tgtccgtaattctgcaagcctcgggagcgcagctcggcagctggcctccctcgttgacgaatccacgactctctccacc
 gggggatccacgggtgccaccatgggtgagcaaggcggcggagcgtgttaccgggggtgggtcccatctgggtgagctc
 gacggcgacgtgaacggccacaaggttagcgtgtccggcgaggcgaggcgatgccactcgggaagctgacact
 gaactgtctctcaccacccggcaagctgcccgtgcccttggccacacctgtgaccacacctgaactcagctgtgagctgtt
 cagcgcgtacccgcagacatgaaggcagcagacttcttaagctcccatgcccggaaggctacgtccagagcagcacc
 alctcttcaaggacagcggcaactacaagaccgcgcgaggttgaagtgaagtggaggggacacacctgggtgagcagctg
 agctgaaggcactgacttcaaggaggacggcaacatctggggcacaagctggagtaactacaacagccacaacg
 tctatatactggccgcaagaagcgaagaagcggatcaagggtgaacttcaagatccgccacaacatcaggcaggcgaagcgt
 gacgtctgcgacacactacagcagaacaccccatggcgacggccgtgctgtgtgtccgcaaacactactctag
 cacccagctccgootgagcgaagaccaccaagagaaggcgcgtacatgtctcgtgaggtctgtgacccgcccgg
 gatcactctcagctggagcagctgtacaaatgaagcggccgcgtcagacataacpctctggattacaanaattgtggaag
 attgactgtattcttaactatgttgcctctttacgctatgtggatagcgtctttaaagcctttgtatcatctattgttccgctat
 ggtttcatittctctctgtataaactctggttctcgtctcttatagggaggttggcgccgtgtcagcgaacgtggcgtggt

Fig. 7b (3 of 3)

ggcactgtgttgcagacgaacccccactgggtggggcattgccaacacctgtacagctcttcgggactttcgtttccc
 cctccctattgccacggcgggaactcatcgccgccttgccctggccgctgctggacaggggctcggctgttgggcaactgaca
 attccgtgtgtgtgtcggggaagctgacgtccttccatggctgctcgcctgtgttgcccaactggattctgcggggagctcc
 ttctgtctacgtcccttcggccctcaatccagcggaccctcctcccgccgacctgctgccggcctcgtgcggcctcgtgcggcctctccgcgtctt
 cgccttcgcccacagcagctggatcctccttggggcgcctccccgcctggaaatcgagctcggtaaccttaagaccaat
 gacttaacaggcagctgtagatcttagccattttaaaagaaaaggggggactggagggctaatctactcccaacgaag
 acaagatctgcttttgcctgtactcggctcctcctgttagaccagatctgagcctgggagctcctcggcctaactagggaaccc
 actgctaaagcctcaataaagcttgccttgagtgcttcaagtagtgtgtgccgtctgtgtgtgactcgtgtaactagagatcc
 ctacagacccttttagtcagtggtgaaatctctagcagtagtagtcatgtcatcttattatcagttattataactgcaaaagaat
 gaatatcagagagtgagaggaactgtttattgcagcttataatggttacaaataaagcaatagcatcacaaatttcacaata
 aagcattttttcactgcattctagtgtgtgttgcacaactatcaatgtatcttatcatgtctggctctagctatcccgccctaa
 ctccgccagttccgccattctccgcccatggcctgactaatttttattatgcagagggcgaggccgctcggcctcgt
 agctattccagaagtagtgaggagccttttttggagggcctaggcttttgcctcgagacgtacccaattcgccctatagtga
 cgtattacgcgcgtcactggccgtcgttttacaacgtcgtgactgggaaaacctggcggttaaccaacttaatcgcttga
 gcacatcccccttcgccagctggcgttaafagcgaaggcccgaccgacgcgccctcccaacagtgcgcagcctgaa
 tggcgaatggcgcgcagcgcgcctgtagcgcgcgaatgaagcgcgggggtgtgtgtgttacgcgcagcgtgacccgtac
 acttgcagcgcgccttagcgcgcctccttgccttctccttcttcttccgccacgttcgcgcggcttccccgtcaagctcta
 aatcgggggctcccttaagggttcgatttagtgtttacggcacctcgcaccccaaaaacttgattagggtgatgggtacgt
 agtggggcctacgccctgatagacgggttttgcgcctttagcgttggagtcacgttcttaatagtgactctgttccaactg
 gaacaacactcaaccctatctcgtctatcttattgattataagggtatttgcgaatttcggcctatttggttaaaaatgagctga
 tttaacaaaatttaacgcgaattttaacaaaatttaacgtttacaattcc




Fig. 8a

Fig. 8b (1 of 3)

cagggtggcacttttgggggaafgtggcgggaacccctatttgtttatttctaaatacatfcaaatatgtatocgtcatgaga
 caataacocgtataaagtcttaataatattgaaaaggaagatgagatgattatcaacatttccgtgtgcccatttccctttt
 gggcgccttttgccttctgttttgcacccagaaacgcgtggtgaaagaaagatgctgaagatcagttgggtgacgaggt
 gggtgacatcagaaactgcatcacaacagcgttaagatccttgagaggttttgcggccggaagaaactgtttcacaatgagatgaga
 taaagtctgtcatgttggcgggtattatccgtattgacggcggcgaagagcaactgggtggccgcatcactatctcaga
 atgacttgggtgagactaccagctcacagaaagcaatctacggatggcagacagtaagaatattgacgtgctgcat
 aacocatggtgataacactgcggcgaacttactctgacaacgaltcggaggacgggaagagatcaaacgccttttgccaac
 atgggggagatcgttaactgccttgatcgtttgggaacccggagctgaatgaagcgcataccaacgacgagcgtgacacac
 gatgctgtgagcaatggcaacaacgtttggcgaactatctaactgggaactacttacttagcttcccgccaacattatag
 actggatggaggcgataaaagttgcaggacacactctgcctgccttccgggtggctgtttattgctgataaafctgg
 agccgggtgagcgtgggtctcgggtatcattgacgacactggggcgagtggttaagcccctccglatgtagttatcac
 gacggggagtcaggcgaactatggtatgaacgaatagacagatgctgagataggtgctcactgattaagcatttgtaact
 gtcagacaaagttaactataatactttagattgatttaaaacttattttaaataagatcagtgtagaagatccttttgata
 atctatgacaaaatcccttaactgtagttttcttgcactgagcgtcagaccccgtagaaaagatcaaaaggatctcttgag
 atcctttttctgcgctaactctgctgcttgcacaaacaaaaccacgcgtaccagcgggtgtttgttggcgatcaagagct
 accaactctttccgaaggtaactgcttgcacagagcgcagataccaatactgcttcttagtgtagcgttgatggagc
 accacttcaagaactctgtgacccgctcactacatcctgcctctgataactgttaccagtgctgctgcacagtggtgataag
 ctgtgcttccaggggtgagctcagaacgatagttaccggataaggcgcagcggctggcgtaaacgggggttctgtgac
 acagccacagctgtgagcgaacgactacacgaactgagataactacagcgtgagatgagaagagccacgactctcc
 gaagggaagaaaggcgacaggtatocggtaagcggcagggtcggaaacggagagcgcacgaggagcttccagg
 ggaaacgctctgatactttatgctcctgggttctgcacacctgactgagcgtcgtattttgtgtagtctgtacaggggg
 cggagcctatggaaacacgcagcaacgggctctttacggttctgccttggcttggcttggcttggcttggcttggctt
 cgtatccctgattctgtgataacggtattaccgctttgagtgagctgataacgcttcccgacggcgaacgacgacgagc
 cagcagtgctgtagcggaggaagcggaaagcgcacacacgacccacacgacccctcccgacggcgttgccgactcataa
 tgcagctggcgaacgaggtttccgactggaaagcggcgtagcgcgaacgaatattgtaggtgactcactattag
 gcaocccaggtttacattttagcttccgctgtatgttggtagaattgtgagcggataacaatttccacaggaacacag
 tatgacactgattacgcaagcgcgaatfaaactcactaaagggaacaaagcgtggagctgcaagcttgccgactgcat
 actgttgcatacatataataatgtacattatattgctcactgccaactaccgccactgttgacattgattatgactagttata
 atagtaatacaattggggctcattatgctcatagccatataaggagcttccgctacataacttgcgttaaatggccctgg
 ctgacggcccaacgaccccgccactgacgtaataatgacgtatgttcccatgtaacgcaataggacttgccttga
 cgtcaatgggtggagatttaccggttaactgccacttgcgaatgacatcaatgtatcatatgccaagacgcccctattga
 ctgcaatgacgggtgaatggccggccttgcactatggccagctacatgacttattggacttctacttgcgtgacatcactgt
 attatgactcgtattaccatggtgatggcttttggcagatcatcaatggcggtggatagcgtttgactcaggggatttcc
 aagctctcaccocactgacgtcaatgggagtttttggcaccacaaatcaacgggacttccaaaatgtcgttaacaactcc
 cccactgagcgaatggcggtgtagcgtgtgacgtggaggtctatataagcagagcgtctgttaatgaaacgggtgtct
 ctggttagacacgactgagcctgggagctcttgcgttaactgggaacccaactgcttaagcctcaataaaggctgcttga
 ctgctaagtagtctgtgtgcttgggtgtgacttctgtaactagagatccctcagacccctttagctgctgtgtggaanaact
 cttagcagtgccggcgaacaggcgtcctgaaagcgaagggaacacagactctctcagcagcagactcgggttctga
 agcggcgcagggcaaggcggaggggggcgaactgtgtagtacgccaataattttgactagcggagcgtgaagggaaga
 gtagtgggtgcgaagcgtcagtattaaagcgggggagaaatgacgcgtggggaacaaatcgggttaagcgaaggggg
 aagaaaaaataataaataacatagatgtggcgaagcaggggagctagaagatcgtgagcttaactcgtgctgttaaga
 aactcgaagcgtgtgacaaaatactgggacagctacaaccttcccttcagacaggtcagaagaactgatactattata
 alacagtagcaacctctatgtgtgcatcaaaaggatagagataaagacacacgaagcgtttagacaaagatagaggaaag
 agcgaagaataaagtagaacaccgcagcagaagcggccgctgacttctagacctggaggagggatagggggacaa
 tgggaagaatgaaattatataataaagtagtaaaatggaacaaataggagtagcaccaccaagggcgaagggaagggtg
 gtcagagagaagaaaaagagcagtgagggaatggagcttgttcttgggttctgggagcagcagggaagcactatggcgc
 agcctcaatgacgtgacggtacggccagacaaatattgtctgtatagtcacagcagaacaaattgtgagggtctati

[illegible]

Fig. 8b (3 of 3)

ccgcctgcctgccgcgtgctgacaggggctcggctgttgggcactgacaattccgtggtgttcggggaaagctgacgt
 cctttccatggctgctcgcctgtgttgcacctggattctgcggggagctccttctgclacgcttcctcggccctcaatccag
 cggaccttccctccgcggcctgctgcgggctctgcggcctcttcgcgctctgccttcgcccacagcagtcgggatctc
 cctttggggccgctcccccgcctggaattcagagctcggtaaccttaagaccaatgacttacaaggcagctgtagattagcca
 ctttttaaaagaaaaagggggactgggaaggctaaftcactcccaacgaagacagatcgtttttgctgactgggtctct
 ctggttagaccagatctgagcctgggagctctctgctaaactagggaaacccactgcttaagcctcaataaagcttgccttga
 gtgcttcaagtagtgtgtgcccgtctgttgtgtgactctggttaactagagatccctcagacccttttagcagtgtggaaaaatct
 ctgacagtagtagtgcattctctattatcagttattataacttgcaagaaatgaatatcagagagtgagagggaactgttta
 ttgagcttataatggttacaataaagcaatagcatcacaaatttcacaaataaagcaatttttctgactgacttctagtgtgtt
 gtcacaaactcaatcaatgtatcttatcatgtctggctctagctatccgcccctaactccgccagttccgccattctccgccc
 atggcgtgactaatittttttattatgcagaggccgaggccgctcggcctctgagctattccagaagtagtgaggaggcctttt
 tggaggccttaggcttttgctgagacgtacccaattcggcctatagtgtgagctgtattacggcgcgtcactggcgcgtgttta
 caacgtcgtgactgggaaaaacocctggcgttacccaacttaatcgccttgacgacatccccccttcgccagctggcgttaata
 gcggaaggaggccgcacggatcgcccttcccaacagttgcgacgcctgaatggogaatggogcgacggccctgtagcg
 ggcgattaaagcgggcggtgtgtgtgttacgagcggtgaccgtactacactgccaaggcccttagcgcccgcctcttc
 gctttctcccttcttctgccacgttcggcggttcccgctcaagctctaaatcggggcctcccttaggggtccgatttag
 tgccttacggcaccctgaccccaaaaaacttgattagggtgatggttcacgtagtgggccaatcgccctgatagacgggttttc
 gcccttgacgttgtagtccacgttctttaatagtgactcttgttccaaactggaacacactcaaccctatcgtgctattct
 ttgtattataagggaatttgcgatttcggcctattggttaaaaaaatgagctgatttaacaaaaatttaacgcgaattttaacaaa
 atattaacgtttacaatttc




Fig. 9a

Fig. 9b (1 of 3)

cagggtggcattctcggggaatgtgcggcggaacccctatttgtttatttttcaaatacattcaaatatgatccgctcatgaga
 caataaacctgtataaatgtctcaataatattgaaanaaggagatgatgatgtacaaatttccgtctgcccttattccctttt
 gcggcatttgccttctgttttgcctcaaccgaacacgtgtggaagataaagatgctgaagatcagttggcgacaggt
 ggggtacatcgaactggaictcaacagcggtgaagatccttgagagtttccgccgaagaacgtttccaatgatgagacatt
 taagttctgtctatgtggcgcggttatatccgttatgtacgcggcggaagagcaactcggctgccgcatacatattcaga
 atgactgtggtgatactcaccgtcacagaaaagatcttaccagatggcatgacataagagaattatgcaggtgtgccat
 aacctgatgtgataactcggcggaacattctctgacaacgctgcggagaccgaagagatcaaccgtttttgccaacac
 atggggggtatgttaactgccttgatcgttgggaaccggagctgaatgaagccataccaacgacgagcgtgacacacac
 gatgctgtgacaatggcaaacacgttgccgaacattataactgcgggaacttactactagcttccggcaacaataatag
 actggtgatggggcgataaagttgcaggacacattctgcctcggcccttcggctgctgtgtttattgtcgtataaaggt
 agccgggtgagcgtggtctcgcgtatcattgcagcactggggccagatgataagccctccgtctgtatgtatcacac
 acgggggagcagggcaactatgatgaacgaatagacagatcgtgagatggtgcctcattgataacattggttgaact
 gtacagacaagttaactatatacttttagattgatttaaaactcattttaaatttaaaaggatctgtagatccttttgat
 atctatctgacaaatcccttaacgtgagttttgttccactgagcgtgcagacccgtagaanaagatcaaggatctcttgat
 atcttttttctggcgtaactgtctgctgcaaaaaaacaacacgctacacgggtgtttgtttgccggatcaagagct
 accaacttttttccgaaggtactgtgcttcagcagcgcagataccaatattgcttctgtagtgcgtgtagtggccg
 accacttaagaactctgtgacccgctacatacctcgtctgttaactctgttaccagtgctgtcgaattggcggtataag
 tctgtcttaccgggtggactcaagacgatattgctggataaggcgagcagcggcggtggaacgggggggtctgtgcac
 acagcccgagcttgagcgaacgactacacacgaactgagatacctacagcgtgagcgtalgaagaagcgccacgcttcc
 gaagggaagaaggcggaacaggtatccgttaagcgcagggtcgtgcaacgagagagcgcacggagaggtctccagg
 ggaaacgcctgtgatactttatagctcgtcgtcgttccgccactctgactgagcgtcgtattttgtgagctcgtgaaggg
 cggagcctatgaaanaacgccgaacgcggccttttaccggtctcgtcgttctgctgcttccatctgattgttttctg
 cgttatccctgattctgtgataaccgttataccgctttgagtgagctgataccgctgcgcgaagcgaacgagcgc
 cagcgaagtcagtggagaggaagcgggaagcgcacacacacgcctcctccgcgcgttggccgattactaa
 tgcagctggcagcagagcttccgactggaaagcggcgagtgagcgaacgcaattatgtgagtgactcactcattag
 gcaccccgagcgtttacattatgcttccgctcgtatgttgtgtgaattgtgagcggaatacaattcacaggaacacgc
 tatgacatgattacgcgaagcgcgaattacccctactaaaagggaacaaagcgtgagcgtgcaagcttaattgtatgctta
 tgcataactcttgtatgttgcacatgataacgatgtaggaacacatgcttcaagggaagaaagccaccgtgcatgc
 cgattgtgtggaagtaagggtgacatcgtgcttattaggaagcgaacagcggctgtgacatggattggacgaacct
 gaattggcgatgtcagagatattgttattagtgcttagctcgtacatacaaaacggctctctgtgtagcagcagctgagc
 ctggagcgtctctggcaactagggaacccactgcttaagcctcaataaagcgttgccttgagtgctcaagtgatgtgtgcc
 gcttgtgtgactcgtgtaactagagatccctagacccttttagctgtgtggaatctctagcagtgccgcgggaaca
 gggacgtgaaagcaagggaacacagagctctctcgaacgagactcggctgtgaagcgcgcagcgaagagcgc
 gaggggcgccgactgtgtgtagtcccaaaatttgactagcggagagctagaagagagatgggtgagagagcgtc
 agtataagcgggggaagtagatcgcgatgggaaaaaattcggtaaggccagggggaaggaanaaataataaataa
 acatatagtatggcgcaagcagggaagcagacagattccagttatctcgtcgtgttagaacaatcagaagcgtgtgaca
 ataactgggacagctacaacacctcttcagacagatcagaagaactatgataataatcagtagtgaacaccttatt
 gtgtgtatcaaggatagataanaagacacaaaggaaagcgtttagacaaatagagagaagcgaacaaaggttaagac
 caccgcacagcaaggccgctgattctcagacctggaaggagagatagaggcaaatgggaaggtgaattatataa
 tataaagtagtaaaattgaaacattaggagtagcaccaccaagcaanaagaaagtggtgtgcagagagaanaagagc
 cagtggaatagagagcttgtctctgggtcttgggagcagcagaagacatggggcgacctcaatgacgtgacggt
 tacaggccagacaattatgtctgtatgtgcagcagcagaacaattgtgtagggctattgagggcgaacagcatgtgt
 gcaactcagctctggggcatcagcagctccagcagaatctcgtcgttgggaagactcaactaaaggatcagactctc
 tggggatttgggtgtccttggaaaactattgcacactcgtgtgcttggatgctgtgtgagtagataaatactcttggaa
 agattggatcacagacotggatgggtggggacagaanaattacaattacaaagcttaatacactcttaattgaagaa
 tgcgaacacagcaaaaagaatgaacagaatatttggaaatagataaattgggcaagttgtgtggaattgttttaacata
 aattgtcgtgtgtatataaaattatcataatgatagtaggagcgttggtaggttaagataattgtgtgtactcttatagt
 aatagattagcaggagatatacattatcgtttcagaccactcccaaccccgagggggacccgaagcggccgaagg

Fig. 9b (2 of 3)

aatagahgagaaggtgagagagagacagacagatocattcgtattgtaacggatcgcagggatcggtaacttt
 taagaagaagggggggaattggggggtacagtgaggggaagaatagacataatgcaacagacatacaactaa
 gaattacaanaaactaacaaatfacaanaaattttatcgtacacagagactagccctgagagatcgtatcaatatacagaac
 cacacttctagaggttttacttctttaaanaaacctccacacactccctgaacctgaacataaaatgaatcgaattggttg
 ttaactgtttattgcagctfalaatgggttacaataagggcaatgacatcaacaatttcacaaataagccatttttaccatgc
 tagttttggtttgtccaaactcaatgattcttcatgtctgtatcacaatccctggaaagctgcgcctgtcttaggttgag
 gtatcaactcttactactttaccctgtttggataggcagtagctcagcggccctctgtcttaggttagtgaanaatgtaact
 ctcttaaccccttactgtctcagctttagctcgcaggggaggtgtgtctgtgatacagaagaatgctcgtcagct
 cagatcctctagaattacacggcgatcttccgccctctgtggtcttttagaggatctctctgtattttctgcgtcaggtttccgg
 taagaacctctgtactctgcccacaacacactcctccgcgcacattttcgcggttcttgaactggccacgtaactcac
 gatctcttttccgtatcgtcttccgtgtcctcaaaaacaaacggcgccgggaagtctacccggcgatcgtcgtgggaaga
 cctcgacacactgctcgaagatgttgggtgttgaggcaagatggaftccaattcagcgggagccactgtatagcctttg
 acttaacagagactcagggcgctcaacgatgaagaagtgttctgtctgtccagtaagctatgtctccagaatgtagccat
 ccactcctgtcaacaaaggcgttgcgtctcgtcgtgattttacataaacggacataatcagagactctcacaacagttcg
 cctcttgaataacggccagcgttttcccggtatccagatccacaacccctcgtctcaaaaatggaacaaatttaccgaccgg
 cccgtttatcatccctccgggtgaatcagaatagctgatgtatctcagtgagccatcatcttgcctgatacctgcgaga
 tggaaacctctggcaaccgcttcccgacttcttagagagggggagccaccagagaacatttcgtgtaaatgataaact
 cgtatttgcatacagatgcttittgaggaagaaggaatagggttgcaccagcagcagcactttgaactgttaactcga
 aggtctctcagaacagctcttctcaaatctalacataaagacactggaatccacatatacaatctcaggtgtgtagaaac
 attccaaactctgtggaatggaacacacttaaatcgcagtatccgggaatgattgattgccaataatgagactcttc
 atgcgagaatcacgaggcagttctatgaggcagagcgacacatttaggcagacagtagatccagaggaaggttcgat
 cagtgcaattgtcttccctcagaaggactctggcacaataatgtaattcattaaaacggggagtagatgagatgtgacga
 acgtgtctacatcgactgaatccctgtaactcgttttagaaltcatgataataatttttgatgattggagccttttttgacat
 caaaatttttgcaccccttttggaaacgaacacacagctgtagcgtcggaaatgcccaactgttggagcaatcaggttca
 taatgtcgttcgcggcgcaactgcaactccgataaataacgcgcgccaacacgggcataaagaattgaagagaggtttca
 ctgcatacagcagattctgtgattgtatcagccatactgtttcatagctcttccaaacggagcgaacttcgaagtactcag
 cgtaaatgagttccactcgtatgtgctatgttaaaagcaattgttcagggaaccaggggctatcttctcagactgtatgac
 gttgtctcagaggttccatcttcaggggataaagtgccggcggccttcttattgttttggcgtctccatgttgaattcc
 gttccctccggggagagaggtcgtgattcgtctaacgaggagacgactgccgagctgcgtccggaggcgttcgaga
 atcgggaacacccgcggcgaggaacagggccacactaccggcccaaccccgctcccgaccgcccttccgg
 ccgtcgtctcggcgcccccgtgagcagcgcgtattggccaacggccatccggctcggcgctgccattgtcctcctg
 gcgtgtcctcgtcggagggtactagtgaagcgtgcggcttccgtttgtcagcttccggacgcccgcgaaccgaaaggac
 ctcccgacttagggggagagcaggaaagctcgcggggggggcccaacagggttagcggcggaagatccgggtgacgtg
 cgaaaggagctgaagaatgtgcgagaccagggtcggcgccgtcgtgttccggaaacacggccagagcagcgcg
 tccctgcgaacccagggtcgttggaaanaggcgcaaccccaaccccggtgggaatcgtatcagcttgactgttgcatt
 ttttgaattctcaagcttattgtaattgcttataaataaagaagtggtgatttttgaataaactgcaacagtc
 ctacaattctctctgtgtgttgtgtctgtccactccgtctcgtcgtcactatcttcaactttcagagggttcccccgc
 agatccgggtcaccctcaggctcgggtcgaacaacctgtgagcaaggcgaggagctgttcaacgggtgtgtgtccacta
 ctgtcgtgagcttgagcggcagcttaacggcccaagctcagcgtctccggcgaggcgaggcggtgacccactcagg
 caagctgacctgaagttcagctcaccacccggcaagctgcccgtgcccggccacccctcgtgaccacctgactacg
 gctgcagctgtcagccgctaccccgaccatgaagcagcacgaacttcaagctccggcatgcccggaagctcactg
 caggagctgacactatcttcaaggagcagcgcaactacaaagaccggcgagggtgaagttcagggcgacacccgtg
 gtagaacgtatcagctgaaggcgtcagcttcaaggagcagcgaactcgtgggcacaaagctggagtaacactaca
 acagcccaacagcttataatcagggcgacangcagaagaacggcatcaaggtgaactcaagatccgcacacacatcag
 ggcggcagcgtgcagctcgcgaccactacagcagaacaccccccctggcgagggcccggtgtcgtcgtccgacacac
 caactacgtgacacccagctcgcctgagcaaaagaccccaacgagaaagcgtcgtacatcgtctcgtcgtgagtcgta
 ccgcccggcggtacacactcggcatggcagctgtacaaagtaaaaggcgtcgcacataacactcgtggaatacaaat
 gtgaagattgactgtattcttaactatgttgcctctttacgctatgggatacgtcgtttaaagcttgccttgcatactgct

Fig. 9b (3 of 3)

tcccgtatggccttcaattctcctccttgataaactcctgggtgctgtctctttagaggagttgtggccctgttcaggcaacgtg
 gogtgggtggaactgtgttctgacgcaacccacacgtgttggggcattgcaaccacctgtcagctccttccgggacttgc
 gcttccccctccctattgccacggcgaactcaccgcccctgcttgcctccgcctgtctggacaggggctcggctgttgggg
 actgacaattccgtgggtgtgtcggggaagctgacgtccttccatgctgtcgcctgtgttggcaccctggattctgcgggg
 gacgtccttctgtacgtccctcggccccaatccagcgggaacctcttccggcggcctgtgcggcctcgggcctcttc
 cgcgtctcgcctccgcccagacgagtcggatccttggggccgcccgcctccgcctggaattcagagctcgtgactctttaa
 gaccaatgacttacaaggcagctgtagatcttagccactttttaaaagaaaagggggactggaaaggcctaaticacccca
 acgaagacaagatctgcttttctgtactgggtctctctgttagaccagatctgagcctgggagcctctctggttaactagg
 gaacccactgtctaaagcctcaataaagccttgccttgatgtgtcactcaagtagtgtgtgcccgtctgtgtgtgactctgtaactag
 agatccctcagacccttttagtcagtggtgaaatctctagcagtagtactgtcatcttattattcagttatttaacttgcaa
 agaaatgaatatcagagtgagagggaacttggttattgacgcttataatggttacaataaagcaatagcatcacaaatttca
 caataaagcatttttttactgcattctagttgtgggtgtccaaactatcaatgtatctatcatgtctggcctagctatccgc
 cctacaiccgcccagttccgccattctccgcccatggcctgactaattttttattatgcagaggccgagggccgctcgg
 cctctgagctattccagaagtgtgaggaggtgttttggaggcctagccttctgtcgtcagacgtaccocaaatcgcocctatag
 ttagtctgattacggcgtcactggccgtcgttttacaacgtcgtgactgggaaacccctggcgttaccacaaatcatalcgc
 ttgcagcacatcccccttgcagcgtggcgtatagcgaaggccgcaccgacgcgcctcccaacagttgcgcagc
 ctgaatggcggaattggcgcgacgcgcctgtacgcgcgcttaagcggcggcgtgtgtgtgtttagcgcgcagcgtgacc
 gctacacttgccagcgccttagcgcgcgcctcttctgcttctcccttctcgcacgttgcgcgttccgcgttcccggtcaag
 ctctaaatcggggcctccctttagggctccgatttaggtttacggcacctcgaccccaaaaacttgattgggtgaltggt
 caogtagtggggccatcgcctgatagacgggttttgcgccttgacgtgtgagtcacgttcttaataatgtgactctgttcca
 aactggacaacactcaacctatctcggctcttcttctgattataaggagatttgcggatttccgcctatttggttaaaaatga
 gctgatttaacaaaaattaacgcgaattttaacaaaatattaacgtttacaatttc




Fig. 10a

Fig. 10b (1 of 3)

caggctggcacttttcggggaatgtgcgcggaaacccctattgtttatttttcaaatcaaatatgtatccgctcatgaga
 caataaacctgataaattgcttaataatgaanaagggaagatgatgtattcaacatttcctgtgcgcttactccttttt
 ggccgctatttgccttctgtttttgtcaccaccgaanaacgtgggtgaaagttaaagatgctgaagatcagttgggtgcacgagt
 gggttaccatgaactgatatcaacagcgttaagatcttgagagttttcgcgcgaagaacgttttccatgatgagcaattt
 taagtttctgtatgtgttcgggtattatccgtatfgacgcgggcgaaggaacatcggfctgcgcgatacattatctcaga
 atgactgtgttgatctaccagctacagaaaaatcattctacgtgatgcatcagagtaagagaattatgcatgtctgcctat
 aacctgagtgtacataactcggcccaacttctctgacaacgacgtcggaggaccgaaggagctaacctttttgtcacaaac
 atgggggagctgttaactcgccttgatcgttgggaacgtcgtgaatgaagccataccaacgacgagcgtgtgacacac
 gatgcctgtagoaaatgcgaacacgttgcgaacattataactgggaactacttactctagcttccggcaacaataatga
 actggatggagcggataaagttgcaggacacttctgcgtcgcgccttccggcctgtgttatgtctgataaactcgg
 agccgttgagctgtgggtctcgcgttcatgtcagcactggggccagatggtaagcctccctglatcgtatgtatctacac
 gacggggatgcagcaactatggatgaacgaataagacagatcgtcagatagggtgcctactgattaaagatcgtgtaact
 gtcagccaagtgttactatatactttagatgatttaaaacttatttttaataaaaggatcagtggtgaagatccttttgata
 atctcatgaacaaatcccttaactgtagttttcgttccactgagcgtcagacccctgtagaanaagatcaaggatcttttgag
 atctcttttttctgcgtgaatctgctgttgcgaacaaaaaacaccacgtaccagcgtgtgtgtttgttgcataaagact
 accaactctttttcgaaggatgaactgtgttgcacagagcgcagataccaataactgtcttctctgtgtagcgttatgtggcc
 accacttcaagaactctgtgacacgcctacataactcgtctgtaactctgttaccagtgctgtcgcagtgccgagtagaag
 tctgtcttaccgggttgactacaagcagatagtattaccggataaaggcagcggctgaacgggggttctgtgcac
 acagccagcgttggagcgaacgacctaacccgaactgagatactacagcgtgagctatgagaanaagccacacgttcc
 gaaggagagaagcggcagacgttatctccgttaagcgcagggctcgaacaggagagcgcacgagcagactctcaggg
 ggaaacgcctgtgtattatgtctcgttgcgttttgcacactcgtactgagcgtgattttgtgactcgtcagggggg
 gcgagcctgtggaanaacgcacgaacggcgttattacgttctggccttttgcgttggcctttgtctacatgtttctctc
 cgttatccctgattctgtgataaaccgtattaccgcttggatgagctgataccgctcgcgcgacgaacgaccgagcgc
 cagcagtgatgtgagcggaggaagcggaaagcgcgcccaatgcaaaacgcctctcccgcgcgttgccgattcattaa
 tgcagctggcagcagcaggttccgactggaaagcgggcagtgagcgcgaacgcaattaatgtgagttagctcactcattga
 gcacccagcgtttacatttatgcttccgctcgtatgtgtgtggaattgtgagcggataacaatttccacagaagaacagc
 tatgacatgattacgcgaacgcgcgaatgaacccctacaaagggaacaaagctggagctgcaagcttggccattgcat
 actgttttccatcatcataatgtacatttatgtgctcatgtccaaactaacgccatgttgatcattgattattgactgtatta
 atagatlaicattacgggttcattgttcatagcccatatattgaggttccgcttataaacttgcgttaaatgtcccccgtg
 ctgacgcgcgaacgcaccccccgcacattgacgttaataatgacgtatgttccatagtaaacgcgaalgggacttccatga
 cgtcaatgggttgagattttacgggtaaacgtgccacttggcagatcatcaagtgatcatatgccaagtaagcccccattga
 cgtcaatgaggttaaatggccgcctggcattatgcccagctacatgaccttattgggaacttctacttggcagctacatctagt
 attagctatcgcctattacactgtgtgatgcgttttggcagctacatcaatggcgtgtggatagcgggttgaactcgggtttcc
 aagctctcacccattgacgtcaatgggagttgttttggcacaanaataacgggagacttccaaatgtcgtcaaacactcgc
 ccccatgagcgaactggggcgttagggcgtgtacgggtgggaggtctatataagcagagctcgtttagtgaacggggtctct
 ctgtgttagacagatcagcctggcctgggagctctggcactatagggaacccactgcttaagcctcaataaagctgccttga
 gtgtcttaagtgtgtgtccgtctgtgtgtgactcgtgtaactagatgccctcagacccctttatgtcgtgtggaaatct
 ctgacgtgtgcgcggcgaacaggacgtgaaagcgaagggaacacagagctctctgacgcagcagactcgtgtgtgtg
 agcgcgcacggcgaaggcggaggggcggcactggtgagtagcccaaaatttactagcggagcgtctagaaggaga
 gagatgggtgcgagagcgtcatgattaaagggggaatgatagcgtgatgggaanaaattcgttttaaggccagggggg
 aagaanaaataataaataacataatgattggcgaacgggagcgtagaacgattcgcagtttaactcgtgcctgttgtaga
 acatcagaaaggctgtgacaaatactgggacagctacacccctctcagacaggtacgagaagaacttgaatcattatata
 atacagtgcgaaccccttattgtgtgcataaaggatagagataaagacacccaggaagcttttagacaagatagaggaag
 agcaanaanaaagtgaagaccaccgcacagcaagcggcgcgtgaltctcagactggagaggagagatgaggggacaat
 tggagaaagtgaattatataataaagtataaantgaacattngagtagcaccaccaaggcgaagaagagaagtggt
 gtgcagagagaanaaagacagcgtgggaatggagcgttttgccttgggttctggagcagcaggaagacattatggcgc
 agcctcattgacgtcgtggtcagggcagcaaatattgtctgtatgtgcagcagcagaacaatttctgaggggtatt
 yaggcgcgaacagcatctgttgcacactcagactcgtgggcatcaagcgtccacgcaagaatctcgtcgtgtggaaagata

[illegible]

Fig. 10b (3 of 3)

ctccatttgccacggcggaacatcgcgcgcctgcoctgcccgtgctggacaggggctcggctgtgggcaactgacaat
 tccgtgggtgtgicgggggaagctgacgtctcttccalggctgctcgcctgtgttggcaactggattctgcgggggacgtcctt
 ctgctacgtcccttcggccctcaatccagcggaccttcttcccgccgctgctgccggctctgcggcctcttccgcgtcttc
 gcocttcgcccctcagacgagtcggatctcccttggccgcgcctcccgccgtggaaftcggagctcggtaacctttaagccaatg
 acttacaggcagctgtgagcttagccactttttaaaagaaaagggggagctggaagggttaactctcccaacgaaaga
 caagatctgcttttgcctgtactgggtctctctggttagaccagatctgagcctgggagctctctggctaactagggaacca
 ctgcttaagcctcaataaagcctgcoctgagtgcttaagtagtgctgctcccgtctgtgtgtaactctggttaactagagatccc
 tcagacccttttagtcagtgctggaaaatctctagcagtagtagttcatgtcaicttattatcagtaattataacttgcaaaagaaatg
 aatacagagagtgagagggaactgtttatgcagcttataatgggtacaaaataagcaatagcatcacaaattcacaaataa
 agcattttttcactgcattctagtgtgtgttgtccaaactcatcaatgatatctatcatgtctggctctagctatcccgccctaac
 tccgccaggttccgccattctccgccccatggctgactaattttttattatgcagaggccgagggccgcctcggcctctga
 gctattccagaagtagtgaggaggtttttggaggcctaggccttttgctgcgagacgtacccaattcgcctctatgtgagtc
 gtaftacgcgcgcctcactggccgtctgtttacaacgtcgtgacgtgggaaaacccctggcgttacccaacttaatgccttgag
 cacatccccttccgccagctggcgtaatagcgaaggcccgcaaccgacgcgccttcccaacaggttgcgcagccctgaal
 ggogaaatggcgcgacgcgcctgtagcgcgcattaagcgcggcggtgtgtgtgttgcgcgcagcgtgacggcctaca
 ctggccagcgccctagcgcccgctcttccgtttcttcccttcttctcgcacgttcgocgggttccccgtcaagctctaa
 atcgggggctcccttttaggggttccgatttagtgcctttacgcacctcgacccccaaaaaacttgattagggtgaigtgcacgta
 gtgggcccacgcccctgatagacggtttttcgcctttgacgttggagtcacagttctttaatagtgactctgttccaaactgg
 aacaacacctaaccctatctcggctattctttgattataagggaatttggcatttggcctatttggttaaaaatagagctgatt
 taacaaaatttaacgcgaattttaacaaaattataacgtttacaatttcc




Fig. 11a

Fig. 11b (1 of 3)

cagggtgcacatttcggggaaatgtgcgcggaacccctattgtttatcttttaaatatcacaatgatcatgcctcatgaga
 caataaacctgataaattgctcaataatattgaaaaagggaagatgagattacaaacttccgtgtcgcgccttatccctttt
 gggcatttgccttccctgttttctccaccagaacccgtggtggaagttaaaagatgctgaagatcagttgggtgcacagat
 ggggtatcatgaaactgcatctcaacagcggtaagatccttgagaagtcttcgcccggaagacgtttccaatgatgacactt
 taagattgctgatgtggcgggtatccctgattgacgcggcggaagacgaactggcgccgcatacatacttcagaga
 atgacttgggtgagtagtaccacgtacagaaaacatcttaccggatgcatgaaagagaattatggcagtgctgcac
 aacatgagtgataaacacttgcggccaacttactctgacaaagatcggagacggaaagagagtaaacgctgttttgcacaac
 atggggagatcgtgaactcgccttgatcgttgggaacccggagctgaatgaagccatccaaacgacgagcgtgcacaacac
 gatgctgtagcaatggcaaacggttgcgcaaatattactgggaactacttacttagcttcccggaacaattaatag
 actggatggagggcggaataaagtgcaggaccactctgogctcggcccttcggcgtggctggttatgtgcgataaactgg
 agccgtgtgagctgtggctcgcggatcattgcagcactgggccaagtgtgaagccctccgtatcgtgatctatcac
 gacggggagtgacggcaactatggatgaacgaatagacagatcgtgagatagtgctcactgattaaagcattgtaact
 ctgacaccaaagtttactatatactttagattgattttaaactcatttttaattttaaaggatctaggtgaagatccttttgata
 atctcatgacaaaactccctaatgctgagtgttctgtccactgagcgtcagacccctgataaaagatcaaaagatcctttgag
 atctctttttctgcgctaatctgctgttgcacaaaaaaacccacgcctaccagcgggtgttgttggcggatcaagagct
 aacactctttttcgaagtaactgcttgcacgagcgcgacataccaaactgctcttctagtgtagccgtgatttagggcc
 aacctatgaagaactgtgtagcaccgctcatatcctcctcctgctatcctgttaccagtgctgcggcagtgctgacgataag
 tctgtctcactgggttggactcaagcagatagttaccggataaggcgcaagcgttggcgtgaacgggggggtctgtcac
 acagcccaagtttggagcgaacgacctacaccgaactgagatacttaccgtgtagctatgaaagaagcgcacgcttcc
 gaaggagaaaggcgacaggtatccggtaaggcggaagggtcggaaacaggagagcgcacgagggagcttccaggg
 ggaacgcctgtgtatctttatagctcctgtcgggttcgccacctgactgagcgtcgtatttgtgtagctgtcgtccggggg
 cggagcctatgggaanaacgccagcaacggcgccttttaccgttccgttcgtgccttttgcatacagtttcttccgt
 cgttatccctgattctgtgagataaccgtattaccgctttgagtgagctgataccgctcgcgcgagccgaacgacgacgac
 cagcgagctcatgtgagcgaaggaagggaagcgcacacacgcctcctccgcgcgttggtgcctgattcataa
 tgcagctggcagacaggtttccgactggaagcgggacgtgagcgcacgcaattatgtgagtgatgactactattag
 gcaacccaggctttacactttatgcttccgctcgtatgtgtgtggaattgtgagcggataacaattccacaggaacacgc
 tatgacatgattacgcaacggcgcgaattaaocctactaaagggaacaaagcgtggagctgcaagcgtggccattgcat
 acgtgtatccatatacataatattgatactttatgtgctcatgtccaaactaacgoccatgttgacattgattgacagtagtata
 atagtaactaattacgggtgctattgctacagccatatactgagttccgcgttaccataactacggttaaatggccgcctgg
 ctgacccgccacagcccccgcctattgacgtcaataatgacgtatgttccatagtaaacgcaatagggaacttccattga
 cgtcaatgggtggagatttaccggttaactgcccacttggcagtagcatcaagtgtatcatatgccaaagtagcccccattga
 cgtcaatgacgttaaatggccgcgcgtgcaattatgcccagtagaactgaactatgggaacttcttacttggcagtagactatc
 attagtcacgtctattaccactgggtatgcggttttggcagtagcatcaatgggggtggatagcgggttgactacacggggcttcc
 aagtctccacccattgacgtcaatgggagtttgtttggcaccaaaatcaacgggacttccaaatgtcgtcaataactccg
 ccccatgacgcaaatggcggtgagcgtgtacgggttgggggtctatataagcagagctcgtttatgtgaacggggctctct
 ctgtgtagaacagatctgagcctgggagctctctgctactagggaacccactgcttaagpccatcaataaagctgtcttga
 gctctcaatgagtgtgtgccgtctgttgtgtactctggttaactagatccctcagaccccttttagctgtgtggaatct
 ctgagctgtgcgcgcgaacgacgcctgaagcgaagggaacccagagctctctcgaacgacagacgcgtgtgtcga
 agcgcgcgcgcgcgaagcgcgagggggcggcactggtgtaglacgccaaaatattgactagcggagcgtagaaaggaga
 pagatgggtgtgagagcgtgacgtattatagcggggggaattatgactgcgtaggggaaaaaattcgttaaggccaggggg
 aaaggaaaataataataaatacatagtagtggcgaagcaggcagcgtagaacgattcgcgttaactcgtgcctgttga
 acatcagaagcgtgtgacaaactcgggacagctacaaactcccttaagacagagatcagaagaactatgactattatata
 atacagtagtgaacccctattgtgtgtcatcaagaatagatgaataaagacaccaaaggagagcttgaacagatagaaggaa
 agcaaaacaaaggtaagaccaccgcacagcaagcggcgcgtgacttccagacgtcggaggaaggagatagaggacaat
 tgggaagtgtattatataataatagaatgaanaattgaacattaggagtagcaccaccaaagggaaggaagagtg
 gtgcagagaggaaaaaagagcagtggggaataggagcttgttcttgggtcttgggagcagcaggaagcactatggcgccg
 agcctcaatgacgtgacgtgacagccagacaataattgtctgtatagtgacagcagagaacaatttgcaggggctatt
 agggcgcaacgacatctgtgcaactcacaactgtggggcatcaacagcgtccacggcaagaatctgctgtgggaagata

Fig. 11 b (2 of 3)

cctaaaggatcaacagctcctgggatttgggggtgctctggaaaactcatttgcaccactgctgtgcttgggaatgctagtgtg
 ggttaataaactctggagacagattggaatcacacgaccctggatggagtgaggacagagaataataacattacacaagagctta
 atacactcttaatttgaagaatgcgaaccagcagaagaaagaatgacagaataattggnaittagataaattgggcaagttt
 gtggaaattgttttaacatacaaaattgctgtggtatataaaaattattcataatgatagtaggagcctgtgtaggtttaagaataatg
 tttttgcttacttictatagtgaatagagtttagggcgaattatccattcattcttcagacccactcccaaccccgaggggg
 acccgacagagcccggaaggaaatagaagaaggagggtgagagagagacagagacagacatcattgattgttgcaagctgtg
 tgcaggtatcgggttaacttttaaaagaanaagggggggtgggggtgacagcagcaggggaagaatgtagacataataatg
 caacagacattacaacataaagaattacaacaaaacattacaacaaattccaattttcagatcacagagactgacgtcgcagag
 atctgataataacagccataccacattgttagagggttttactgctttaaaacactccacacctcccccgaacctgaacatgaacaa
 taaatgaatgcgaattgttgttgaactgtttattgcagcttataatggttacaataaaggcaataatgacatacaaatccaacaa
 taaggcaattttttacatgcaattcattgtttgtttgcacaactcatcaatgtatctatcatgcttgatctcaaatccctcggaag
 ctgcgctctgtcattggttgaggtatatacttttaacttttaccgttggattaggcagtagctctgacggccctctctct
 tagtttagtgaanaatgtacatctcttaccctcattggcttccagcttagctgcagggggaggtgtgtctggatccgagctc
 gaattggccgttacttactgtacagctgtctcatccgagagatgctaccggggcgtctacggaactccagcaggaccattgtg
 atcgcgtctctcgtgttggtctttgtctcaggcggcagctgggtgctcaggttagtggtgtctgggcagcagcagggccgtc
 ggcgtatgggggtgttctgtctgttagtggctggcggcagctgcacgtctgcctctcgtatgttgtgtgcgggaattgaaatccac
 ttgatgcgttcttctgtctgtcggccatgatataagacgttggctgtgtgtgtgtatctgactcagcttctgcccagcaggttgc
 gttctcttggaatcgatgcccttagctcgtatgggttcaacagggtgtcgtccctcgaacttaacctggcggcggtgtctgt
 agttgcccgtctgtctgaagaagatgtgtcgtctcctggaactgtagcttccggcagtgccggaactgaagaagctgtgctgtct
 calgtgtgcgggtgtgcaggcgtgaagcaactgcacgccgtaggttcagggtgtgtcagagggtggccagggccagcaggcga
 gcttgccgggtgtgcagatgaactcagggtcagctgtcgttaggtggcatcggccctgcggccacggccagcagcagcgaact
 ttggcgggtttagctgcgcgtccagctcagccaggatggcgacacaccccggtgaacagctctcgtcccttgatcccaatgg
 tgaattccgtggaggcgtgafctggctcgggtgtcttctatggagggtcaaaacagcgtggatggcctctcaggcagatctg
 cgtgttaactaaacagagctctgtatataaggctccacccgtacacagcctaccctcaggaagcttgattaaacctgtctggct
 ccagatctggcctcgcgcggcgggttttggcgctccgcggcgcccccctctccacggcgagcgtgcacgtcagacga
 gaaggcgccagcgagcgtctgtatcttccgcccggacgtcaggacagcgccctgctgctcaataagatcggcttag
 aaccocagctatcagcagaaggacattttagaacgggacttgggtgactctagggcactgttttctttccagagagcgggaac
 agcgcagggaaaaatgctccctctcggcgattctcgggaggagctctcgtggggcgggtgaacgccgattataataagg
 acgcgcgggtgtggccagagctatgttccgtgcagccgggatttgggtcgggttctgtttgttggatcgtgtatcgtca
 ctgttgatgtcggcgtgctggcgtggccggggcttctgtggccgcgggcgcgtcgtgggagcgggaagcgtgtggag
 agacccgcgaaggcgttagtcttgggtccgcgaaggttgccctgaactgggggttgggggggaagcgcacanaaatggc
 ggtgttcccgagcttgaatgaagaagcgtgtgaaggcggtctgtgagctgttgaanaacaggtggggggcattgtgtggg
 cgcgaagaacccaaggcttgaagccttgcataatcggggaagactctattcgggtgagatgggctggggccacactctgt
 gggaacctgacgtgaagttgttcaactgaactggaagacccgggttctgtctgtgtgtcggggcgcaggtatgcgtgtcc
 gttgggcaactgcacccgttaactttgggagcgcgcgtcgtcgtcgtgtgacgtcaacctgttctgtgttataatgcagg
 gtggggccacacttggcgttaggtgtgcgttagccttttctcgtcgcaggacagagggttggcgtcaggttaggtctgctcct
 gaactgaacagcgcggcgaacctgtgtgagggagggagataatgtaggcgtcagttcttctgtcgtttatgtaactatctt
 ttaagtgtgaagctcgggtttgaactatgcgtcgggtgtggcaggtgtgtttgtgaagtttttaggcacatttgaagaatg
 aatcatttgggtcaatatgaattttcaggttagactgaataattgtcgcctaatttggccgtttttgtgttttttagtagcaga
 gottgggtgcgaagattcggggcggcgcagctccggcgggcagggggggggcgtggagcgcagcgcagcgcagcc
 ccaatagtcgcgaaggcggaacgagctggaagtgcagcgtctccagggagagggcgatggggggcaggtgtgcaccc
 ggccgcgcagcagggggcggcgcgcgtctgtgttgcgtcttgggggttgccttggagggtgcacaggagagcagtgcc
 ccacagcgtgtgacacacacagcgggtgagtgctgaagcgtcaacctggcgagggtgtggccacagcttgtggaactg
 caaccagaccgtgtgtgagccctcgttgacagcgtgacgttctccgacgtgtgtgagcgcagcggccgtgcgaagccg
 tgcaccgagtgctgtgggtccacagagatgtcggcgccgtgtcgtggagggccagacagcgcgtgtgcgcgtcgtctac
 ggctacttaccagtagtagacgactgggcgtctgcgagcgtgcgcgtgtgtgcagagcggcgtcggcgtcgtgtctct
 gcaggagcaagcagaacacgcgtgtgcgagaggtgcgcgcagcagctattccagcagggccaaacacgtggagccgc
 tgccttccctgcacgtgtgtgcgagacacgagcggccagctccgcgagtgacacagctggcgacgcgcgaggtgcga

Fig. 11b (3 of 3).

[illegible]

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 02064804 A [0006]
- US 6388170 B [0008] [0009] [0009]
- WO 0134825 A [0010]
- IT 2004000227 W [0064]

Non-patent literature cited in the description

- KAY, M.A.; GLORIOSO, J.C.; NALDINI, L. *Nat Med*, 2001, vol. 7, 33-40 [0063]
- NEFF, T. et al. *J Clin Invest*, 2003, vol. 112, 1581-1588 [0063]
- BORDIGNON, C.; RONCAROLO, M.G. *Nat. Immunol.*, 2002, vol. 3, 318-321 [0063]
- SADELAIN, M. *J Gene Med*, 2002, vol. 4, 113-121 [0063]
- BONINI, C. et al. *Science*, 1997, vol. 276, 1719-1724 [0063]
- HACEIN-BEY-ABINA, S. et al. *Science*, 2003, vol. 302, 415-419 [0063]
- BURTON, E.A.; GLORIOSO, J.C.; FINK, D.J. *Gene Ther*, 2003, vol. 10, 1721-1727 [0063]
- SADELAIN, M.; RIVIERE, I.; BRENTJENS, R. *Nat Rev Cancer*, 2003, vol. 3, 35-45 [0063]
- MILLER, A.D. *Retroviruses*. Cold Spring Harbor Laboratory Press, 2000, 437-474 [0063]
- EMERMAN, M.; TEMIN, H.M. *Mol Cell Biol*, 1986, vol. 6, 792-800 [0063]
- ZHU, Y. et al. *Mol Ther*, 2001, vol. 4, 375-382 [0063]
- KLUMP, H. et al. *Gene Ther*, 2001, vol. 8, 811-817 [0063]
- FURLER, S. et al. *Gene Ther*, 2001, vol. 8, 864-873 [0063]
- MARTINEZ-SALAS, E. *Curr Opin Biotechnol*, 1999, vol. 10, 458-464 [0063]
- FOLLENZI, A. et al. *Nat Genet*, 2000, vol. 25, 217-222 [0063]
- GHATTAS, I.R.; SANES, J.R.; MAJORS, J.E. *Mol Cell Biol*, 1991, vol. 11, 5848-5859 [0063]
- QIAO, J. et al. *Hum Gene Ther*, 2002, vol. 13, 881-887 [0063]
- LOIS, C. et al. *Science*, 2002, vol. 295, 868-872 [0063]
- BARON, U.; BUJARD, H. *Methods Enzymol*, 2000, vol. 327, 401-421 [0063]
- BRAY, M. et al. *Proc Natl Acad Sci USA*, 1994, vol. 91, 1256-1260 [0063]
- ZUFFEREY, R. et al. *J Virol*, 1999, vol. 73, 2886-2892 [0063]
- ALLES, L. et al. *Mol Ther*, 2002, vol. 6, 615-626 [0063]
- CAVALIERI, S. et al. *Blood*, 2003, vol. 102, 497-505 [0063]
- NALDINI, L. et al. *Proc Natl Acad Sci USA*, 1996, vol. 93, 11382-11388 [0063]
- BAEKELANDT, V. et al. *Hum Gene Ther*, 2002, vol. 13, 841-853 [0063]
- DEGLON, N. et al. *Hum. Gene Ther*, 2000, vol. 11, 179-190 [0063]
- SOKOLIC, R.A. et al. *Blood*, 1996, vol. 87, 42-50 [0063]
- WONG, E.T.; NGOI, S.M.; LEE, C.G. *Gene Ther*, 2002, vol. 9, 337-344 [0063]
- KOZAK, M. *Gene*, 2003, vol. 318, 1-23 [0063]
- MIZUGUCHI, H. et al. *Mol Ther*, 2000, vol. 1, 376-382 [0063]
- HENNECKE, M. et al. *Nucleic Acids Res*, 2001, vol. 29, 3327-3334 [0063]
- MAZURIER, F. et al. *Blood*, 2004, vol. 103, 545-552 [0063]
- VIGNA, E.; NALDINI, L. *J Gene Med*, 2000, vol. 2, 308-316 [0063]
- GARDINER-GARDEN, M.; FROMMER, M. *J. Mol Biol*, 1987, vol. 196, 261-282 [0063]
- LAVIA, P.; MACLEOD, D.; BIRD, A. *EMBO J*, 1987, vol. 6, 2773-2779 [0063]
- JOHNSON, P.; FRIEDMANN, T. *Gene*, 1990, vol. 88, 207-213 [0063]
- SCACHERI, P.C. et al. *Genesis*, 2001, vol. 30, 259-263 [0063]
- VIGNA, E. et al. *Mol Ther*, 2002, vol. 5, 252-261 [0063]
- BARON, U. et al. *Nucleic Acids Res*, 1995, vol. 23, 3605-3606 [0063]
- UNSINGER, J. et al. *Mol Ther*, 2001, vol. 4, 484-489 [0063]
- FUX, C. et al. *J Gene Med*, 2003, vol. 5, 1067-1079 [0063]
- XIE, M.; HE, Y.; GAN. *SNat Biotechnol*, 2001, vol. 19, 677-679 [0063]
- TRINKLEIN, N.D. et al. *Genonze Res*, 2004, vol. 14, 62-66 [0063]
- TAKAI, D.; JONES, P.A. *Mol Biol Evol*, 2004, vol. 21, 463-467 [0063]

EP 1 616 012 B1

- ADACHI, N. ; LIEBER, M.R. *Cell*, 2002, vol. 109, 807-809 [0063]
- FARSON, D. et al. *Hum Gene Ther*, 2001, vol. 12, 981-997 [0063]
- DE PALMA, M. et al. *Nat Med*, 2003, vol. 9, 789-795 [0063]
- FOLLENZI, A. et al. *Hum Gene Ther*, 2002, vol. 13, 243-260 [0063]